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Epidemiology
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS). It affects more than 2 million individuals worldwide and twice as many women as it 
does men, although men appear to have a more negative prognosis.1 In the Netherlands, 
approximately 1 in 1000 persons are diagnosed with MS.2 The onset of MS mainly occurs in 
early adult life (20-40 years).3 The cause of MS is unknown, but a complex interplay between 
environmental and genetic factors contribute to the development of MS. Environmental and 
lifestyle risk factors such as vitamin D deficiency (related to reduced exposure to sunlight), 
diet, obesity in early life and cigarette smoking are risk factors for MS development.4 A 
genetic predisposition has been established and several genes have been associated in MS 
(the most significant remains the HLA-DRB1*1501 haplotype).5
Pathology
From a pathological point of view MS is a chronic inflammatory, demyelinating and 
neurodegenerative disease of the brain and spinal cord in which the adaptive immune 
system plays a key role in the pathogenesis of MS. The immune response to myelin results 
in a cycle of periodic attacks to the myelin. The myelin is wrapped around the nerve cells 
by oligodendrocytes and essential for an efficient processing of signals throughout the 
brain. Why the adaptive immune system attacks the myelin is unclear. Focal inflammatory 
demyelinating lesions in the CNS represent a process marked by leakage of the blood-brain 
barrier, influx of immune cells, inflammation of the tissue. These lesions, after an attack, 
can be seen using magnetic resonance imaging (MRI). In the past, these lesions were only 
visualized in white matter but with recent developments in MRI techniques, lesions are also 
detectable in gray matter.6
Besides demyelination, axonal and neuronal loss (neurodegeneration) and astrocytic gliosis 
are important hallmarks of the MS pathology. Neurodegeneration is relevant because it is 
the main underlying mechanism of permanent clinical disability and cognitive decline.7
Clinical features
The MS patient can experience a sudden exacerbation of symptoms, due to the attack of the 
immune system on myelin. A period of symptoms is called a relapse (or ‘schub’). Depending 
on the localization of the acute inflammatory demyelinating lesions and the extent of the 
inflammatory process, the patient may experience a variety of symptoms, such as optic 
neuritis (inflammation of the optic nerve), muscle weakness or sensory deficits.  Disability 
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of patients with MS is usually rated using the expanded disability status scale (EDSS).8 This 
scale ranges from 0 (no objective neurological impairment ) to 10 (death due to MS). 
The majority of MS patients (85%) initially experience a relapsing remitting disease course 
(RRMS). This course is characterized by an (almost) complete clinical recovery after episodes 
of neurological deficits. In the initial phase of the disease, patients may present with only 
one episode of neurological deficits  and not fulfill the MS diagnostic criteria (see section 
‘Diagnosis’ below). This disease course is referred as a clinically isolated syndrome (CIS). 
Almost 60-80 percent of the CIS patients convert to MS. Up to 80 percent of the RRMS patients 
will subsequently develop a secondary progressive course (SPMS) in untreated populations. 
After this conversion point the inflammatory component of the disease is less prominent 
but an increase of neurodegeneration occurs. The remaining 15 percent of the patients have 
a primary progressive course (PPMS) from onset without relapses. Classifying patients in 
these phenotypes is important for communication, prognostication, design and recruitment 
of clinical trials, and treatment decision-making. However, these phenotype categories do 
not provide information about the ongoing disease process. Using additional information 
about disease activity detected by clinical relapses or imaging as well disability progression 
is meaningful. MS patients can be classified as active or not-active and progressing or not-
progressing. This classification is now added to the standard disease course description in 
the new definitions of the International Advisory Committee on Clinical Trials in MS.9
Diagnosis
The problem of diagnosing MS is largely solved by using MRI, clinical presentation and 
neurological assessment, but can still be complicated in some patients. This may occasionally 
result in an undesirable late diagnosis and subsequently delayed treatment. The diagnosis 
is based on the demonstration  of  both dissemination in space and time as reflected in the 
diagnostic criteria, currently the revised McDonald diagnostic criteria (2017).10 Dissemination 
in space is defined as ≥1 lesions in ≥2 typically MS regions: (juxta)cortical, infratentorial and 
spinal cord. Dissemination in time is defined by development of new MS lesions during 
follow up or an active lesions with gadolinium enhancement. 
Biomarkers: Blood and CSF
In MS, there are only very few body fluid biomarkers that are accepted as reliable and 
practicable parameters so far. Biomarkers play a role in determining MS (e.g. cerebrospinal 
fluid-specific oligoclonal bands (OCB)), in differential diagnosis (e.g. anti-aquaporine-4 and 
anti-MOG serology in neuromyelitis optica spectrum disorders),  in monitoring disease 
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modifying treatment (DMT) (e.g. anti-interferon antibodies and anti-natalizumab antibodies) 
and predicting adverse effects (screening anti-JCV antibodies in natalizumab treatment for 
the risk of PML).11 
Currently, the most promising body fluid biomarker in MS, reflecting acute neuroaxonal 
damage is neurofilament light (NfL). This is a cross disease axonal damage biomarker12 
that increases in cerebrospinal fluid (CSF) and serum of RRMS patients during relapses 
and concomitantly to the appearance of new T2 and/or GE lesions, returning to baseline 
within a couple of months after the acute event.13, 14  In addition, serum NfL levels decrease 
in individual RRMS patients after disease modifying therapy (DMT) initiation.15-19 The 
magnitude of the decrease in NfL levels correlates with the efficiency of the DMT in reducing 
relapse rate, and NfL was reported to further decrease in individuals switching from first-line 
to second-line DMTs.10 NfL holds high potential to monitor inflammatory disease activity in 
individual MS patients in the clinical setting. The fact that NfL is detectable in serum makes 
this biomarker more suitable for treatment monitoring then CSF -NfL. CSF collection is too 
invasive for longitudinal sampling when monitoring treatment. 
The list of promising biomarkers in MS is extensive and the road to clinical application 
long. Nevertheless, biomarkers reflecting and predicting disease activity and progression 
are crucial for personalized medicine and may provide guidance in the rapidly evolving 
treatment armamentarium in MS. MS biomarker research is thriving and data are being 
generated rapidly.11 
Aims and outlines of this thesis
The main aim of this thesis was to explore novel biomarkers that are associated with disease 
progression and to explore biomarkers in monitoring treatment and treatment safety. With 
this aim, different markers reflecting potential roles in neuroinflammation, demyelination, 
and axonal damage were analyzed. For monitoring DMT and DMT safety, natalizumab 
concentrations and neurofilament light were explored. Two other biomarkers with a more 
diagnostic purpose were also worthy to analyze. 
Part 1:  Diagnostic biomarkers
In this part two biomarkers with a diagnostic purpose were analyzed: kappa/lambda free 
light chains and messengerRNA from blood platelets. The main aim of chapter 1 was to 
validate kappa free light chains and lambda free light chains indices as a diagnostic biomarker 
in MS compared with OCB in a large multicenter study including samples from eighteen 
MS-centers across Europe.  This set up was chosen because large scale studies comparing 
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diagnostic performance of the two methods (free light chains and OCBS) and to define the 
cut-off of free light chains were lacking.
The need for a reliable blood-based biomarker (less invasive than CSF) for making a 
straightforward MS diagnosis is obvious. Therefore, in chapter 2 messengerRNA from 
blood platelets was analyzed.  As a result of their involvement in the immune response and 
potential role in the progression and development of the disease, we hypothesized that 
blood platelets of MS patients contain a disease-related RNA-signature which could be used 
as a diagnostic tool.
Part 2: Disease course biomarkers
Validated and discriminative body fluid biomarkers reflecting and predicting natural disease 
progression are lacking, therefore in this part, we analyze three potential markers for 
predicting disease progression. 
In chapter 3 we evaluated if cerebrospinal fluid mtDNA concentration in multiple sclerosis 
can serve as a marker of ongoing neuropathology and help differentiating between MS 
disease subtypes. In chapter 4 acid sphingomyelinase activity and altered sphingolipid 
metabolism was explored as potential biomarkers in serum of MS patients, to predict active 
and progressive disease, and response to disease modifying therapy. In chapter 5 Tissue 
Transglutaminase was measured and correlated to clinical and MRI parameters to evaluate 
if this biomarker is a promising marker for  progression of multiple sclerosis.
Part 3: Treatment monitoring biomarkers
The main aim of chapter 6 was to investigate the potential of serum neurofilament light 
(sNfL) as a biomarker of disability progression with minimal contribution of disease 
activity, i.e. relapses and new T2 or GE MRI lesion formation, collectively referred to as 
focal inflammatory activity. We measured sNfL longitudinally in a cohort of natalizumab-
treated RRMS patients followed clinically. We examined whether sNfL at baseline (at the 
initiation of NTZ treatment) predicted disability progression. In chapter 7 we compared MS 
disease activity after different washout periods in patients switching from natalizumab to 
fingolimod. In addition, we investigated several body fluid factors that possibly influence 
recurrence of disease activity, including serum natalizumab concentration and lymphocyte 
counts. In the last chapter (chapter 8) we wanted to give neurologists insight in natalizumab 
concentrations at time of re-dosing, therefore we investigated longitudinal natalizumab 
concentrations in 80 patients in relation to disease activity, with possible influencing factors.
The thesis concludes with an overview of the findings presented in part 1, 2 and 3, including 
interpretation of the data in light of the available evidence and some future directions.
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Objective: To validate kappa free light chains (KFLC) and lambda free light chains (LFLC) 
indices as a diagnostic biomarker in multiple sclerosis (MS).
Methods: We performed a multicenter study including 745 patients from eighteen centers 
(219 controls and 526 CIS/MS patients) with a known oligoclonal band (OCB) status. KFLC 
and LFLC were measured in paired cerebrospinal fluid (CSF) and serum samples. Gaussian 
mixture modeling was used to define a cut-off for KFLC and LFLC indexes. 
Results: The cut-off for the KFLC-index was 6. 6 (95% confidence interval (CI) 5.2 – 138.1). 
The cut-off for the LFLC-index was 6.9 (95%CI 4.5 – 22.2). For CIS/MS patients, sensitivity 
of the KFLC-index (.88; 95%CI .85-.90) was higher compared with OCB (.82; 95%CI .79-.85; 
p<0.001), but specificity (.83; 95%CI .78-.88) was lower (OCB: .92; 95%CI .89-.96; p<0.001). 
Sensitivity and specificity for the LFLC-index were both lower compared with OCB.
Conclusion: Compared with OCB, the KFLC-index is more sensitive but less specific for 
diagnosing CIS/MS. Lacking an elevated KFLC-index is more powerful for excluding MS 
compared with OCB but the latter is more important for ruling in a diagnosis of CIS/MS.
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1Introduction
Cerebrospinal fluid (CSF) assessment is often part of the diagnostic workup for multiple 
sclerosis (MS) and its value is supported by the latest 2017 revisions of the McDonalds 
criteria.1  CSF examination is frequently performed in diagnosing MS for excluding alternative 
diagnoses although in the current MS criteria2 assessment of oligoclonal IgG bands (OCB) 
plays a limited role. However a recent study showed the added value of OCB in the MS 
diagnostic criteria.3 In the 2017 revisions the OCB have a prominent role in patients with 
a clinically isolated syndrome (CIS). The presence of both magnetic resonance imaging 
(MRI) criteria for dissemination in space (DIS) and CSF-specific OCB will enable to establish 
the MS diagnosis in patients with a single clinical episode suggestive of CNS inflammatory 
demyelinating disease. The OCB assessment also has important prognostic value in CIS and 
MS4, 5. However, the assessment of OCB is labor intensive, requires trained personnel and is 
in some cases examiner- and method-dependent, which may affect its reliability. 
Alongside intact immunoglobulins, which are composed of two heavy and two light chains, 
plasma cells produce and secrete immunoglobulin free light chains (FLC), of either kappa 
(KFLC) or lambda (LFLC) chains. KFLC and LFLC can be detected in both CSF and serum.6-10 
Since the late 1970s, multiple studies have reported increased CSF levels of KFLC in MS.6-14 
The analytical specificity of the earlier methods (e.g. radioimmunoassay15, 16, quantitative 
enzyme-linked immunosorbent assay8, 17) was insufficient, but with the recent emergence 
of the more sensitive nephelometric and turbidimetric FLCs assays, research in this field has 
been revived. Nephelometric (and turbidimetric) FLC level determination has the additional 
advantage compared to OCB of being assessed by an automated procedure and being 
quantifiable.18  
Using the FLC assay19, recent studies showed that both CSF KFLC levels and the KFLC index are 
increased in patients with CIS or relapsing remitting MS (RRMS) compared with controls.8, 
14, 18, 20-22 The use of an index measure is necessary, for example [CSF KFLC/serum KFLC]/[CSF 
albumin/serum albumin], to include blood-CSF barrier permeability.10, 14 The KFLC index has 
comparable sensitivity and specificity to OCB for diagnosis of MS and CIS.14, 21, 23 However, 
large scale studies comparing diagnostic performance of the two methods and to define the 
cut-off of FLC are lacking. The main aim of this study was to validate KFLC and LFLC indices 
as a diagnostic biomarker in MS compared with OCB in a large multicenter study including 




Eighteen MS centers participated, located in the Netherlands, Spain, France, Belgium, 
Hungary, Italy, Poland, Turkey, Denmark, Serbia, Austria and Switzerland. We selected 745 
paired CSF/serum samples from patients with known OCB status, diagnoses as CIS (n=242), 
RRMS (n=235), primary-progressive MS (PPMS)(n=41) and secondary-progressive MS 
(SPMS)(n=8). We also included inflammatory neurological disease controls (INDC)(n=67), 
non-inflammatory neurological disease controls (NINDC)(n=76), symptomatic controls (SC)
(n=49) and healthy controls (HC)(n=27) as defined previously.24 The different control groups 
were pooled into one control group (n=219). The CIS and MS patients were also pooled (CIS/
MS) (n=526).
The large majority (84%) of the CIS/MS patients fulfilled the 2010 McDonald criteria2 but 
in some cases the patients were diagnosed according the 2005 McDonald criteria25 (16%). 
Table 1 presents the demographic and clinical characteristics of the patients and controls. 
All participants gave written informed consent at the center where the CSF/serum was 
conducted.
CSF and serum samples
Only CSF samples that were immediately centrifuged and stored in polypropylene tubes 
within two hours at -80° C, at the local center, were included. The assessment of OCB had 
been performed by isoelectric focusing (on agarose or polyacrylamide gel) followed by 
immunofixation by the centers as part of the diagnostic work-up. 
Samples were taken between 2005-2016, with a median age of 2.9 years (IQR 1.7-5.7).
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1We used fresh aliquots and in our lab we did not freeze and thaw the samples during the 
analyses. As far as we know, no effects of freezing and thawing have been reported.
KFLC,  LFLC and albumin analysis
KFLC, LFLC and albumin concentrations in CSF and serum samples were analyzed using the 
turbidimetric analyser SPAplus® (The Binding Site, Birmingham, UK) with the serum free 
light chain immunoassay (Freelite®, The Binding Site, Birmingham, UK) according to the 
manufacturer’s instructions. All samples were measured centrally in the Neurochemistry 
Laboratory of the Department of Clinical Chemistry of the VU University Medical Center 
(VUmc), Amsterdam, The Netherlands. All samples were run blinded for the clinical data.
To verify the QC data supplied by the manufacturer we calculated intra-assay coefficient 
of variation (CV) by taking the mean CVs of 4 replicates of 5 samples (CSF/serum) within 
one run. We calculated inter-assay CV based on n=5 samples (CSF/serum)  measured in 5 
different days. CV values for KFLC and LFLC were all found to be lower than those supplied by 
the manufacturer (suppl. Table 1). CV values for albumin were comparable to those supplied 
by the manufacturer. Assay linearity was experimentally confirmed for albumin (serum and 
CSF) and the FLC assays in serum and showed that  recalculated values varied by 25.7% 
(KFLC) and 14.2% (LFLC) from the original value.  
For 29 samples CSF albumin results were below detection. Here, we assigned a random 
uniform value between 35 mg/ml (lowest detected value in undiluted rerun) and 175 mg/
mL (formal detection limit).
FLC indices
We determined the CSF/serum quotients (Q FLC) of KFLC and LFLC and calculated indices, in 
order to take possible blood-CSF diffusion into account. The FLC indices were defined as [Q 
FLC] x [serum albumin/CSF albumin]. 
Statistics
Differences in demographics, clinical characteristics, FLC concentrations and FLC indices 
were tested via the Mann-Whitney U test for comparison of 2 groups of non-normally 
distributed data. For comparison of more than 2 groups, Kruskal-Wallis test with post hoc 
Dunn’s multiple comparison test was applied. For normally distributed continuous variables, 
an independent samples t-test, or one-way ANOVA with post hoc Bonferroni correction was 
applied. For binary variables, a Chi-square test was performed. These statistical analyzes 
were performed in SPSS 22.0 (IBM Crop., Armonk, NY, USA).
Gaussian mixture modeling was used to define cut-offs for abnormal FLC indices using 
the R statistical software program version 3.2.1 mixtools package. First, the number of 
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distributions that best described the data was determined with the R boot.comp function. 
Next, we defined a data-driven cut-off as the point where the lines of two fitted normal 
distributions crossed each other. The main analyses included all subjects. Data were log-
transformed because FLC indices were not normally distributed. Based on the defined 
cut-off subjects were classified as positive or negative for kappa or lambda FLC as binary 
result, similar as the available results for OCB status. As extra comparisons we combined 
the different tools to compare with the single measurement OCB. The three combinations 
were: KFLC with OCB, LFLC with OCB and KFLC with LFLC. We defined the outcome of the 
combination as followed: when one of the measurements is positive the combination is 
positive, when both are negative the combination is negative.   
To compare the sensitivity, specificity and accuracy between the two different diagnostic 
tools (OCB and FLC), the McNemar test was used (SPSS 22.0 (IBM Crop., Armonk, NY, USA). 
The positive and negative predicted values (PPV and NPV) were compared using the R 
package DTcompair. P-values <0.05 were considered statistically significant.
Results
Paired CSF and serum samples from a total of 745 patients were included in this multicenter 
study (see supplementary figure 1 for the flow-chart of patient selection). The patient 
groups (n=526) consisted of 242 CIS and 284 MS patients. The control group (n=219) 
consisted of 76 NINDC, 67 INDC, 49 SC and 27 HC. The control group was older (mean 42 
years ±12) compared to the CIS/MS patient group (mean 35 years ±10, p<0.001). There was 
no significant difference in sex distribution between the two groups (p=0.20). Only 7.7% 
of the control group had a positive OCB status. The diagnosis of these patients are: Tolosa 
hunt (n=2), meningitis (n=1), neurosarcoidosis (n=2),  lupus (n=1), transient global amnesia 
(n=1), stroke (n=1), post-infectious myelitis (n=1), myelitis (n=1), encephalitis (n=1), epilepsy 
(n=1), ADEM (n=1), neurodegeneration (n=1), INDC, exact diagnosis unknown (n=2), neuritis 
optica (n=1).
For a detailed list including the diagnoses of non-inflammatory neurological diseases and 
inflammatory neurological diseases included in the groups, see supplementary tables 2A 
and 2B.
FLC concentrations and FLC indices
Table 2 shows the levels and indices of the KFLC and LFLC in CIS/MS patients and controls. 
CSF KFLC and CSF LFLC concentrations were significantly increased in CSF of CIS/MS patients 
compared to controls (both p<0.001). In addition, KFLC and LFLC concentrations in CSF were 
higher in MS compared to CIS patients (both p<0.001).
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1KFLC and LFLC serum concentrations were significantly higher in the control group compared 
to CIS/MS (both, p=0.001) but did not differ significantly between CIS and MS (KFLC p=0.33, 
LFLC p=1.00). 
See figure 1A for the KFLC indices per subgroup and figure 1B for the LFLC indices per 
subgroup. KFLC and LFLC indices were significantly increased in CIS/MS compared to controls 
(both p<0.001). In addition, FLC indices were higher in MS compared to CIS (KFLC p=0.07, 
LFLC p<0.001). 
FLC index cut-off 
In the total cohort (n=745) (all diagnostic subgroups), a bimodal distribution of the log-
transformed KFLC index values fitted the data best. This yielded a cut-off for the log-KFLC 
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index of 1.89 (95%CI 1.65-4.92) (Figure 2A), which corresponds to an KFLC index of 6.6 
(95%CI 5.2– 138.1) on the original scale.
For the LFLC index, a bimodal distribution yielded an optimal cut-off for the log-LFLC index 
of 1.9 (95% CI 1.5-3.1) (Figure 2B), which corresponds to an LFLC index of 6.9 (95%CI:4.5 – 
22.2) on the original scale.
Diagnostic sensitivity and specificity of the indices compared to OCB
KFLC index
When pooling CIS and MS as one group (CIS/MS), the sensitivity to identify CIS/MS from 
controls of the KFLC-index (.88) was significantly higher than of OCB (.82; p<0.001) at the 
cost of a significantly lower specificity (KFLC-index: .83, OCB: .92; p<0.001) (see Table 3).
When identifying CIS patients from controls, the sensitivities did not differ significantly 
between KFLC and OCB (KFLC-index: .81, OCB: .77; p=0.15) but the specificity of OCB 
was significantly higher (KFLC-index: .83, OCB .92, p<0.001). Identifying MS patients from 
controls, the sensitivity of the KFLC-index (.93) was significantly higher than of OCB (.86; 
p<0.001) but the specificity (.83) significantly lower (.92; p<0.001). 
The accuracies were similarly high for both biomarkers for all three comparisons. The 
positive predictive values (PPV) were higher for OCBs (in all three comparisons p<0.001). The 
negative predictive value (NPV) was the same for both markers (p=0.56) in CIS vs controls, 
but when pooling CIS/MS and in MS alone the NPV were slightly higher for KFLC (p=0.010, 
p<0.001). (see Table 3).
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When pooling CIS and MS in one group (CIS/MS) the sensitivity to identify CIS/MS from 
controls of the LFLC-index (.66) was significantly lower than that of OCB (.82; p<0.001). The 
specificity to discriminate CIS/MS from controls was also significantly lower (.86) than for 
OCD (.92; p=0.019).
When identifying CIS patients from controls, the sensitivities did differ, the LFLC-index was 
significantly lower than the OCB (LFLC-index: .60; OCB: .77; p<0.001). The specificity of LFLC in 
CIS was lower compared to OCB (LFLC-index: .86; OCB .92; p=0.019).  Identifying MS patients 
from controls, the sensitivity of the LFLC-index (.75) was significantly lower than of OCB (.86; 
p<0.001). The specificity (.86) was also significantly lower compared to OCB (.92; p=0.019). 
The accuracies and NPV were significantly lower of LFLC compared to OCB for all three 
comparisons. The PPV was significantly lower for LFLC compared to OCB when comparing MS 
with controls and in the other comparisons the PPV of LFLC was similar with OCB. (see Table 
3). 
Table 3. Diagnostic sensitivity and specificity of the FLC indices compared to OCB.
OCB KFLC p-value LFLC p-value
CIS/MS vs controls
Sensitivity .82 (95%CI .79-.85) .88 (95%CI .85-.90) <0.001 .66 (95%CI .62-.70) <0.001
Specificity .92 (95%CI .89-.96) .83 (95%CI .78-.88) <0.001 .86 (95%CI .81-.91) 0.019
Accuracy .85 (95%CI .82-.88) .86 (95%CI .84-.89) 1.000 .74 (95%CI .70-.77) <0.001
PPV .96 (95%CI .94-.98) .92 (95%CI .90-.95) <0.001 .92 (95%CI .90-.95) 0.001
NPV .68 (95%CI .63-.73) .73 (95%CI .68-79) 0.010 .53 (95%CI .48-.58) <0.001
CIS vs controls
Sensitivity .77 (95%CI .72-.82) .81 (95%CI .76-.86) 0.150 .60 (95%CI .54-.66) <0.001
Specificity .92 (95%CI .89-.96) .83 (95%CI .78-.88) <0.001 .86 (95%CI .82-.91) 0.019
Accuracy .84 (95%CI .80-.88) .82 (95%CI .78-.85) 0.149 .73 (95%CI .68-.77) <0.001
PPV .92 (95%CI .88-.95) .84 (95%CI .79-.88) <0.001 .83 (95%CI .77-.89) 0.001
NPV .78 (95%CI .73-.83) .79 (95%CI .74-.84) 0.56 .66 (95%CI .61-.72) <0.001
MS vs controls
Sensitivity .86 (95%CI .82-.90) .93 (95%CI.90-.97) <0.001 .75 (95%CI .70-.80) <0.001
Specificity .92 (95%CI .89-.96) .83 (95%CI.78-.88) <0.001 .86 (95%CI .81-.91) 0.019
Accuracy .89 (95%CI .86-.92) .89 (95%CI .86-.92) 1.000 .80 (95%CI .77-.84) <0.001
PPV .94 (95%CI .91-.97) .88 (95%CI .84-.91) <0.001 .88 (95%CI .84-.92) 0.002
NPV .84 (95%CI .79-.88) .91 (95%CI .86-.95) 0.001 .73 (95%CI .68-.78) <0.001
KFLC: kappa free light chains; LFLC: lambda free light chains; NPV: negative predictive value; OCB: oligoclonal 
bands PPV: positive predicted value.
To compare the sensitivity and specificity between the two different diagnostic tools (OCB and FLC), the McNemar 
test was used.
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Combination of the different tools compared to single  measurement.
Three combinations were made, KFLC index-OCB, LFLC index-OCB and KFLC index-LFLC 
index, and all were compared with the analysis of OCB alone. Sensitivity and specificity 
were calculated for all the subgroups compared to the control group. The sensitivity of 
the combination OCB with the KFLC-index increased to .88, and the specificity  of this 
combination decreased to .83. The same results were obtained for the combinations of LFLC 
index-OCB and KFLC index-LFLC index compared to single OCB, showing a slightly higher 
sensitivity (LFLC index-OCB .87, KFLC-LFLC index .87) and a lower specificity (respectively 
.83 and .80).
Sensitivities and specificities in alternative subgroups
Including patients with the diagnosis CIS (according to McDonald 2005 criteria) as  RRMS 
patients resulted in lower sensitivities of OCB, KFLC and LFLC were seen when comparing 
CIS patients with controls. However, the p-value did not change relevantly when comparing 
the new sensitivities for OCB, KFLC and LFLC. No relevant differences were seen when 
comparing MS to control group.
No relevant differences were seen when we exclude patients with the CIS diagnosis according 
to McDonald 2005 criteria.
When excluding INDC from the control group, higher specificities were seen for OCB, KFLC 
and LFLC when comparing CIS/MS with the controls. However, the p value did not change 
relevantly when comparing the new specificities for OCB, KFLC and LFLC (data not shown).
Discussion
Our study indicates that the KFLC-index is a valid test for diagnosing CIS/MS. Compared to 
OCB the KFLC-index is more sensitive at the cost of a lower specificity. This trade off resulted 
in a higher NPV for the KFLC-index compared to OCB, but a lower PPV. In addition, our 
results indicate that the LFLC-index is not a valid test for diagnosing CIS/MS. 
Our sensitivity and specificity for the KFLC index in CIS/MS were lower than a few much smaller 
previous studies18, 23, 26, which reported sensitivity in the range of .93-.95 and specificity in 
the range of. 91-1.00. The study of Desplat-Jégo et al9 showed a  lower sensitivity of .70 and 
a lower specificity of .82 for the KFLC index in MS patients. The more recent study of Vasilj 
et al27 showed a lower sensitivity of 0.71, however a higher specificity of .98. The results of 
the comparison of KFLC and OCB are in line with results of a recent multi-center study14, 
where a cut-off of 5.9 was employed to validate KFLC in CSF as a diagnostic biomarker in 60 
CIS patients, 60 MS patients compared to 60 OND, reporting a higher sensitivity of the KFLC 
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1index (.78) compared to OCB (.72) for diagnosis of CIS. In MS, the sensitivity of the KFLC 
index and OCB were comparable (.93 vs .93). However, the specificity (.95) in CIS and MS 
was higher compared to our study. Another paper used the same 5.9 cut-off, this resulted in 
a sensitivity and specificity of .96 and .98 in MS patients.21 
This discrepancy in the crude sensitivity and specificity of the KFLCs may be due to the more 
heterogeneous control group in our study compared to the previous studies, due to pooling 
of the CIS/MS group or the inclusion of not only clinical definite MS patients. For example, 
similar as for the OCBs, KFLCs can be elevated in inflammatory controls28, and thus specificity 
will be lower when included. Nevertheless, this is a very relevant control group in differential 
diagnosis of MS. The unprecedented large number of patients and the large heterogeneous 
control group in this study gave us a reflection of the real-life clinical situation thus avoiding 
spectrum bias and allowed us to give a more representative sensitivity and specificity for 
OCB, KFLC and LFLC indices. 
Noticeable is that the sensitivity and specificity of OCB to discriminate MS patients from 
controls were lower in our study than previously reported.10, 29, 30 However, a meta-analysis 
published in 201331 (13,467 patients) showed that the diagnostic specificity of OCB diminished 
if other inflammatory etiologies were considered. Therefore, the lower specificities in our 
study may also be due to inclusion of various control groups. 
The cut-off in this study was calculated using a data-driven Gaussian mixture modeling 
approach. We chose a different approach compared to other studies that applied for 
example receiver operating characteristics (ROC) curve analysis and area under the curve 
(AUC) values9, 10, 18, 23, 27, 32, because we reasoned that the cut-off should be defined by 
biological levels (data driven) and not based on clinical diagnosis, which is an imperfect 
golden standard. We determined a cut-off of 6.6 for abnormal KFLC indices and 6.9 for 
abnormal LFLC indices. Our cut-off for KFLC is in line with a previous multi-center study 
showing a KFLC-index cut-off of 5.9.10 This almost comparable cut-off for the KFLC index 
in two multi-center studies supports its robustness and implies that it can be used as an 
universal cut-off. 
There are some limitations in this study. One limitation was that not all patients were 
diagnosed based on the same MS criteria; most patients by McDonald 2010 (84%) but a few 
with McDonald 2005, which may have influenced the diagnosis of CIS patients particularly. 
CIS patients diagnosed before 2010 may very well be MS patients according to McDonald 
2010, because in the 2005 criteria MS diagnosis was more stringent. None of the patients 
were diagnosed by the new 2017 criteria, because of the retrospective set-up, and thus 
imaging information was not collected. We addresses this problem by pooling all CIS and MS 
patients. Another reason for pooling CIS and MS is that we did not have the data to test CIS 
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converting to MS versus non-converting CIS, because we did not have follow-up data. We 
performed several sensitivity analyses in CIS or MS patients separately, and by reclassifying 
and excluding specific clinical groups (Table 3). In these analyses, similar results were 
observed, suggesting that our results are robust for the total population. Another limitation 
is that we did not repeat the OCB analysis per patient centrally, but relied on the original 
local outcomes. However, we received the samples and OCB status from expertise MS 
centers (participating in the BioMSeu consortium) using standardized protocols.33 Moreover, 
inter-laboratory agreement is reported to be good for OCBs, for example an inter-laboratory 
agreement of kappa>0.8 between 19 participating laboratories in Spain was observed.34  
One more important note is that the best set up for the study would have been if the test 
population should be suspected MS cases and not already diagnosed with MS. Still, as 
provided in supplementary table 2B, we included various inflammatory neurological disease 
controls and quite some patients initially suspected for demyelinating disease. 
Alongside the sensitivity and specificity results of the indices, we found significantly 
increased FLC concentrations and quotients in CSF of CIS/MS patients compared to the 
control groups. However, our main focus in this study were the FLC indices and not in the 
concentrations of the FLC. To control for blood-CSF barrier function, we used indices instead 
of concentrations. 
Combination of different markers (KFLC index-OCB, LFLC index-OCB and KFLC index-LFLC 
index) compared to the single measurement OCB, showed that the combination KFLC index-
OCB compared to single OCB gave a slightly higher sensitivity (.88). However, the specificity 
became lower (.83). The same results were seen in the combination LFLC index-OCB and 
KFLC index-LFLC index compared to single OCB. By definition the sensitivity become higher 
and the specificity lower when you decide beforehand that the combination test will be 
positive when the test is positive in one of the two. 
For clinical practice, the KFLC index is more accurate in excluding CIS/MS compared to OCB 
but for ruling in a diagnosis of CIS/MS, analysis of OCB appears to be more accurate. If we 
replace OCB by KFLC in diagnostic practice there is a slightly higher chance that a patient 
with a diagnosis different from MS will get the diagnosis of MS and maybe unnecessarily 
exposed to potential negative side effects of early treatment. Since the KFLC-index is more 
sensitive at the cost of a lower specificity, we should stress that replacement of OCB by the 
KFLC-index is not optimal to arrive at high diagnostic certainty. However, with the higher 
sensitivity of KFLC, an earlier treatment start may be considered. Whether it is an option to 
start treatment based on the KFLC result and clinical/MRI findings according to the novel 
McDonald criteria, or whether the treatment may be adapted after a first year evaluation, is 
subject of further studies and discussions.
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1In conclusion, this study indicates that the KFLC-index is a valid tool in the diagnostic 
process of MS. Since this marker is measured by a faster and rater-independent analytical 
procedure, it should be considered as a potential cost-effective replacement of the OCB, 
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Supplementary Figure 1. Flow-chart of patient selection.
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Blood platelet RNA enables the 
detection of multiple sclerosis
Chapter 2
Abstract
Objective: In this proof of concept study, we evaluate the diagnostic potential of spliced 
blood platelet RNA for the detection of MS.
Methods: We isolated and sequenced platelet RNA of blood samples obtained from 
57 MS patients and 66 age- and gender-matched healthy controls (HCs). 60% of the 
matched samples were employed to develop a particle swarm-optimized (PSO) support 
vector machine classification algorithm. The remaining 40% of the samples served as an 
independent validation series. The MS patients are part of an early inception cohort, in 
which patients were included at diagnosis and followed annually.
Results: In total, 1249 RNAs with differential spliced junction expression levels were 
identified between platelets of MS patients (n=57) as compared to HCs (n=66), including 
EPSTI1, IFI6, and RPS6KA3, in line with reported inflammatory signatures in the blood of MS 
patients. The spliced platelet RNA was subsequently used as input for the development of 
a diagnostic MS classifier capable of detecting MS with 80% accuracy in the independent 
validation series (n=50, AUC: 0.87, 95%-CI: 0.77-0.97, p<0.001).
Conclusions: Spliced platelet RNA may enable the blood-based diagnosis of MS, warranting 
large-scale validation.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder affecting the central 
nervous system. Clinical assessment, magnetic resonance imaging (MRI), and cerebrospinal 
fluid (CSF) analysis play important roles in the diagnostic process.1 The field of MS biomarker 
discovery is thriving and the search for precise diagnostic tests continues. So far, no blood-
based biomarker for MS has been confirmed.2 Minimally invasive blood-based biomarkers 
would complement current MS diagnostics and monitoring. 
During the final stages of thrombopoiesis, platelets are loaded with pre-mature messenger 
RNAs (pre-mRNAs) before being released from the megakaryocyte.3 As a result, platelets 
contain a rich RNA repertoire that can change during megakaryocyte development but also 
during platelet formation and platelet circulation (Figure 1A). Especially the change of RNA 
transcripts during circulation, possibly achieved by specific splicing queues, is of relevance 
in the present study. Platelets respond to activating signals from their environment with 
specific splicing of their pre-mRNAs and potential uptake of RNA from different cell types, 
leading to a unique and dynamic RNA repertoire.4–6 It has been shown that RNA isolated 
from tumor-educated platelets, platelets subjected to RNA changes in patients with cancer, 
may lead to highly accurate identification of traces of the tumor in blood,7 independent of 
inflammatory conditions.4 
Blood platelets are able to participate in inflammatory responses by secreting different 
cytokines and interact with different cell types, such as leukocytes and vascular cells.6 
Furthermore, platelets may be involved in the progression and pathogenesis of MS.8,9 It 
has been observed that platelets from MS patients exhibit high levels of activation.10–12 
Interestingly, in vivo murine studies demonstrated that platelet depletion reduces MS disease 
severity, suggesting that platelets could serve as target for new therapeutic approaches.12 As 
a result of their involvement in the immune response and potential role in the progression 
and development of the disease, we hypothesize that blood platelets of MS patients contain 
a disease-related RNA-signature which could be used as a diagnostic tool (Figure 1A).
Results
Platelet collection 
Blood was collected from healthy controls (HCs) (n=66) and MS patients (n=57) in EDTA-
coated Vacutainer tubes. All patients were diagnosed according to the revised McDonald 
criteria1 and had relapsing remitting MS for at least 10 years. Of the MS patients, 17 were 
male and 40 were female, resulting in a ratio of 1:2.4 (Table 1 and S1). All 66 HCs were age- 
and gender-matched. At the time of blood draw, the disability status of MS patients was 
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examined according to the Kurtzke Expanded Disability Status Scale (EDSS) and an MRI scan 
was acquired. Although all patients were in clinical remission, 29 of them showed new T2-
hyperintense lesions compared to an earlier performed MRI scan (Table 1). 
Platelet RNA as a diagnostics tool for MS 
Platelet RNA was sequenced and analyzed according to a previously published protocol13 
(Figure 1B). Briefly, platelets were isolated from whole blood by differential centrifugation, 
platelets were lysed, and RNA was isolated. The RNA was subsequently subjected to RNA 
amplification and prepared for RNA-sequencing on the Illumina platform. 
We employed our previously published thromboSeq classification software for algorithm 
development.4,13 First we randomly selected from the full dataset 17 MS and 19 HCs samples 
(30% of the total sample size) and assigned those to the training series, employed for 
biomarker RNA panel selection. Then, the algorithm optimized the biomarker panel towards 
accurate prediction by a readout of the randomly selected evaluation series (n=17 MS and 
n=20 HCs). This resulted in a total of 1,249 spliced RNAs which were found to be optimal for 
blood-based MS diagnostics (Table S2). Of this subset, 645 RNAs were increased in platelets 
of MS patients as compared to HCs, including the RNAs EPSTI1 and IFI6, whereas RPS6KA3 
had decreased levels in MS patients as compared to HCs (Table 2; Table S2). 
The classification algorithm reached an accuracy of 84% (area under the curve (AUC): 
0.87, 95% confidence interval (95%-CI): 0.76-0.99; Figure 2) in the evaluation series. 
We subsequently locked the threshold parameters of the algorithm prior to validation, 
employing a separate MS (n=23) and HCs (n=27) sample series, who were not included 
in algorithm development, resulting in an accuracy of 80% (AUC: 0.87 95%-CI: 0.77-0.97, 
sensitivity: 83%, specificity 78%; Figure 2). Post-hoc leave-one-out cross validation analysis 
of the training series resulted in accuracy of 86% (AUC: 0.96, 95%-CI: 0.91-1.00; Figure 2). 
We confirmed the sensitivity of the spliced RNA panel for the detection of MS by randomly 
selecting other training and evaluation series with similar sample sizes (n=1000 iterations, 
median AUC: 0.89, IQR: 0.08), and confirmed the specificity of the spliced RNA panel by 
randomly shuffling the groups of the individual samples (n=1000 iterations, median AUC: 
0.50, IQR: 0.17).
Discussion
We provide evidence that processes involved in MS result in alterations of platelet RNA 
profiles. Furthermore, we were able to demonstrate that RNA derived from circulating blood 
platelets may act as novel blood-based biomarker for MS. Specific splicing of platelet RNA 
in the presence of tumors has already been proposed in previous studies.4,7,14 In the case of 
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MS, platelets appear to play an important and active role in the disease. Platelets seem to 
not just be involved in inflammatory and immune responses but may also contribute to the 
pathogenesis of MS.10,12,15 Here we show that blood platelets isolated from patients with MS 
show a distinctive RNA signature potentially of value for blood-based MS diagnostics.
This study has several drawbacks. First, although we enrolled age- and gender-matched 
healthy controls, no individuals were included with other auto-immune or neuroinflammatory 
disease, potentially reducing the diagnostic accuracy. Second, the sample size was still small, 
potentially resulting in suboptimal algorithm development. Additional samples should be 
collected and evaluated. To reach true clinical relevance, follow-up studies should also focus 
on early-stage MS cases and patients presenting with a clinically isolated syndrome to assess 
the potential for early detection. All patients in the present study displayed a relapsing-
remitting disease course. Future studies should include a broad spectrum of MS subtypes. 
Furthermore, additional studies are needed to gain insight into its ability to potentially 
predict disease progression, and DMT response prediction. 
To our knowledge, this is the first study utilizing RNA found in circulating platelets as a blood-
based biomarker for distinguishing MS patients from healthy individuals. The technique’s 
potential for early diagnosis and treatment-response prediction, however, still need to be 
assessed in further studies. 
Methods
Patients
MS patients participated in a prospective Amsterdam MS cohort study. They were included 
in this cohort at diagnosis and subsequently followed annually untill year six and had 
additional follow-up at year 11. Patients have been diagnosed with MS according to the 
revised McDonald criteria 20171 and were relapse-free and without steroid treatment for 
at least two months (Table 1 and Table S1). All 66 HCs were age- and gender-matched. 
This study was conducted in accordance with the principles of the Declaration of Helsinki. 
Approval of sample collection was obtained from the institutional review board and the 
ethics committee. 
Wet- and dry-lab procedures
Blood processing resulting in platelet RNA seq data, and subsequentially algorithm 
development was preformed according to previously described methods.13 For particle 
swarm-optimized (PSO) enhanced algorithm development, we applied the predefined 
settings; libsize correlation between -0.1 and 1.0, FDR between 0.00001 and 1.0, correlated 
transcripts between 0.5 and 1.0 and ranked transcripts between 200 and all detected 
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transcripts (4,812). We selected the particle (algorithm settings) with best performance 
in the evaluation series following evaluation of 100 particles during 10 iterations (1000 
particles in total).
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Figure Legends
Figure 1. Schematic overview of platelet generation, circulation and possible alteration/education in the presence of MS. 
(A) 1) Blood platelets are generated from megakaryocytes residing in the bone marrow. During the final stages of 
thrombopoiesis, platelets are loaded with pre-mRNAs before budding from the megakaryocyte. 2) Circulating platelets 
respond to activating signals from their environment with specific splicing of their pre-mRNAs and uptake of RNA from 
different cell types. 3) Blood platelets in MS patients show increased levels of adhesiveness and activation. 4) Processes 
involved in MS could potentially lead to specific splicing of platelet RNA, resulting in a disease-specific RNA signature.
(B) Schematic overview of the thomboSeq workflow. Blood was collected in 6 ml EDTA-coated tubes after which the 
platelet RNA is isolated, amplified, and labeled for sequencing. The RNA isolation and amplification steps are subjected 
to quality control using Bioanalyzer analysis.
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Figure 2. Platelet RNA profiles for MS diagnostics. 
(A) ROC-curve of diagnostics of healthy controls and multiple sclerosis patients. Training, evaluation and validation 
series are indicated separately.        
Acc = Accuracy, AUC = area under the curve.
(B) Cross-tables of diagnostics with the optimum point from the ROC-curves. 
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Table 1. Patient characteristics. 
Table 2. Top RNAs with differentials spliced junctions. 
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Background –  Mitochondrial dysfunction is increasingly recognized as an important feature 
of MS pathology and may be relevant for clinical disease progression. However, it is unknown 
whether mitochondrial DNA (mtDNA) levels in the CSF associates with disease progression 
and therapeutic response.
Objectives:  To evaluate if CSF concentrations of mtDNA in MS patients can serve as a 
marker of ongoing neuropathology and may be helpful to differentiate between MS disease 
subtypes. To explore the effect of disease modifying therapies on mtDNA levels in the CSF. 
Methods: CSF mtDNA was measured using a digital PCR CSF mtDNA in two independent 
MS cohorts. The cohorts included 92 relapsing-remitting (RRMS), 40 progressive MS (PMS) 
patients (27 secondary progressive and 13 primary progressive), 50 various neurologic 
disease controls and 5 healthy controls.  
Results: Patients with PMS showed a significant increase in CSF mtDNA compared to non-
inflammatory neurologic disease controls. Patients with higher T2 lesion volumes and lower 
normalized brain volumes showed increased concentration of mtDNA. Patients treated with 
fingolimod had significantly lower mtDNA copy levels at follow-up compared to baseline.
Conclusions: Our results showed a non-specific elevation of concentration of mtDNA in 
PMS patients. mtDNA concentrations respond to fingolimod and may be used to monitor 
biological effect of this treatment.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central 
nervous system (CNS) and is characterized by a high degree of heterogeneity in progression 
and treatment response. To date, validated and discriminative body fluid biomarkers reflecting 
and predicting natural disease progression, crucial for monitoring patients in clinical trials, 
are lacking.1,2 In addition, a biomarker guiding treatment decisions in early disease would be 
very useful in daily clinical practice. Cerebrospinal fluid (CSF) is an accessible source of CNS-
derived products and its composition can reflect molecular changes occurring in the CNS. 
In recent years, impaired mitochondrial function is increasingly recognized as a key 
pathological hallmark of MS.3,4 Demyelination leads to an increase in energy demand in 
order to maintain an appropriate intra-axonal ion balance and could thereby affect the 
number, transport and activity of mitochondria.5-8 Indeed, the number of mitochondria is 
highly increased in chronically demyelinated axons as well as in reactive astrocytes5,7 and 
extensive neuronal mtDNA deletions have been observed in MS cortical brain samples.9 
Furthermore, significantly higher neuronal mtDNA copy numbers were found in MS normal-
appearing gray matter compared to grey matter of non-neurological disease controls.10 
Mitochondria contain circular DNA (mtDNA) encoding 37 genes11,  which  is more resistant to 
degradation by nucleases than nuclear DNA and can thereby be detected in CSF. A significant 
decrease in circulating cell-free mtDNA in CSF samples of both asymptomatic patients at 
risk of AD and symptomatic AD patients was observed12,13  as well as in PD patients14. In 
contrast, CSF mtDNA concentration is markedly enhanced in children with traumatic brain 
injury, suggesting that mtDNA can be released due to acute cellular degeneration.15 So 
far, it is unknown if CSF mtDNA concentrations are related to MS pathology. Based on the 
observations that mitochondrial dysfunction plays a crucial role in MS pathology and the 
possible role of mitochondrial dysfunction in clinical disease progression, we here explored 
the potential of mtDNA levels in the CSF as a candidate biomarker of identify patients with 
progressive disease. We also explored the effect of disease modifying therapies on free 
mtDNA levels in longitudinally obtained CSF samples in a Swedish cohort.
Subjects and Methods
Patients and controls: Dutch cohort
Patients were recruited either in response to an appeal in the periodical of the Dutch MS 
society, or from patients visiting or admitted at our clinic. Patients were invited to voluntarily 
undergo a lumbar puncture, MRI and clinical testing in the period from September 2000 to 
November 2005.16 We included all patients with extensive clinical and radiological data and 
CSF storage within 2 hours after collection. MS patients were diagnosed according to the 
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Poser criteria.17 Patients were classified as having a relapsing-remitting (RRMS), secondary 
progressive (SPMS) or primary progressive (PPMS) disease course according to the criteria 
of Lublin and Reingold.18 In this study we also combined SPMS and PPMS patients in a 
progressive MS group (PMS). The control group was divided in non-inflammatory (NINDC) 
or inflammatory (INDC).19 
2.1.2 Patients and controls: Swedish cohort
The prospective Swedish cohort consisted of longitudinally collected CSF samples in patients 
on disease modifying treatment (DMT). 
CSF samples were collected during routine visits to the neurology clinic at Karolinska 
University Hospital beginning from the launch of fingolimod (Novartis Pharma AG, Basel, 
Switzerland) in Sweden 2011. The sampling period for cases was from April 2011 to May 2015 
and for controls from February 2014 to December 2014. The MS cohort consisted of RRMS 
patients with confirmed disease, where a repeated CSF sampling was indicated for example 
to exclude diseases like Lyme´s disease. In addition, RRMS patients starting fingolimod were 
invited to donate a CSF sample at baseline and at 6-12 months. All MS patients fulfilled both 
the 2010 revised McDonald criteria1. There were no significant concomitant diseases, such 
as infections, and corticosteroids had not been given within three months of sampling. 
2.2. Clinical examination: Dutch and Swedish cohort
Patients (with MS) underwent clinical examination prior to lumbar puncture, including the 
Expanded Disability Status Scale (EDSS),20 which was performed by trained medical doctors. 
All participants provided written informed consent and the local ethics committee approved 
the study. Laboratory personnel were blinded for clinical and radiological data at the time 
of CSF analysis. 
2.3.1 CSF collection: Dutch cohort
CSF was obtained by lumbar puncture between the L3/L4 or L4/L5 intervertebral space 
and collected in polypropylene tubes (Sarstedt, Nurmbregt, Germany). CSF samples were 
centrifuged within two hours at 1800 g at RT for 10 min and stored at -80 °C in aliquots of 
0.5 or 1 ml in Sarstedt polypropylene tubes according to BioMS-eu guidelines.21 
2.3.2 CSF collection: Swedish cohort
Samples were centrifuged immediately after lumbar puncture at 440g for 10min at 
room temperature to separate cells from the CSF supernatant. The supernatants were 
subsequently batched and stored at -80°C until use according to BioMS-eu guidelines.21 
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2.4 MRI acquisition and analysis: Dutch cohort
MRI examination was performed within 3 weeks of CSF collection and only available for 
the Dutch group. MRI scanning was performed at 1.0 Tesla (Siemens Magnetom Impact, 
Erlangen, Germany). As earlier described.22 (see supplementary text-MRI protocol) 
2.5 Cell-free mtDNA analysis
The concentration of cell-free circulating mtDNA in CSF was measured directly in 4.5 µl 
of unpurified CSF by droplet digital PCR in a QX200 platform (Bio-Rad, Hercules, CA, USA) 
following the digital PCR MIQE guidelines 23 and see the supplementary text about primers. 
To avoid contamination of CSF with cells that could be a source of cellular mtDNA, we used 
simultaneous detection of mtDNA and the Bcl-2-associated X (BAX) gene (a single copy 
nuclear gene) in a multiplex ddPCR reaction. The sequence of the BAX probe is:  6 - carboxy 
- 2’,4,4’,5’,7,7’ – hexachlorofluorescein HEX-CCCGAGCTGGCCCTGGACCCGGT-BHQ1. Primer 
sequences targeting BAX gene are: Forward, TTCATCCAGGATCGAGCAGG and Reverse, 
TGAGACACTCGCTCAGCTTC. These primers amplify a single amplicon of 103 base pairs 
corresponding to apoptosis regulator BAX isoform alpha. We confirmed that either single 
or multiplex assay of mtDNA-85 and BAX-103 using the procedures described above yields 
the same results. The ddPCR multiplex assay was performed in a 20 µl reaction volume 
consisting of 1X ddPCR Supermix for probes (BioRad186-3023), 900 nM forward and reverse 
primers, 100 nM mtDNA FAM labeled probe, 300 nM BAX HEX labeled probe and 4.5 µl of 
unprocessed CSF sample. A volume of double distilled water equivalent to CSF sample was 
used as non-template control (NTC). At least 2 NTCs were included in each ddPCR 96 well 
plate. If the nuclear BAX gene copies/µl is higher than 1, this indicates contamination of CSF 
with mtDNA from cells and the CSF samples that contained 1 or more copies of BAX were 
discarded from this study. The detection limit of nuclear gene using our ddPCR method is 0.5 
cells/ µl and more sensitive than CSF cell counts.
Droplet emulsion formation was performed by mixing the 20 µl reaction with 70 µl 
droplet generation oil using a microfluidic droplet generation cartridge and QX200 Droplet 
Generator. End point PCR amplifications were performed using C1000 Thermal Cycler with 
the following conditions: 95 °C 10min; 40 cycles of 94 °C, 30sec and 60 °C 1min; 98 °C 10min. 
The presence or absence of amplification per droplet was evaluated using QX200 Droplet 
Reader and analyzed using QuantaSoft protocol. The results were expressed in copies of 
mtDNA/µl CSF. 
The accuracy and linearity of the reaction conditions of  this ddPCR method to quantify 
mtDNA content in CSF has been thoroughly characterized in previous work (linearity of this 
reaction is 0.999 and the dynamic range is 4-3000 copies/µl).13 
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2.6 Statistical analysis
For statistical analysis, SPSS version 22.0 (Windows) was used. The concentration of mtDNA 
copies were not normally distributed and therefore a natural logarithm was taken. For 
correlation analyses subjects were divided in different groups according to their lesion 
volumes and normal brain volumes based on a median split. We had to make subgroups for 
the volume related comparisons due to non-linearity of the data. 
Based on EDSS scores, patients were divided into three categorical groups (EDSS 0-3.5, 
4.0-5.5, 6-10). The three groups largely reflects, respectively,  patients with no/limited, 
moderate and severe walking impairment.
Differences between the distinct groups were analyzed using linear regression. All results 
were corrected for disease duration as a confounder. In all statistical analyses, age and 
disease duration were both relevant confounders, but due to collinearity only disease 
duration was included as a covariate (as this was the strongest confounder).
To compare baseline and follow up mtDNA copies in the fingolimod-RRMS group, a Wilcoxon 
Signed rank test was performed. A p-value <0.05 was considered significant for main effects. 
3. Results
3.1 Dutch cohort: mtDNA concentration is significantly increased in progressive MS cases 
A total of 120 patients (50 RRMS patients, 40 progressive MS patients (27 SPMS patients, 13 
PPMS patients), 23 NIND and 7 IND controls) were included in the study. The study group 
consisted of 64 women and 56 men with a mean age of 45.5 ± 11.0 years. The median 
disease duration, calculated as the time lapse between the onset of neurological symptoms 
and the time of the lumbar puncture, was 6.5(IQR 0.02 -38.77) years. See table 1 for detailed 
patient characteristics. 
Figure 1 shows the relative increase in the concentration of mtDNA copies for each subtype 
(supplementary figure 1 shows the subtypes with SPMS and PPMS combined as PMS). SPMS 
and PPMS patients showed a significant increased concentration of circulating cell-free 
mtDNA in the CSF compared to NINDC (ratio 3.52, p=0.01 and ratio 2.85, p=0.05, respectively). 
Patients with RRMS showed a trend towards lower concentrations of mtDNA compared to 
SPMS patients (ratio 0.49, p=0.06) (supplementary table 1).Patients with progressive MS 
(PMS) showed a significant increased concentration of circulating cell-free mtDNA in CSF 
compared to NINDC (ratio 3.23, p=0.01). There was a trend for increasing concentrations 
comparing PMS patients with RRMS patients (ratio 1.87, p=0.05). mtDNA concentration did 
not differ between PMS patients and INDC (ratio 2.66, p=0.12) (supplementary table 2). 
MITOCHONDRIAL DNA  57
3
Figure 1. Comparison of mtDNA levels between the subtypes (Dutch cohort).
Scatter plot representing mtDNA concentrations for each individual grouped by diagnosis. The horizontal lines 
correspond to median and interquartile range. NINDC: median 13 (IQR, 5–35) copies/μL; INDC: median 9 (IQR, 
7–42) copies/μL; RRMS: median 22 (IQR, 8–65) copies/μL; SPMS: median 35(IQR, 9–146); PPMS: median 22 (IQR, 
7.5–247.5) copies/μL. *p = 0.01, based on linear regression, adjusted for disease duration. **p = 0.05, based on linear 
regression, adjusted for disease duration. INDC: inflammatory neurologic disease controls; NINDC: non-inflammatory 
neurologic disease controls; PMS: progressive multiple sclerosis; RRMS: relapsing-remitting multiple sclerosis.
Table 1. Patient characteristics and MRI measures, Dutch cohort.
3.2 Validation
To validate the ddPCR results we re-analyzed the high level samples with real time qPCR. 
The data shown in  supplementary figure 2A and 2B show a strong significant correlation 
between ddPCR and real time qPCR for the quantification of mtDNA in CSF samples from 
control and the MS subtypes (r=0.93, p<0.05). 
58 CHAPTER 3
Moreover, there was no correlation between CSF leukocyte count and mtDNA copies 
(Spearman’s rho 0.37, p-value>0.05), indicating that high levels of mtDNA copies were not 
a consequence of cell contamination. Lastly, previous studies have shown there was no 
correlation between mtDNA content in CSF and the presence of 14-3-3 protein, a cytoplasmic 
protein that would be increased in the CSF if samples were contaminated with cells.13
3.3 Disease modifying treatment: Dutch cohort
Nineteen RRMS patients used disease-modifying treatment (DMT) (all interferon-β) at the 
time of lumbar puncture. There was no significant difference in the concentration of mtDNA 
copies between the groups with and without DMT (ratio=1.12 p=0.624). The median CSF 
mtDNA concentration was 16 copies/µl (IQR 7.75-65.25) in the group without DMT and 18 
copies/µl (IQR12-77) in the interferon using groups.
3.4 mtDNA copy numbers in relation to EDSS: Dutch cohort
There was no significant correlation between EDSS scores and the number of mtDNA copies/
µl, although a trend (p=0.08) for a positive correlation was observed when dividing patients 
into different groups (Category 0-3.5 n=39, category 4-5.5 n=30, category 6-10 n=21,  see 
supplementary table 3). 
3.5 mtDNA copy numbers in relation to MRI outcomes in MS patients: Dutch cohort
To study a putative association of mtDNA concentrations and ongoing disease activity, 
we correlated mtDNA concentration levels in MS patients with radiological parameters, 
including T2 lesion volume, gadolinium-enhanced lesions, T1-hypointense lesion volumes 
(BHLV), and normalized brain volume (NBV) as a measure of atrophy. 
The T2 lesion volumes were measured in 78 patients and divided into two groups based on 
the medians. Group 1 had a median T2 lesion volume of 1.53 (IQR 0.13- 4.30) ml and group 
2 had a median T2 lesion volume of 10.53 (IQR 6.55- 16.96) ml. The group with higher T2 
lesion volumes showed increased concentrations of mtDNA copies compared to group with 
lower T2 lesion volumes (ratio 2.13, p=0.03).  
The cohort was divided into two groups based on the presence (n=64) or absence (n=14) 
of gadolinium-enhanced lesions on MRI. There was no significant difference in mtDNA 
concentrations between patients with or without gadolinium-enhanced lesions. 
Black hole volumes were measured in 66 patients and divided into two groups using the 
median. Group 1 had a median BHLV volume of 0.063 (IQR 0.03-0.12) ml and group 2 a 
median BHLV of 0.89 (IQR 0.38-2.34 )ml. There was no significant difference in mtDNA copy 
concentrations between these groups (ratio 0.93, p=0.85). 
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Of 81 patients the normal brain volume (NBV) was available and patients were divided into 
two groups based on the median. Group 1 had a median NBV 1.14 (IQR 1.09-1.18)L and 
group 2 with a median NBV 1.29 (IQR 1.22-1.33)L. Comparing these two groups, the group 
with higher NBV showed significant lower concentrations of mtDNA (ratio 0.42, p=0.02)
(table 2).  
Table 2. MRI outcomes (Dutch cohort).
Table 3. Patient characteristics, Swedish cohort.
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3.6 Analysis of cell-free mtDNA content in CSF in the Swedish cohort
A total of 42 RRMS patients, 20 other neurological disease controls (ONDC) and 5 healthy 
controls (HC) were included in the study. The RRMS patients were divided in two groups: 23 
fingolimod-RRMS patients and 19 differently treated RRMS patients.
The control group consisted of 20 patients undergoing a diagnostic work-up for possible 
neuroinflammatory disease, but where no pathological signs of inflammation were seen on 
MRI or with established markers of immune activation in the CSF (pleocytosis, oligoclonal 
bands, albumin quote, increased IgG index). The diagnoses of this group were paraesthesia 
(n=6), pain syndromes (n=5), psychiatric illness (n=4), vertigo (n=3), essential tremor (n=1), 
Bell´s palsy (n=1), dysphasia (n=1). In addition, 5 individuals served as healthy controls. See 
table 3 for further characteristics of the groups.
For fingolimod users, mtDNA copy number concentrations were almost 50% lower on 
follow-up (median=9.6 copies/µl) compared to baseline (median=17.9 copies/µl), z=-2.52, 
p=0.012, r = -0.37  (see figure 2 and see supplementary figure 3 for a graph with individual 
changes ). 
Figure 2. The effect of fingolimod on mtDNA concentration levels (Swedish cohort). 
To compare baseline and follow-up mtDNA copies in the fingolimod relapsing-remitting multiple sclerosis group (n = 
23), a Wilcoxon signed rank test was performed. The follow-up moment lies after 6–12 months. The horizontal lines 
correspond to median and interquartile range. *p = 0.012 (z = −2.52, r = −0.37).
There was no significant difference in mtDNA copy levels in the fingolimod-RRMS patients (n=23) compared to the 
RRMS group using other DMT (dimethyl fumarate: n=7, interferon-beta: n=12)(ratio=1.65 p=0.089).
There were no significant differences in mtDNA copy levels between the RRMS, ONDC and HC groups in this Swedish 
cohort, see figure 3 and supplementary table 4.
Most of the RRMS patients had an EDSS between 0-3.5. Therefore comparing the different EDSS categories, such as 
performed for the Dutch cohort, was not possible (category 0-3.5 n=35, category 4-5.5 n=3, category 6-10 n=3, missing 
EDSS n=1).
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Figure 3. Comparison of mtDNA levels between the subtypes (Swedish cohort). 
Scatter plot representing mtDNA concentrations for each individual grouped by diagnosis. The horizontal lines 
correspond to median and interquartile range.
RRMS: median 16.8 (IQR, 9.9–30.5) copies/μL; ONDC: median 9.8 (IQR, 6.4–18.6) copies/μL; HC: median 14.3 
(IQR, 7.5–51.3) copies/μL; HC: healthy controls; ONDC: other neurological disease controls; RRMS: relapsing-
remitting multiple sclerosis.
Discussion
The major finding of this study is that concentrations of free circulating mtDNA copies are 
increased in CSF of patients with progressive MS compared with non-inflammatory control 
patients. Also, there was a trend for a modest positive correlation with EDSS specifically 
in progressive MS patients. In addition, we showed that patients with a high T2 lesion 
volume displayed higher mtDNA concentrations compared to patients with a relative low 
T2 lesion volume. The group with lower normalized brain volumes showed higher mtDNA 
concentrations compared to patients with higher normal brain volumes, suggesting a 
positive correlation between the concentration of free circulating mtDNA copies and brain 
atrophy. Altogether, our data may suggest that increased concentrations of cell free mtDNA 
are associated with MS disease activity and progressive disease. 
Reduced levels of mtDNA have been reported in both AD and PD cases and it has been 
speculated that a decrease in mtDNA might be a common phenomenon observed in 
neurodegenerative diseases. In contrast to this, elevated mtDNA levels as we found in PMS, 
have also been detected in CSF samples from children with traumatic brain injury and were 
highly predictive of a poor outcome.15 This might suggest that high values of free circulating 
mtDNA in CSF can be seen as a potential biomarker of acute cellular and mitochondrial 
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stress. It is nowadays widely accepted that neurodegeneration and concomitant brain 
atrophy are common pathological features of MS, particularly in the progressive phase of 
the disease. In MS, demyelination leads to an increase in axonal energy demand, which may 
superimpose effects of neurodegeneration in MS, which is a possible explanation for the 
higher concentrations of mtDNA in progressive MS in this study.
Enhanced mtDNA concentrations in the CSF correlated with high T2 lesion volumes and were 
inversely correlated with normal brain volume suggesting that the increased concentration 
of mtDNA is due to ongoing neuro-axonal damage which is known to be more extensive in 
progressive forms of MS.24,25 Even though longitudinal follow-up MRI scans are lacking, the 
cross-sectional correlations corroborate the finding of higher levels in clinical PMS groups. 
Increased mtDNA levels in the CSF might not only reflect disease progression, but might also 
contribute to the disease process. Mitochondrial DNA is a damage-associated molecular 
pattern (DAMP), which can bind to glial Toll-like receptor-9 and trigger an inflammatory 
response.26 Hence, it is conceivable that enhanced mtDNA levels in the CSF might elicit a 
glial immune response, however additional research is needed to explore the functional 
effects of increased mtDNA concentrations in the CSF of MS patients. 
The cellular origin of enhanced mtDNA levels in the CSF of progressive MS patients is yet 
unknown, however it is conceivable that mtDNA is released upon neuro-axonal injury or 
oligodendrocyte damage, as these are prominent features of progressive MS. Alternatively, 
mtDNA might be secreted into the extracellular compartment by extracellular vesicles 
derived from distinct CNS cells, such as reactive astrocytes, which, particularly in lesions 
that are packed with mitochondria.
Interestingly, an almost 50% decrease in mtDNA copy number was found upon fingolimod 
treatment. Fingolimod is a sphingosine-1-phosphate (S1P) receptor modulator that limits 
the egress of lymphocytes from lymph nodes, preventing them from contributing to 
autoreactive inflammation in the CNS.27 Fingolimod crosses the blood brain barrier and can 
also act on S1P receptors present on  oligodendrocytes, oligodendrocyte precursor cells, 
astrocytes, microglial cells and neurons 
We observed decreased levels of mtDNA copies in patients using fingolimod (compared 
to baseline), suggesting a possible role of mtDNA as a biomarker of fingolimod treatment 
response. It is likely that fingolimod reduces inflammation-mediated cellular damage and 
subsequent release of mtDNA. However the precise mechanism underlying reduced mtDNA 
CSF levels upon fingolimod treatment warrants further investigations. Further comparisons 
with other disease modulatory treatments are needed in order to understand if this effect 
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is specific for fingolimod or a generic response to reduced inflammation and concomitant 
CNS cell injury. 
Altogether, combining our results of no significant difference between the concentration of 
mtDNA in CSF between RRMS and SPMS and the significantly decreased levels of mtDNA 
in CSF in RRMS patients plus the knowledge that fingolimod has been tested in progressive 
MS trials but with negative outcomes28, our study showed a non-specific elevation of 
concentration of mtDNA in PMS patients.
The relatively small sample size and overlap in mtDNA concentrations between patient 
groups warrants cautious interpretation of our data. It is important to validate our findings 
in future research, including longitudinal clinical follow-up to further explore the prognostic 




1. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions 
 to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.
2. Lublin FD, Reingold SC, Cohen Ja, et al. Defining the clinical course of multiple sclerosis: the 2013 
 revisions. Neurology. 2014;83(3):278-286.
3. Witte ME, Mahad DJ, Lassmann H, van Horssen J. Mitochondrial dysfunction contributes to 
 neurodegeneration in multiple sclerosis. Trends Mol Med. 2014;20(3):179-187.
4. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. 
 Nat Rev Neurol. 2012;8(11):647-656.
5. Witte ME, Bø L, Rodenburg RJ, et al. Enhanced number and activity of mitochondria in multiple 
 sclerosis lesions. The Journal of pathology. 2009;219(2):193-204.
6. Zambonin JL, Zhao C, Ohno N, et al. Increased mitochondrial content in remyelinated axons: 
 implications for multiple sclerosis. Brain. 2011;134(Pt 7):1901-1913.
7. Mahad DJ, Ziabreva I, Campbell G, et al. Mitochondrial changes within axons in multiple sclerosis. 
 Brain. 2009;132(5):1161-1174.
8. van Horssen J, Witte ME, Ciccarelli O. The role of mitochondria in axonal degeneration and tissue 
 repair in MS. Multiple sclerosis (Houndmills, Basingstoke, England). 2012;18(8):1058-1067.
9. Campbell GR, Ziabreva I, Reeve AK, et al. Mitochondrial DNA deletions and neurodegeneration 
 in multiple sclerosis. Ann Neurol. 2011;69(3):481-492.
10. Blokhin A, Vyshkina T, Komoly S, Kalman B. Variations in mitochondrial DNA copy numbers in MS 
 brains. J Mol Neurosci. 2008;35(3):283-287.
11. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. The New England journal of 
 medicine. 2003;348(26):2656-2668.
12. Podlesniy P, Figueiro-Silva J, Llado A, et al. Low cerebrospinal fluid concentration of mitochondrial 
 DNA in preclinical Alzheimer disease. Ann Neurol. 2013;74(5):655-668.
13. Podlesniy P, Llorens F, Golanska E, et al. Mitochondrial DNA differentiates Alzheimer’s disease 
 from Creutzfeldt-Jakob disease. Alzheimers Dement. 2016;12(5):546-555.
14. Pyle A, Brennan R, Kurzawa-akanbi M, et al. Reduced CSF mitochondrial DNA is a biomarker for 
 early-stage Parkinson’s disease. Running Head: Cell-free mtDNA in Parkinson’s disease. Ann 
 Neurol. 2015;78:1000-1004.
15. Walko TD, Bola RA, Hong JD, et al. Cerebrospinal fluid mitochondrial DNA: a novel DAMP in 
 pediatric traumatic brain injury. Shock (Augusta, Ga.). 2014;41(6):499-503.
16. Eikelenboom MJ, Petzold A, Lazeron RHC, et al. Multiple sclerosis: Neurofilament light chain 
 antibodies are correlated to cerebral atrophy. Neurology. 2003;60(2):219-223.
17. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines 
 for research protocols. Annals of neurology. 1983;13(3):227-231.
18. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international 
 survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New 
 Agents in Multiple Sclerosis. Neurology. 1996;46(4):907-911.
MITOCHONDRIAL DNA  65
3
19. Teunissen C, Menge T, Altintas A, et al. Consensus definitions and application guidelines for 
 control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple sclerosis 
 (Houndmills, Basingstoke, England). 2013;19(13):1802-1809.
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status 
 scale (EDSS). Neurology. 1983;33(11):1444-1452.
21. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of 
 cerebrospinal fluid collection and biobanking. Neurology. 2009;73(22):1914-1922.
22. Teunissen CE, Koel-Simmelink MJ, Pham TV, et al. Identification of biomarkers for diagnosis and 
 progression of MS by MALDI-TOF mass spectrometry. Mult Scler. 2011;17(7):838-850.
23. Huggett JF, Foy CA, Benes V, et al. The digital MIQE guidelines: Minimum Information for 
 Publication of Quantitative Digital PCR Experiments. Clin Chem. 2013;59(6):892-902.
24. Steenwijk MD, Geurts JJG, Daams M, et al. Cortical atrophy patterns in multiple sclerosis are 
 non-random and clinically relevant. Brain : a journal of neurology. 2015.
25. Popescu V, Agosta F, Hulst HE, et al. Brain atrophy and lesion load predict long term disability in 
 multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry. 2013;84(10):1082-1091.
26. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses 
 to injury. Nature. 2010;464(7285):104-107.
27. Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing 
 multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
28. Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple 
 sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 
 2016;387 (10023):1075-1084.
66 CHAPTER 3
SUPPLEMENTARY figures and  tables
Supplementary Figure 1.  Comparison of mtDNA levels between the subtypes (Dutch cohort).
Scatter plot representing mtDNA concentrations for each individual grouped by diagnosis. 
The horizontal lines correspond to medians and interquartile range.
*indicates p=0.01 based on linear regression, adjusted for disease duration.
INDC=inflammatory neurologic disease controls, NINDC=non inflammatory neurologic disease controls, 
PPMS=primary progressive multiple sclerosis, SPMS=secondary progressive multiple sclerosis, RRMS=relapsing 
remitting multiple sclerosis
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Supplementary Figure 2A and 2B:. Relationship between ddPCR and real time PCR for the quantification of mtDNA 
in CSF in samples from control and MS groups.
A) Amplification plots of mtDNA-85 by real time qPCR. Representative CSF (2ul) samples from each of study groups 
were analyzed in sextuplicate in 20 ul qPCR reaction using intercalated dye detection. NTC = non-template control: 
reaction containing all PCR reagents but without CSF sample was analyzed in parallel. Inset: Shows the melting curve 
of the PCR products and the absence
68 CHAPTER 3
Supplementary Figure 3. The effect of fingolimod individually on mtDNA concentration levels (Swedish cohort).
To compare baseline and follow up mtDNA copies in the fingolimod-relapsing remitting multiple sclerosis group (n=23), 
a Wilcoxon Signed rank test was performed. The follow-up moment lies after 6-12 months.
Supplementary Table 1. Clinical results/outcomes subtypes (SPMS and PPMS separated) (Dutch cohort)
The concentration of mtDNA copies were not normally distributed and therefore a natural logarithm was taken. Using 
log transformation of the regression coefficients, ratios of the mitochondrial DNA concentrations between the different 
subgroups were calculated. Patients with SPMS showed an 3.52 times higher CSF concentration of circulating cell-free 
mtDNA compared to non-inflammatory control patients (p = 0.01).
ratio P value 95% confidence interval
Low bound Upper bound       
INDC to NINDC 1.21 0.73 0.39 3.78
RRMS to NINDC 1.73 0.15 0.80 3.70
SPMS to NINDC 3.52 0.01 1.33 9.32
PPMS to NINDC 2.85 0.05 0.99 8.16
RRMS to INDC 1.43 0.54 0.46 4.45
SPMS to INDC 2.90 0.10 0.79 10.65
PPMS to INDC 2.35 0.21 0.61 9.08
SPMS to RRMS 0.49 0.06 0.24 1.02
PPMS to RRMS 1.64 0.24 0.71 3.85
The analyses was adjusted for disease duration. INDC=inflammatory neurologic disease controls, NINDC=non 
inflammatory neurologic disease controls, PPMS=primary progressive multiple sclerosis, SPMS=secondary progressive 
multiple sclerosis, RRMS=relapsing remitting multiple sclerosis.
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Supplementary Table 2. Clinical results/outcomes per subtypes (Dutch cohort).
The concentration of mtDNA copies were not normally distributed and therefore a natural logarithm was taken. Using 
log transformation of the regression coefficients, ratios of the mitochondrial DNA concentrations between the different 
subgroups were calculated. Patients with progressive MS (PMS) showed a 3.23 times higher CSF concentration of 
circulating cell-free mtDNA compared to non-inflammatory control patients (p = 0.01).
ratio P value 95% confidence interval
Low bound Upper bound       
INDC to NINDC 1.21 0.73 0.39 3.78
RRMS to NINDC 1.73 0.15 0.80 3.70
PMS to NINDC 3.23 0.01 1.32 7.93
RRMS to INDC 1.48 0.54 0.40 4.41
PMS to INDC 2.66 0.12 0.77 9.17
PMS to RR 1.87 0.05 0.99 3.55
All adjusted for disease duration. INDC=inflammatory neurologic disease controls, NINDC=non inflammatory 
neurologic disease controls, PMS=progressive multiple sclerosis (SPMS and PPMS combined), RRMS=relapsing 
remitting multiple sclerosis.
Supplementary table 3. Results EDSS (Dutch cohort) 
The concentration of mtDNA copies were not normally distributed and therefore a natural logarithm was taken. 
Based on EDSS scores, patients were divided into three categorical groups (EDSS 0-3.5, 4.0-5.5, 6-10). Using log 
transformation of the regression coefficients, ratios of the mitochondrial DNA concentrations between the different 
groups were calculated. There was a trend of increasing median mtDNA copies µl /CSF with increasing EDSS categories.
ratio P value 95% confidence interval
Low bound Upper bound
EDSS 4.0-5.5 to EDSS 0-3.5 1.64 0.19 0.78 3.42
EDSS 6-10 to EDSS 0-3.5 2.13 0.08 0.91 4.99
EDSS 6-10 to EDSS 4.0-5.5 1.30 0.52 0.58 2.95
The analyses was  adjusted for disease duration. EDSS=expanded disability severity scale.
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Supplementary table 4. Clinical results/outcomes subtypes (Swedish cohort).
The concentration of mtDNA copies were not normally distributed and therefore a natural logarithm was taken. Using 
log transformation of the regression coefficients, ratios of the mitochondrial DNA concentrations between the different 
subgroups were calculated.
Ratio p value 95% confidence interval
Low bound Upper bound
ONDC to RRMS 0.58 0.07 0.32 1.04
HC to RRMS 0.97 0.95 0.40 2.34
ONDC to HC 1.69 0.22 0.73 3.92
The analyses was adjusted for disease duration. HC= healthy controls, ONDC=other neurologic disease controls, 
RRMS=relapsing remitting multiple sclerosis
Supplementary text – MRI protocol
The protocol consisted of axial pre- and post-contrast T1-weighted (repetition time [TR]=700 
ms, echo time [TE]=15 ms, 5.0mm slice thickness, 0.5mm inter-slice gap) images for atrophy 
measurements and BH assessment and T2-weighted ([TR]=2700 ms, [TE]=90 ms, 5.0mm 
slice thickness with 0.5mm inter-slice gap) images for lesion quantification. 
T1 hypointense or black hole lesion volumes, T2 lesion volumes and presence of gadolinium 
enhanced lesions were quantified using home-developed semi-automated seed-growing 
software based on a local thresholding technique.
Post-contrast T1-weighted images were used to assess brain atrophy. We measured 
normalized brain volumes (NBV), using Structural Image Evaluation, using Normalization of 
Atrophy Cross-sectionally (SIENAX; part of FSL, see http://fsl.fmrib.ox.ac.uk). 
Supplementary text – PCR primers
The sequences of the primers and hydrolysis probe targeting mtDNA are as follows: 
A) Forward mtDNA-85F (5’-CTCACTCCTTGGCGCCTGCC-3’), B) Reverse mtDNA-
85R (5’-GGCGGTTGAGGCGTCTGGTG-3’), C) Hydrolysis probe FAM-mtDNA-85P 
(6-carboxyfluorescein -5’- CCTCCAAATCACCACAGGACTATTCCTAGCCATGCA-3’-Black Hole 
Quencher-1). These primers hybridize an mtDNA target sequence not associated with 
known polymorphisms according to the National Institutes of Health (USA) genetic sequence 
database GenBank. Basic local alignment search within the GRCh38 human genome 
reference sequence indicated that these primers do not have a full complementary target 
in the human genome. The PCR amplicon obtained with these mtDNA primers corresponds 
to bases 14,848-14,932 of the human mtDNA Cambridge reference sequence NC_012920.1. 
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PCR assay conditions were optimized to obtain a single amplicon by melting curve analysis 
and agarose gel electrophoresis. The amplification efficiency observed with these primer 
combinations was more than 0.95. The amplicon was sequenced and found to correspond 
to the expected mtDNA sequence.

C.E. Leurs, M.A. Lopes Pinheiro, L. Wierts, S. den Hoedt, M.T. Mulder, A.J.C 
Eijlers, M.M. Schoonheim, L.J. Balk, B.M.J. Uitdehaag, J. Killestein, H.E. de 
Vries.
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Acid sphingomyelinase: 




Background Multiple sclerosis (MS) lacks reliable biomarkers that reflect disease activity. 
Recent evidence suggests that an altered sphingolipid metabolism is associated with MS 
pathogenesis. 
Objective To explore acid sphingomyelinase (ASM) activity and altered sphingolipid 
metabolism as potential biomarkers in serum of MS patients, to predict active and 
progressive disease, and response to disease modifying therapy (DMT). 
Methods Levels of serum ASM activity were longitudinally analyzed in 40 clinically isolated 
syndrome, 64 relapsing remitting (RR) and 10 primary progressive MS patients, and 22 
healthy controls (HC). ASM activity and sphingolipid levels were measured in a different 
sample of 61 RRMS patients using DMT.
Results A significant difference in ASM activity levels was observed between MS patients 
and HC (p<0.001). There was no correlation between ASM activity levels and disease activity, 
progression or response to DMT. Ceramide (Cer)-C16:0 , Cer-C24:0 and sphingomyelin (SM)-C20:0, 
SM-C22:0, SM-C24:0 and SM-C24:1 showed a significant increase during fingolimod use.
Conclusion Although higher levels in MS patients were found, ASM activity levels do not 
show potential as a biomarker for predicting disease activity, progression or response 
to DMT. Two ceramides and four types of sphingomyelin require further investigation as 




Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central 
nervous system (CNS), characterized by heterogeneity in disease activity, progression, and 
treatment response. The need for reliable blood based biomarkers is obvious.1-5 
Recent evidence suggests that alterations in the sphingolipid pathway may reflect disease 
activity.6, 7 Due to the activity of enzymes essential in the sphingolipid pathway, such as 
sphingomyelinases, ceramides of different chain lengths may be produced and participate 
in different cellular processes such as differentiation, proliferation and programmed cell 
death.8, 9 Increased serum ceramide levels have been detected in CSF of patients with MS.10, 
11 
So far, one study demonstrated an altered protein expression of acid sphingomyelinase 
(ASM) in MS brain samples and identified that reactive astrocytes are the primary source 
of enzyme activity and subsequent ceramide production.7 In general,  ASM is present in 
lysosomes and it may be secreted upon different stimuli.12 Interestingly, both its secretion 
and activity has been associated with inflammatory processes.13, 14
Currently, the only disease modifying treatment (DMT) in MS with a clear role in the 
sphingolipid pathway is fingolimod, which is a phosphorylated sphingosine-1-phosphate 
(S1P)-receptor antagonist. 15 The natural substrate for the S1P receptor, S1P, is also part of 
the sphingolipid metabolism (see figure 1). 
We here explore the potential of ASM activity levels in the serum as a candidate biomarker 
to identify MS patients with an active or progressive disease course. Furthermore, several 
targets of the sphingolipid metabolism were explored longitudinally in relation to DMT.
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Figure 1. Schematic simplified pathway for the sphingolipid metabolism
Subjects and Methods
2.1 Patients
We included 114 MS patients from the MS Center Amsterdam and 22 healthy controls (HC). 
All patients were part of a prospective early inception cohort.16 Patients were followed since 
diagnosis and had at least six-year of follow-up. MS subtypes included clinically isolated 
syndrome (CIS, n=40), relapsing remitting MS (RRMS, n=64) and primary progressive MS 
(PPMS, n=10) according to  the 2005 McDonald criteria.17 A total of 34 CIS patients converted 
to definite MS during the six-year follow-up.
To study the effect of DMT, we additionally selected 61 well-monitored RRMS patients from 
our outpatient clinic on second-line treatment, including 47 RRMS patients on fingolimod 
and 14 RRMS patients on natalizumab. See Table 1A and Table 1B for patient characteristics.
ACID SPHINGOMYELINASE 77
4
Table 1A and 1B. Patient characteristics.
A CIS RRMS PPMS HC
Disease progression part
N= 40 64 10 22
Gender, n female (%) 27(67.5) 44(68.8) 5(50) 6(27.3)
Age in years, mean, SD 36.3±7.6 33.8±8.7 43.8±8.0 44.4±9.1
Disease duration in years, mean (SD) 0.6±0.5 1.8±2.2 2.8±2.6 n.a.
EDSS at baseline, median (IQR) 2.0(1.5-2.5) 2.0(2.0-3.0) 3.0(2.5-4.0) n.a.
Disease modifying treatment at baseline,  n 0 5a n.a. n.a.
Disease modifying treatment at follow-up, n 0 24b n.a. n.a.
Disease duration is calculated with the visit date and the date of onset.
EDSS: Expanded Disability Status Scale; n.a., not applicable; SD: standard deviation
a interferon-β n=3, glatiramer acetate n=1, natalizumab n=1
b interferon-β n=19, glatiramer acetate n=1, fingolimod n=2, natalizumab n=3
B
DMT part Fingolimod Natalizumab
N= 47 14
Gender, n female (%) 28(59.6%) 5(35.7)
Age in years, mean, SD 38.4±9.8 34.4±11.5
Disease duration in years, mean (SD) 11.6±7.6 8.9±8.5
Disease duration is calculated with the visit date and the date of onset.
DMT: disease modifying treatment; n.a., not applicable; SD: standard deviation
2.2. Clinical outcomes
Relapses were defined as a period of new neurological deficits, existing longer than 24 hours 
and not attributable to another cause than MS. Disease progression was measured using 
the Expanded Disability Status Scale (EDSS)18. We defined disability worsening as ≥1 point 
increase in the EDSS score, or ≥0.5 point increase for patients with a baseline score of ≥6.0.19 
EDSS assessment was performed by certified raters. Disease activity was assessed according 
to the 2013 Lublin criteria.20 
We determined patients as responders to fingolimod if there was no disease activity at two 
years of use following the 2013 Lublin criteria.20 
2.3. MRI acquisition 
At baseline, all patients received 1T or 1.5T MRI scans (Siemens Impact), following a standard 
McDonald protocol including 2D dual-echo PD/T2 and post gadolinium T1. 
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At year six, patients (n=65) received 3T-MRI scans (GE Signa HDxt), with the protocol 
including a 3D-T1 weighted fast spoiled gradient-echo sequence, a 2D dual-echo PD/T2 and 
a 2D spin-echo T1-weighted sequence. Brain volumes were analyzed using SIENAX21, after 
lesion filling, providing normalized total brain volume (NBV).
Radiological activity was defined as a new or enlarged (> 50%) lesion on T2-weighted images 
compared with the MRI scan performed at year six follow up compared to the baseline 
scan.  The delta number of T2 lesions on MRI was used to group patients into four separate 
categories for the number of lesions were considered: 0, 1–3, 4–9 and 10 or more T2 
lesions.22 
For the DMT part, patients received MRI scans according to the magnetic resonance imaging 
in MS (MAGNIMS) guidelines on MS diagnosis and patient monitoring.23, 24 
2.4 Serum collection
Serum samples were collected in evacuated blood collection tubes. The samples were kept 
at room temperature, processed within 24h, and stored at the VUmc biobank at -80 ºC.
2.5 ASM activity assay 
ASM activity was quantified using the Acid Sphingomyelinase Assay Kit (Echelon Biosciences, 
Salt Lake City, USA) according to manufacturer’s instructions supplemented with 0,1mM 
ZnCl2 and the standard curve using recombinant ASM as reference. 
2.6 Lipid extraction
Sphingolipids were extracted as previously described25, 26  and based on the modified Bligh 
and Dyer method.27 Samples were analyzed using liquid chromatography-tandem mass 
spectrometry (LC-MSMS) as reported before.26
Nine-point calibration curves were constructed by plotting area under the curve, separately 
for ceramides, sphingomyelins and S1P, for each calibration standard Cer-C14:0, Cer-C16:0, 
Cer-C18:0, Cer-C20:0, Cer-C22:0, Cer-C24:1, Cer-C24:0, S1P, SM-C16:0, SM-C18:0, SM-C22:0, SM-C24:1, 
SM-C24:0 (Avanti polar lipids, Alabaster, AL, USA; SM20:0 and SM22:0 Matreya LLC, PA, USA) 
normalized to the respective internal standard. Correlation coefficients (R2) obtained were 
> 0.99. Sphingolipid concentrations were determined by fitting the identified sphingolipid 
species to these standard curves based on acyl-chain length. Instrument control and 
quantitation of spectral data was performed using MultiQuant software (AB Sciex Inc.). Data 




For comparing the different ASM activity levels in the different subtypes a one-way ANOVA 
was performed. When comparing HC and MS patients an independent  T-test was used. 
In order to asses associations between ASM activity levels and clinical outcomes and MRI 
variables, logistic and linear regression models were used for binary and linear outcomes 
respectively. Due to non-linearity of the data, ASM activity levels were divided in subgroups 
(quartiles). All results were corrected for sex and disease duration. 
The four patient subgroups based on the number of new T2 lesions were compared using a 
one-way ANOVA.
To compare baseline and follow up ASM activity levels in the fingolimod-RRMS group and 
natalizumab-RRMS group, a paired t test was performed. 
To evaluate the effect over time of fingolimod on the levels of ceramide, S1P  and 
sphingomyelinase in fingolimod-RRMS group, a paired t test was performed.
The regression analysis were performed using SPSS version 22.0 (Windows). P<0.05 was 
considered significant (p<0.0074 after Bonferroni correction for multiple testing, considering 
the levels of ceramide, p<0.0083 for the sphingomyelins).
2.8 Standard Protocol Approvals, registrations, and patient consent
The study was approved by the institutional ethics review board and and was registered 
under number 2002.140. All subjects gave written informed consent prior to participation.
Results 
3.1 ASM activity and MS clinical subtypes. 
When pooling CIS, RRMS and PPMS, higher ASM activity levels were observed in patients 
than in HC (p<0.001)(Figure2A). No significant differences in ASM activity were detected 
between the different MS subtypes (p=0.42)(Figure2B).
80 CHAPTER 4
Figure 2A and figure 2B. ASM activity levels in MS subtypes and healthy controls.
To compare the different ASM activity levels in the different subtypes an one-way ANOVA or unpaired T-test was 
performed. 
A: higher ASM activity levels were observed in patients (n=114) compared with healthy controls (n=22)(p<0.001).   
B: no significant differences were detected between the different MS subtypes(p=0.42).
3.2 ASM activity and clinical outcomes.
At year 6, 72.3% of RRMS patients had experienced relapses (median annual relapse rate 
(ARR) of 0.36 (IQR 0.19-0.53)). There was no significant association between the ASM activity 
(baseline value) and disease activity based on the presence of relapses (yes or no) and ARR.
At year 6, 26.3% showed EDSS progression compared with the baseline EDSS.  There was no 
significant association between ASM activity (baseline value) and EDSS progression. 
3.3 ASM activity and baseline MRI scan.
The study population was divided into two groups based on the presence (n=43) or absence 
(n=66) of gadolinium-enhanced lesions on MRI at baseline (five patient did not receive 
gadolinium). The presence of enhancing lesions (yes or no) did not correlate with  ASM 
activity levels and there was no significant association between the ASM levels and T2 lesion 
volumes.
The T1-hypointense lesion volumes were not normally distributed and therefore a natural 
logarithm was taken (median 183.0 ml, IQR 62.0-342.5). Due to non-linearity of the data, 
ASM activity levels were divided in subgroups (quartiles). The T1 lesions volumes were 2.83 
times higher in group 3 of the ASM activity levels (min 1115 pmol/ml/hr - max 1364 pmol/
ml/hr)  compared to group 1 ASM activity levels (min 418 pmol/ml/hr – max 880 pmol/ml/
hr) (p=0.012). When comparing ASM activity levels of group 1 with group 4 (lowest activity 
levels vs highest activity levels), no significant association was found with T1 lesions volumes 
(ratio 1.44, p=0.39). 
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3.4 ASM activity levels and brain volume measurements on MRI at year 6.
At year 6 of follow-up, the normalized brain volumes (NBV, mean 1496.8±50.6), normalized 
grey matter volumes (NGMV, mean 815.3±42.2), normalized white matter volumes (NWMV, 
mean 681.5±30.5), normalized deep grey matter volumes (NDGMV, mean 59.8±3.6) and 
normalized total lesion volumes (median 6.8, IQR 4.1-13.2) were measured. Baseline ASM 
activity levels were not associated with any of the assessed volume measures at year 6 (all 
p-values ≥0.05). 
3.5 Predictive value of ASM activity levels for MRI activity.
Baseline ASM activity levels did not significantly associate with the four separate categories 
in delta number of T2 lesions (p=0.36). When the number of new T2 lesions was used in 
a linear regression model as a continuous variable, there was no significant association 
between ASM activity and the delta T2 lesions (ratio 1.00, p=0.18).
3.6 ASM activity levels during the years.
There were no significant differences between ASM activity levels at baseline compared 
with year 6 (p=0.86).
3.7 Effect of fingolimod and natalizumab on ASM activity levels
Next, we analyzed the potential effect of fingolimod (n = 47) and natalizumab (n =14) on 
ASM activity levels in additional patients specifically selected based on DMT usage. 
There was no significant change in ASM activity levels during follow up with fingolimod 
(p=0.11) or natalizumab (p=0.24).
3.8 Effect of fingolimod on different sphingolipids. 
A total of 25 out of 47 fingolimod users were randomly selected for sphingolipid analysis. 
Ceramides with 7 different acyl chain lengths were analyzed: Cer-C14:0, Cer-C16:0, Cer-C18:0, 
Cer-C20:0, Cer-C22:0, Cer-C24:0 and Cer-C24:1. After Bonferroni correction for multiple testing 
Cer-C16:0 and Cer-C24:0 showed a significant increase during fingolimod use (p=0.0002 and 
p=0.0005, respectively)(Figure3AB).
Sphingomyelins with 6 different acyl chain lengths were analyzed: SM-C16:0, SM-C18:0, SM-
C20:0, SM-C22:0, SM-C24:0 and SM-C24:1. After Bonferroni correction for multiple testing SM-C20:0, 
SM-C22:0, SM-C24:0 and SM-C24:1 showed a significant increase during fingolimod use (Figure 
4ABCD).
S1P levels slightly, but non significantly  decreased when comparing before and during 
fingolimod (p=0.12).
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3.9 Treatment responder vs treatment non-responder.
A total of 30 patients on fingolimod did not show disease activity (no clinical relapse and/or 
occurrence of contrast-enhancing T1 and/or new or enlarging T2 lesions on brain MRI) after 
two years of fingolimod use. Ten patients did show disease activity. There was no significant 
association between the ASM activity levels or sphingolipids at baseline and treatment 
response at year 2.
Figure 3A and 3B. The effect of fingolimod on ceramide levels.
After Bonferroni correction for multiple testing Cer-C16:0 (4A) and Cer-C24:0 (4B) showed a significant increase during 
fingolimod use (p=0.0002 and p=0.0005, respectively). 
Cer: ceramide; FTY: fingolimod
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Figure 4ABCD. The effect of fingolimod on sphingomyelin levels.
After Bonferroni correction for multiple testing specific serum levels of different sphingomyelins showed an increase 
during fingolimod use: SM-C20:0 (5A), SM-C22:0(5B), SM-C24:0(5C) and SM-C24:1(5D)  (p=0.0012, p=0.0002, p=0.0003 
and p=0.0003,respectively). 
SM: sphingomyelin; FTY: fingolimod.
Discussion
The present study extensively explored the potential of ASM activity levels in serum to serve 
as a candidate biomarker in MS. In parallel, levels of several sphingolipids were determined 
longitudinally in relation to DMT. When pooling all types of MS, a significant higher ASM 
activity level was observed than in HC. The increased levels of ASM activity in MS patients 
compared to HC may reflect ongoing inflammatory processes. The activity of ASM allows 
conversion of sphingomyelin into ceramides. Ceramides may induce neuronal mitochondrial 
dysfunction and axonal damage by participating in different cellular signaling cascades 
and processes such as differentiation, proliferation  and programmed cell death.8, 9 So far, 
ASM activity levels have only been determined in the CSF of MS patients, demonstrating 
increased levels compared to other neurological diseases (OND).28 Besides higher levels of 
ASM activity, the number of exosomes that carry ASM in the CSF was significantly higher in 
MS patients than in patients with OND and this was correlated to CSF ASM activity.28 
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ASM activity was not significantly different in the serum of patients with RRMS, SPMS and 
PPMS and we did not find an association between ASM activity and the ARR, disease activity, 
or MRI variables, including enhancing lesions, which suggests that serum ASM activity is not 
a marker inflammation in MS. EDSS progression was not related to levels of ASM activity 
in the current study whereas previous studies have shown that the quantity of ASM (per 
exosome) in the CSF was correlated to the EDSS of MS patients.28 Correlations between EDSS 
and other components in the sphingolipid metabolism such as HexCer16:0 and HexCer24:1 
were also observed (in CSF), 10 suggesting more potential for CSF than serum with respect 
to suitable MS biomarkers. 
In the second part of this study we investigated the association between the sphingolipid 
metabolism and DMT. ASM activity levels did not reflect treatment response. Our data are 
in contrast with an earlier study which showed that fingolimod in MS patients reduced 
the production of pro-inflammatory lipids (such as ceramide) and reduced the mRNA 
expression of ASM in human astrocytes.7 However, we did observe a significant increase 
of two types of ceramides (Cer-C16:0 and Cer-C24:0) and four types of sphingomyelin (SM-C20:0, 
SM-C22:0, SM-C24:0 and SM-C24:1) during fingolimod use. Only one previous study explored the 
effect of fingolimod (and other MS therapies) on different sphingolipids in MS patients29. 
They observed that IFN-ß treatment strongly increased plasma levels of Cer-C16:0, Cer-C18:0, 
Cer-C20:0, and Cer-C24:1 compared to healthy controls, untreated patients, or patients receiving 
fingolimod or natalizumab medication.30 One hypothesis why increasing levels of ceramides 
and sphingomyelin were observed in our study is that fingolimod is an S1P mimicking agent 
and thereby may decrease levels of endogenous S1P, which in turn may lead to increasing 
levels of ceramides and sphingomyelins due to the sphingolipid rheostat. 
In summary, within a relatively small sample size we have shown that there is no association 
between ASM activity and disease activity, disability progression, or MRI measures of tissue 
damage in subgroups of MS patients. In addition, treatment response was not reflected 
by differences in ASM activity levels and S1P. We identified two ceramides (Cer-C16:0 and 
Cer-C24:0) and four types of sphingomyelin (SM-C20:0, SM-C22:0, SM-C24:0 and SM-C24:1) that 
increased during fingolimod treatment and the utility of these markers in treatment 
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Neurology: Neuroimmunology & Neuroinflammtion
Tissue Transglutaminase associates 
with progression of multiple sclerosis
Chapter 5
Abstract
Objective: The clinical course of multiple sclerosis (MS) is variable and largely unpredictable 
pointing to an urgent need for markers for disease activity and progression. Recent evidence 
revealed that tissue Transglutaminase (TG2) is altered in patient-derived monocytes. 
Therefore, we evaluated the potential use of blood cell-derived TG2 mRNA as biomarker in 
patients with MS. 
Methods: In peripheral blood mononuclear cells (PBMCs) from 151 healthy controls and 
161 MS patients, TG2 mRNA was measured and correlated to clinical and MRI parameters 
of disease activity (annualized relapse rate, gadolinium-enhanced lesions and T2-lesion 
volume) and disease progression (Expanded Disability Status Scale (EDSS), normalized brain 
volume and hypointense T1-lesion volume). 
Results: PBMC-derived TG2 mRNA levels were significantly associated with disease 
progression; i.e. worsening of the EDSS over 2 years of follow-up (std ß=0.26), normalized 
brain volume (std ß= -0.18), normalized grey (std ß= -0.15) and white matter volume (std ß= 
-0.17) in the total MS patient group at baseline. In addition, TG2 expression was significantly 
associated with worsening of the EDSS scores over 2 years of follow-up in RRMS patients 
(std ß= 0.26). Similarly, in the PPMS subtype, TG2 mRNA levels were significantly associated 
with EDSS (std ß= 0.48), normalized brain volume (std ß= -0.56), normalized grey (std ß= 
-0.43) and white matter volume (std ß= -0.65) at baseline. In addition, TG2 mRNA associated 
with T1-hypointense lesion volume in PPMS patients at baseline (std ß= 0.48). 
Interpretation: PBMC-derived TG2 mRNA levels hold promise as biomarker for disease 




Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the 
central nervous system (CNS).1, 2 It is characterized by inflammation, demyelination, axonal 
degeneration paralleled by a complex clinical course.3, 4 MS is considered the most frequent 
acquired neurological disease leading to permanent disability in young adults. The severity 
and clinical course of MS varies among patients and is largely unpreditable5, 6, resulting in 
a need for biomarkers to predict the disease course. To date only a few biomarkers have 
been translated into the clinic of which the majority of the clinically used biomarkers detect 
either conversion from clinically isolated syndrome (CIS) to MS (e.g. IgG oligoclonal bands) 
or treatment response (e.g. anti-drug antibodies).7  In addition, several of the clinically used 
or proposed biomarkers rely on cerebrospinal fluid (CSF) collection, which is an invasive 
procedure. 
Neurofilaments (Nf) are emerging as the most promising biomarker in MS. In fact, CSF-
derived NF light (NfL) chain has been identified as a biomarker for disease activity and for 
treatment response in MS patients. It is considered to reflect early, acute, inflammatory-
mediated axonal damage. However, it correlates less accurately with disease progression.8 
Therefore, there is an unmet need for biomarkers that predict MS progression and can be 
derived from blood. 
Tissue Transglutaminase (TG2 or Transglutaminase 2) is a Ca2+-dependent enzyme that 
cross-links (among others) molecules belonging to the apoptotic pathway9,10, membrane 
trafficking11, 12 and cytoskeleton reorganization.13,14 In addition, its expression is regulated 
by inflammatory mediators.15-17  Recently, we showed the presence of TG2 in infiltrating 
macrophages in MS lesions18 as well as increased TG2 mRNA in MS patient-derived 
monocytes19 suggesting a possible role for monocyte/macrophage-derived TG2 in the 
pathophysiology of MS. Indeed, inhibition of TG2 activity reduced the influx of monocytes 
into the CNS and concomitant ablation of clinical symptoms has been observed in rats 
suffering from chronic-relapsing experimental autoimmune encephalomyelitis (cr-EAE).20 In 
addition, TG2 has been proposed to contribute to encephalitogenic T cell differentiation in 
mice suffering from EAE.21 
The clinical implications of TG2 have already been described for several human diseases. In 
fact, it has been reported that deregulation of TG2 expression and activity are associated 
with tumor invasiveness and metastasis formation.22-24 Moreover, an increase in TG2 can 
be used as an additional biomarker for all grades of cervical dysplasia.25 Furthermore, 
antibodies directed to TG2 are used as a serological marker for the diagnosis of Coeliac 
disease.26,27 Nevertheless, the potential application of TG2 as a blood cell-derived biomarker 
in MS patients has not been studied yet. 
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Hence, the aim of the current study was to assess whether TG2 expressed by peripheral 
blood mononuclear cells (PBMC) is altered in patients with MS and whether TG2 mRNA 
levels associates with measures of disease activity and progression.
Materials and methods
Subjects
From the MS Center Amsterdam (VU University Medical Center), a total of 169 MS 
patients were included from the GeneMSA cohort in the years 2004 and 2005. Patients 
were diagnosed with MS according to the McDonald Diagnostic Criteria28 and also further 
classified either as RR, SP, or PPMS patients.29 Disability was scored at the baseline visit and 
after two years using the Expanded Disability Status Scale (EDSS).30 Inclusion criteria for MS 
patients were: 1) age between 18 and 65 years; 2) EDSS ranging between 0 and 7.5; 3) at 
MRI, all patients had been relapse-free and steroid-free for at least 1 month. In addition, a 
total of 157 healthy control (HC) volunteers were included (blood only). Inclusion criteria for 
HC were: 1) age between 18 and 65 years; 2) no history or family history of MS. The study 
was approved by the local ethical committee. Written informed consent was obtained from 
all participants.
At baseline, in the RRMS group, 37% of the patients (n=39) were treated with disease 
modifying treatment (DMT; n=9 glatiramer acetate; n=29 interferon β; n=1 mitoxantrone). 
In the SPMS group, 22.2% of the patients (n=8) were treated with DMT (n=2 glatiramer 
acetate; n=6 interferon β). In the PPMS group, 9.1% of the patients (n=2) were treated with 
DMT (n=1 interferon β; n=1 methotrexate).
Isolation of primary human peripheral blood mononuclear cells 
At the baseline visit, peripheral blood was drawn by venipuncture, collected into EDTA tubes 
(Becton Dickinson). PBMCs were isolated from the 169 MS patients and 157 HC by density 
centrifugation using Ficoll (Ficoll Isopaque PLUS, GE Healtcare) and stored in liquid nitrogen 
until further processing.
mRNA isolation and cDNA synthesis
Total RNA was isolated from primary human PBMCs using TRIzol Reagent (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer’s instructions. Total RNA was further 
purified using the MicroElute RNA clean up kit (Omega Bio-Tek). The RNA purity was 
assessed using the NanoDrop 1000 (Thermo Scientific). The quality ratios 260/280 and 
260/230 were above 1.9 and 1.7, respectively, for all samples included in the study. Total 
RNA (200 ng/sample) was reverse-transcribed into cDNA using the High-Capacity cDNA 
Reverse Transcription kit (Applied Biosystems) according to the manufacturer’s instructions.
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Semi-quantitative real-time PCR (qPCR)
For semi-quantitative real-time PCR (qPCR), the Power SYBR Green Master Mix (Applied 
Biosystems) was used. The following primer sequences (Eurogentec, Maastricht, the 
Netherlands) were used: TG2 forward 5’-AGAGGAGCGGCAGGAGTATG-3’, TG2 reverse 
5’-AGGATCCCATCTTCAAACTGC-3’, HPRT1 forward 5’-AGCCCTGGCGTCGTGATTAGT-3’, 
HPRT1 reverse 5’-CGAGCAAGACGTTCAGTCCTGTCC-3’, POLR2F forward 
5’-GAACTCAAGGCCCGAAAG-3’, POLR2F reverse 5’-TGATGATGAGCTCGTCCAC-3’.  qPCR 
was performed in LightCycler® 480 Multiwell Plate 384 (Roche, Basel, Switzerland) on a 
LightCycler® 480 Real-Time PCR System (Roche). The reaction mixture (10 μl) was composed 
of 1× Power SYBR Green buffer (Applied Biosystems), 1.86 pmol of each primer and 5 ng 
cDNA. The thermal cycling conditions were an initial 10 min at 95° C followed by 50 cycles of 
15 sec at 95° C and 1 min at 60° C. The specificity of the reaction was checked by melt curve 
analysis of the individual qPCR reactions. The relative expression level of TG2 was determined 
by the LinRegPCR software (version 2014.3; website: http://www.hfrc.nl) using the following 
calculation N0=Nq/ECq (N0=target quantity, Nq=fluorescence threshold value, E=mean 
PCR efficiency per amplicon, Cq=threshold cycle31, after which the value was normalized 
relative to the geometric mean of the mRNA levels hypoxanthine phosphoribosyltransferase 
1(HPRT1) and polymerase (RNA) II polypeptide F (POLR2F). HPRT1 and POLR2F were chosen 
as reference genes as being most stably expressed based on the results of the GeNorm 
software analysis (version 3.5) in which the stability of six different human housekeeping 
genes (GAPDH, MRIP, POLR2F, HPRT1, PGK1, SDHA) was assessed in a random selection of 
MS and HC subject samples.
MRI acquisition and analysis
Of the MS patients, imaging was performed at the baseline visit on a 1.5T MRI scanner 
(Siemens Vision using the standard circularly polarized head-coil) using a standardized and 
previously described protocol.32 The protocol included three-dimensional (3D) T1 weighted 
images (repetition time [TR]: 9.7–20.8 ms; echo time [TE]: 2–4 ms; inversion time [TI]: 300–
400 ms) for brain volume measurements, consisting of 1.0 mm-thick slices and a 1.0×1.0 
mm2 in plane resolution. Additionally, dual echo proton density (PD)-T2-weighted images 
(TR: 2000-4000 ms; TE: 14-20/80-108 ms), with interleaved axial 3.0 mm-thick slices and 
an in plane resolution of 1.0×1.0 mm2 and postcontrast T1-weighted spin-echo images (TR: 
467–650 ms; TE: 8–17 ms; axial 3.0 mm-thick slices with an in plane resolution of 1.0×1.0 
mm2) were obtained for lesion quantification.
Experienced raters manually outlined T2-hyperintense lesions on the PD/T2 images and T1-
hypointense lesions on the T1 weighted spin echo images. Subsequently, lesion volumes 
for T2 lesions (T2LV) and T1-hypointense lesions (T1LV) were calculated. The number of 
gadolinium enhancing brain lesions on postcontrast T1-weighted spin-echo images was 
scored.
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Lesion filling was then applied to the 3D T1-weighted images to prevent an effect of hypo-
intense lesions on brain volumetry.33 Whole brain volumes were than calculated using 
SIENAX (part of FSL 5.0.4) and the recommended settings for brain extraction.34 The whole 
brain volume was then normalized for differences in head-size, resulting in normalized total 
brain volume (NBV), normalized total gray matter volume (NGMV) and normalized white 
matter volume (NWMV) at baseline.
Statistical analysis 
According to the interquartile range (IQR) rule35, 6 HC and 8 RRMS patients were excluded 
from all the analysis based on extreme TG2 mRNA levels (e.g. > 1.5 IQR). All outcomes were 
evaluated for normal distribution. Due to the non-normal distribution of TG2 mRNA levels, 
group comparisons were performed using the logarithmic transformation of TG2 mRNA 
levels as dependent variable in linear regression analyses (correcting for gender and age 
differences). 
Linear regression analysis (MS patients as one group or stratified for the different groups) 
with either EDSS, change in EDSS over two years follow-up (normalized to baseline 
measurement), disease duration, NBV, NGMV, NWMV, T1LV or T2LV as dependent variables 
and TG2 mRNA levels as independent variable were performed while correcting for age 
and gender in order to determine the association between TG2 mRNA levels and clinical 
parameters. Due to the non-normal distribution and to the presence of 0 values in T1LV 
and relative change in EDSS, the association analyses were performed adding +1 to the 
variables prior to logarithmic transformation. Due to the non-normal distribution of T2LV, 
the association between TG2 mRNA level and T2LV was performed using the logarithmic 
transformation of T2LV. 
We additionally investigated the effect of DMTs on TG2 expression, the differences in TG2 
mRNA levels between patients with active/inactive disease (based on presence/absence 
of gadolinium enhancing lesions) and the association between TG2 mRNA and annualized 
relapse rate (ARR) using linear regression analysis corrected for gender and age. In those 
three analysis, the logarithmic transformation of TG2 mRNA was used as dependent variable. 
P<0.05 was considered statistically significant. All the analyses were performed using SPSS 
version 22.0 (IBM Corp, NY, USA).
Results
TG2 mRNA levels in PBMCs of MS patients
A total of 151 HC and 161 MS patients were included in the study. The demographic and 
clinical characteristics of both groups are described in Table 1.
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First, we investigated the levels of TG2 mRNA in PBMCs derived from MS patients and HC 
subjects. The linear regression analysis showed that TG2 mRNA levels were comparable 
between the two groups (median (IQR): HC: 0.41 (0.24–0.65); MS: 0.37 (0.22-0.61); p=0.27). 
In addition, RR MS patients-derived PBMCs showed significantly lower levels of TG2 mRNA 
compared to that of HC subjects (median (IQR): HC: 0.41 (0.24-0.65); RR: 0.35 (0.17-0.57); 
p=0.013), while PPMS patients tended to show higher TG2 mRNA levels than HC subjects 
(median (IQR): HC: 0.41 (0.24-0.65); PP: 0.46 (0.28-1.13); p=0.079). Interestingly, SPMS and 
PPMS patients showed significantly higher TG2 mRNA levels compared to RRMS patients 
(median (IQR): SP: 0.43 (0.26-0.73); RR: 0.35 (0.17-0.57); p=0.01 and PP: 0.46 (0.28-1.13); 
RR: 0.35 (0.17-0.57); p<0.01) (Table 2).
Table 1. Demographic and clinical information of study cohort.
HC MS RRMS SPMS PPMS
N 151 161 103 36 22
Male/Female 57/94 68/93 38/65 16/20 14/08 
Age at BL: Mean ± SD in 
years 
41.9±11.5 45±10 42.7±10 51.4±7.2 51.6±7.9 
Disease duration at BL in 
years, as mean ± SD 
NA 10.6±7.5 8.7±6.7 17.2±7.1 9.1±5.4 
ARR (2 years): Mean ± SD NA 0.10±0.35 0.16±0.43 0.014±0.08 NA 
EDSS at BL: Mean (Range) NA 3.9 (0-7.5) 3 (0-6.5) 5.6 (2-7.5) 5.1 (2-7.5) 
EDSS at 24 months: Mean 
(Range) 
NA 4.1 (1-8) 3.3 (1-6.5) 6.0 (3-8) 5.5 (1.5-8) 
NBV at BL: Mean (ml) ± 
SD 
NA 1500±98.4 1151±104 1465±88 1500±75.6 
NGMV at BL: Mean (ml) 
± SD 
NA 743±60.8 754±61.9 715±54.4 730±51.1 
NWMV at BL: Mean (ml) 
± SD 
NA 757±50.4 757±52.9 750±52.4 769±32.2 
T2LV at BL: Median (25-
75 percentile) 
NA 3.4 (1.5-9.7) 3.56 (1.6-10.2) 3.8 (2.2-13.7) 2.03 (0.8-4.5) 
T1LV at BL: Median (25-
75 percentile) 
NA 0.61 (0.1-2.9) 0.54 (0.1-2.6) 1.36 (0.4-5.7) 0.22 (0.1- 1.6) 
Relapse during 2 years 
follow up (yes/no) 
NA 16/145 15/88 NA NA 
Gd+ at BL (yes/no/
unknown) 
NA 39/120/2 29/72/2 8/28 2/20 
DMT at BL (Untreated/
Treated)* 
NA 112/49 64/39 28/8 20/2 
HC=healthy controls; MS=whole MS group; RR=relapsing remitting; SP=secondary progressive; PP=primary 
progressive; BL= baseline; ARR= Annualized relapse rate; EDSS= Expanded Disability Status Scale; NBV=Normalized 
Brain Volume; NGMV=Normalized Grey Matter 
Volume; NWMV= Normalized White Matter Volume; T2LV= T2 Lesion Volume; T1LV= T1 lesion; DMT at 
BL=disease modifying treatment at baseline; * treatment description to be found in materials and methods section; 
Gd+ at BL=Gadolinium enhancing lesions at baseline; NA=Not Applicable; SD = standard deviation
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Table 2. Linear regression analyses of TG2 mRNA levels between groups.
                                                                                                                                      95% confident interval
p value Ratio Lowerbound Upperbound
HC vs MS .27 .91 .78 1.07
HC vs RRMS .01 .80 .67 .95
HC vs SPMS .32 1.14 .88 1.49
HC vs PPMS .08 1.33 .97 1.86
RRMS vs SPMS .01 1.43 1.08 1.88
RRMS vs PPMS <0.01 1.67 1.20 2.34
PPMS vs SPMS .41 0.85 .59 1.25
HC: M 0.41 (0.24 - 0.65); MS: M 0.37 (0.22 - 0.61); RR: M 0.35 (0.17 - 0.57); SP: M 0.43 (0.26 - 0.73); PP: M 
0.46 (0.28 - 1.13); HC=healthy controls; MS=whole MS group; RR=relapsing remitting; SP=secondary progressive; 
PP=primary progressive; Ratio = Exp(B), exponentiation of the B coefficient; TG2 mRNA levels were not normally 
distributed and therefore the natural logarithm was taken. TG2 mRNA distribution in the different groups is expressed 
as median (IQR)
Association of TG2 mRNA with measures of disease activity 
Next, we determined whether PBMC-derived TG2 expression has any potential relevance 
as read out for disease activity. We observed no significant association between PBMC-
derived TG2 mRNA levels and measures of disease activity. In fact, TG2 mRNA levels did not 
significantly associate with (1) the presence or absence of gadolinium-enhanced lesions, (2) 
presence of relapses during follow-up (3) use of DMTs and (4) annualized relapse rate (ARR) 
either in MS patients or any MS subtype. In addition, no significant association was present 
between TG2 mRNA levels and T2LV (Table 3).
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Table 3. Association of Tg2 mRNA with measures of disease activity.
                                              Median of relative TG2 mRNA                         95% confident interval
Type yes no p value Ratio Lower bound Upper bound
MS Gd+ at BL .30 .39 .16 .83 .63 1.08
Relapse during FU .41 .36 .73 1.07 .71 1.61
DMT at BL .35 .38 .64 .94 .73 1.21
RRMS Gd+ at BL .35 .38 .08 .75 .55 1.03
Relapse during FU .39 .33 .65 1.10 .72 1.69
DMT at BL .30 .35 .92 .98 .73 1.32
ARR






P value Std β
MS .98 - .002
RRMS .77 .03
SPMS .09 - .33
PPMS .07 .43
MS= all groups combined; RR=relapsing remitting; SP=Secondary Progressive; PP= Primary Progressive; Gd+ 
=Gadolinium enhancing lesions; DMT= disease modifying treatment; BL= baseline, ARR= Annualized Relapse Rate; 
T2LV= T2 lesion Volume; Ratio = Exp(B), exponentiation of the B coefficient; NA=Not Applicable; std β= correlation 
coefficient
Table 4. Association of TG2 with measures of disease progression.
MS p value RRMS p value SPMS p value PPMS p value
EDSS(std β) .26 <0.001* .05 .61 .37 .03* .48 .03*
EDSS∆(std β) .16  .05 .26 .02* -.19 .30 .04 .87
NBV(std β) -.18 .02* -.15 .09 -.18 .37 -.57 <0.01*
NGMV(std β) -.15 .03* .12 .16 -.05 .80 -.43 .02*
NWMV(std β) -.17 .03* -.15 .18 -.25 .21 -.65 <0.01*
T1LV (std β) .05 .54 .01 .93 -.04 .81 .48 .046*
MS= all groups combined; RR=Relapsing Remitting; SP=Secondary Progressive; PP= Primary Progressive; EDSS= 
Expanded Disability Status Scale; NBV=Normalized Brain Volume; NGMV=Normalized Grey Matter Volume; 
NWMV= Normalized White Matter Volume; T1LV= T1 Lesion Volume; NA=Not Applicable; std β= correlation 
coefficient; * =significant effect ∆ EDSS Change in 2 years.
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Association of TG2 mRNA with measures of disease progression 
In addition to disease activity, we determined whether PBMC-derived TG2 mRNA is 
potentially relevant as a read-out for disease progression (Table 4). Indeed, TG2 mRNA 
was positively associated with clinical disability, i.e. EDSS score at baseline in MS patients 
(std. ß=0.26; p<0.001) (Fig 1A). Moreover, TG2 mRNA levels associated positively with EDSS 
scores at baseline in SPMS patients (std ß=0.37; p=0.03) and PPMS patients (std ß=0.48; 
p=0.03) (Fig 1G). Interestingly, in MS patients and in particular in RRMS patients, TG2 mRNA 
levels were associated with worsening of disability, as measured by the change in EDSS 
score, over a 2 year follow-up (MS: std. ß=0.16; p=0.05 and RR: ß=0.26; p=0.02) (Fig 1B and 
F, respectively).
Furthermore, in MS patients, a significant negative association of TG2 mRNA with both 
NBV (std ß=-0.18; p=0.02), NGMV (std. ß=-0.15; p=0.03) and NWMV (std. ß=-0.17; p=0.03) 
at baseline was observed (Fig 1C-E, respectively). Similarly, in PPMS patients, a significant 
negative association between TG2 mRNA levels and NBV (std ß=-0.56; p=0.01), NGMV (std 
ß=-0.43; p=0.02;) and NWMV (std ß=-0.65; p<0.01) at baseline was observed (Fig 1H-J, 
respectively). 
Interestingly, in PPMS patients also T1LV at baseline showed a significant positive association 
with TG2 expression levels (std ß=0.48; p=0.04) (Fig 1K).
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Figure 1. Association of TG2 with measures of disease progression in (subtypes of ) MS patients. 
Association of PBMCs-derived TG2 mRNA levels with A) Expanded Disability Status Scale (EDSS); B) relative change 
of EDSS over 2 years follow-up; C) normalized brain volume (NBV); D) normalized gray matter volume (NGMV) 
and E) normalized white matter volume (NWMV) in MS patients. Association of PBMCs-derived TG2 mRNA levels 
with F) relative change of EDSS over 2 years follow-up in RR MS patients. Association of PBMCs-derived TG2 mRNA 
levels with G) Expanded Disability Status Scale (EDSS); H) normalized brain volume (NBV); I) normalized gray matter 
volume (NGMV); J) normalized white matter volume (NWMV); K) T1 lesions volume (T1LV). Linear regression 
analysis was performed controlling for gender and age. Relative change of EDSS was calculated as Log (1+Relative change 
EDSS). T1LV was calculated ad Log(1+T1LV).
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Discussion
During the last decades, there has been an increasing interest in TG2 as a potential 
prognostic marker or therapy target in various human pathologies.36-38 Previous research has 
highlighted the possible role for TG2 in the pathogenesis of MS19,39 as well as in its animal 
model experimental autoimmune encephalomyelitis (EAE). 20,21,40 In search for potential 
blood-derived biomarkers, this study is the first to report PBMC-derived TG2 mRNA levels 
in MS patients, and in its clinical subtypes, in relation to markers of disease activity and 
progression. 
First, we found no difference in TG2 mRNA levels between MS patients as a group and HC 
subjects, probably due to high variability in expression levels in the group of MS patients. 
Next, we observed that in PBMCs derived from RRMS patients significantly lower levels of 
TG2 mRNA were measured compared HC subjects, whereas in PBMCs of SPMS and PPMS 
patients more TG2 mRNA was found. In a previous study, we observed clear enhanced levels 
of TG2 mRNA in blood derived monocytes from MS patients.19 The current study presents a 
different TG2 expression pattern in MS patient-derived PBMCs. Thus far, regulation of TG2 
expression in the whole PBMC population has not been studied, but it is known that TG2 
expression is induced in monocytes and macrophages by the anti-inflammatory cytokine 
interleukin-419.41 Lymphocytes, in particular T-cells, have also been described to produce 
TG2.42,43 Thus, our data may indicate that TG2 expression is regulated by inflammation 
within several cell subtypes of the PBMC population. Nevertheless, PBMC-derived TG2 
mRNA levels do not differ between MS patients and HC subjects and, therefore as such, it 
cannot clearly discriminate between the two groups. 
Regarding the association between TG2 and measures of disease activity (i.e. presence 
of a relapse, annualized relapse rate, Gd+ lesions and T2-lesion volume), no significant 
associations were found, suggesting that the presence of active disease is not associated 
with the level of TG2 mRNA in PBMCs. Moreover, TG2 mRNA levels were not associated 
with the use of DMTs, which target inflammatory processes ongoing during MS. Although 
we cannot draw conclusions on individual MS patients, this finding suggests that the 
inflammatory status of the disease does not affect TG2 expression in PBMC’s. 
In addition, association between TG2 expression and measures for disease progression was 
evaluated. Interestingly, we observed that TG2 mRNA levels significantly associated with 
clinical and radiological measures of disease progression; In fact, TG2 expression showed 
significant association with patients disability (EDSS) as well as NBV, NGMV and NWMV 
at baseline in both the total group of MS patients and in PPMS patients. Furthermore, 
in PPMS patients, TG2 mRNA was also significantly associated with T1LV. Together, these 
data indicate that in particularly in PPMS patients, PBMC-derived TG2 mRNA levels are 
TISSUE TRANSGLUTAMINASE 101
5
associated with progression of the disease and axonal damage. Although the described 
associations were detected cross-sectionally, TG2 mRNA also showed power to associate 
with disease progression longitudinally; in fact, in both the total group of MS patients and 
in the RRMS subtype, TG2 mRNA levels at baseline were associated with worsening of the 
clinical symptoms (change in EDSS) over a 2 year follow-up. Thus, we are the first to point to 
PBMC-derived TG2 mRNA as biomarker for disease progression in MS patients as group, and 
more specifically in the PPMS or RRMS subgroups of MS patients. Subsequent prospective, 
longitudinal studies in MS patients are required to evaluate individual PBMC-derived TG2 
mRNA levels over the course of the disease in association with measures of disease activity 
and in particular, disease progression. This may eventually result in a patient predictive 
blood-derived biomarker for disease progression in RRMS and PPMS patients for which 
there is an unmet need.
To date, many of the proposed candidate biomarkers for MS disease activity and progression 
are measured in the CSF which can only be collected through an invasive procedure, thus 
making a CSF-derived biomarker less patient friendly over prolonged time. In addition, 
there is an urgent need for biomarkers that can predict disease progression and reflect 
ongoing axonal damage specifically in progressive patients. To date, NfL seems to be most 
promising as a marker of MS disease activity and response to DMT44-47 being also validated 
in serum samples.48,49 Although some recent papers also suggest correlations with disease 
progression in MS8,50, this has to be confirmed. In addition, serum level of glia fibrillary acid 
protein (GFAP) has been proposed as biomarker for disease severity in PPMS patients.51 
However, no association with MRI parameters were found.51 
In conclusion, the novel findings reported in this study indicate that PBMCs-derived 
TG2 mRNA levels associate with clinical and radiological measurements of MS disease 
progression and therefore holds promise as biomarker for disease progression in MS and 
especially in PPMS patients.
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Serum neurofilament light levels 
do not reflect disability progression 
in natalizumab-treated relapsing 
remitting multiple sclerosis patients
Chapter 6
Abstract
Objective: To investigate the potential of serum NfL (sNfL) as a biomarker of disability 
progression during natalizumab (NTZ) treatment.  
Methods: We measured sNfL longitudinally in a cohort of 89 NTZ-treated RRMS patients 
followed clinicallyfor a median of 5.2 (range 3-10) years. We examined whether sNfL at 
baseline (BL) and after 12 months of treatment predicted disability (EDSS) progression in the 
following 2 years, and whether the longitudinal trajectories of sNfL levels differed between 
progressors and non-progressors. 
Results: We observed a significant reduction in sNfL levels at 3 months (median sNfL at BL 
14.8 pg/ml, median sNfL at 3 month 11.1 pg/ml), which reached its nadir of close to 50% of 
BL levels at 12 months (median SNfL at 12 months 7.9 pg/ml) after NTZ initiation. Between 
the year 1 follow-up visit and year 3, 35/89 (39.3%) individuals showed EDSS progression. 
We found no difference in the longitudinal dynamics  of sNfL in progressors versus non-
progressors. sNfL levels at BL and at 12 months did not predict EDSS progression in the 
following 2 years.
Conclusion: Our findings confirm the potential of sNfL to monitor the reduction in focal 
inflammatory damage that accompanies NTZ introduction, but sNfL fails to capture longer-
term EDSS worsening during NTZ treatment. 
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Introduction
Multiple Sclerosis (MS) is a chronic inflammatory and degenerative disease of the central 
nervous system (CNS). In a majority of patients, the initial clinical course of the disease 
is characterized by the occurrence of relapses followed by remissions (relapsing remitting 
MS, RRMS). With time, the relapse rate wanes, and patients transition progressively into a 
clinical phase characterized by gradual accumulation of disability (secondary progressive 
MS, SPMS), which builds up independently of the occurrence of relapses. In the last two 
decades, the number of treatments to significantly reduce relapse rates in RRMS has 
steadily risen.1 Of these treatments, natalizumab (NTZ), a humanized monoclonal antibody 
against cell adhesion molecule alpha4-integrin,  is one of the most effective.2  The molecular 
mechanisms driving long-term disability progression in MS are unclear.3 Although most 
prominent in SPMS, disability progression occurs insidiously in early RRMS patients, at least 
partially independently of relapses and/or new T2 or Gadolinium-enhancing (GE) lesions.4 
Treatments that significantly hamper the rate of disability progression are scarce, indicating 
progression involves mechanisms that differ from relapse-related neuroaxonal damage. In 
order to evaluate the potential of novel therapies to reduce progression rate and disability 
accumulation, biomarkers allowing to quantify and/or predict this process are needed.
Neurofilament light (NfL) is a cross disease axonal damage biomarker 5which increases in 
cerebrospinal fluid (CSF) and serum of RRMS patients during relapses and concomitantly 
to the appearance of new T2 and/or GE lesions, returning to baseline within a couple of 
months of the acute event.6, 7  In addition, NfL levels decrease in individual RRMS patients 
after disease modifying therapy (DMT) initiation.8 This finding was reported for all DMTs, 
including injectable DMTs, fingolimod, natazimab, rituximab and alemtuzumab.9-12 The 
magnitude of the decrease in NfL levels correlates with the efficiency of the DMT in reducing 
relapse rate, and NfL was reported to further decrease in individuals switching from first-line 
to second-line DMTs10. Together, these data indicate NfL is a valid marker reflecting acute 
neuroaxonal damage, and holds high potential to monitor inflammatory disease activity in 
individual MS patients in the clinical setting. 
Recent studies suggests that there is an association between serum NfL (sNfL) levels and 
disability progression.7, 13, 14 However, a recent study found no association of baseline NfL with 
year 10 EDSS.15 It remains unclear whether NfL may predict or reflect disability progression 
in the absence of acute focal inflammation-related neuroaxonal damage. In view of the anti-
inflammatory effectiveness of NTZ,  studying NfL levels during NTZ treatment provides the 
opportunity to study the relation of NfL with disease progression independent of inflammatory 
mechanisms.  Therefore, the main aim of this study was to investigate the potential of sNfL as 
a biomarker of disability progression with minimal contribution of relapses and new T2 or GE 




Patients were selected from an ongoing prospective observational cohort study which 
was initiated in 2006 at the VU University Medical Center, Amsterdam, The Netherlands. 
RRMS patients were included in this natalzimab cohort study if they were 18 years or older 
at time of NTZ initiation.16 Patients were monitored clinically and radiologically at yearly 
intervals. We selected 89 patients from this cohort, if a minimum follow-up time of 3 years 
from NTZ initiation was achieved. Clinical disease severity was assessed using neurological 
examination and quantified using the Expanded Disability Status Scale (EDSS). The cohort 
was retrospectively divided into 2 outcome groups, according to the presence of disability 
progression. Clinical progression was defined in two ways. First, as an increase in EDSS of 
1.5, 1 or 0.5 in case of a reference EDSS of 0, 1–5 or ≥ 5.5, respectively between year 1 and 
year 3 (Figure 1).17 Next, we applied the EDSSplus, where disability progression was defined 
as progression on one of three assessments (EDSS, 25-FWT, 9-HPT).16, 18 Progression on the 
timed 25-foot walk test (25-FWT) and 9-hole peg test (9-HPT) were  defined as a minimum 
of 20% worsening on both the 25-FWT or the 9-HPT, confirmed after at least 6 months. 
Progression on EDSS, 25-FWT, 9-HPT or MRI during the first year of treatment was excluded, 
in order to exclude the impact of relapse recovery shortly after start of treatment in patients 
showing improvement.16, 19
The local medical ethical committee consented to this study, and all patients gave written 
informed consent for the collection and use of medical data and biological fluids for research 
purposes. This study was in accordance with the ethical principles of the Declaration of 
Helsinki. 
Serum NfL measurement
Blood was collected at the start of treatment, after 3 months, 1 year, 2 years, and at last 
follow-up (Figure 1) via standard vena puncture and centrifuged at 1800 g for 10 min at room 
temperature. The serum was aliquoted and stored at −80°C until analysis. sNfL levels were 
quantified using an in-house developed Simoa assay, as previously described.20 The assay 
was validated prior to use according to standardized international protocols.21 The samples 
of each individual patient were analyzed within one run, and the personnel performing the 
analyses was blinded for the clinical data.
Magnetic resonance imaging
MRI protocols included proton-density (PD)/T2-weighted and postcontrast T1-weighted 
images as earlier described in the paper of Dekker et al.16 MRI scans were obtained at 
baseline and yearly for John Cunningham (JC) virus negative patients, and 3-monthly for 
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patients with a JC virus antibody positive status, according to the progressive multifocal 
leukoencephalopathy (PML) pharmacovigilance protocol. For this study the yearly scans 
were checked for new disease activity.
Statistical analyses
Statistical data analysis was performed using SPSS for windows, version 22. Graphs were 
constructed using GraphPad Prism version 7.02. A probability level of p<0.05 was considered 
statistically significant. Chi-square tests, Mann Whitney U tests and Kruskal-Wallis tests with 
post-hoc Bonferroni corrections were used to compare baseline demographics and clinical 
characteristics. Neurofilament measures were compared using age and gender-corrected5 
univariate analyses of variance (log-transformed data). Binary logistic regression (backward 
selection) was used to identify predictors for EDSS progression and EDSSplus progression.
Results 
Assessment of disability progression
In total, 89 RRMS patients treated with NTZ followed clinically for at least 3 years were 
included in this study (median total follow-up time of 5.2 years, IQR 4.3-6.7). At baseline, 
mean age was 36.9 years (SD +/- 8.5), 74.2% patients were female and median disease 
duration was 7.4 years (IQR 3.8-12.1) (Table 1). Median EDSS after 1 year follow-up was 3.5 
(IQR 2.5-4.5), and median EDSS after 3 years follow-up was 3.5 (IQR 3.0-4.5) (Table 1). During 
the first 3 years of follow-up excluding the first 3 months, 16.9 % patients experienced a 
relapse, and between year 1 and year 3, 6.7% showed new T2 or Gadolinium enhancing (GE) 
lesion(s) on follow-up brain MRI (Table 1). Between the year 1 follow-up visit and the year 3 
follow-up visit, the time-window to define progression in this study,  35/89 patients (39.3%) 
showed EDSS progression (classified as progressors), and 54/89 (60.7%) did not (classified 
as non-progressors) (Table 1). Median disease duration at BL was longer in progressors 
versus non progressors (Table 1, p=0.03). The proportion of individuals with relapses after 
start treatment was low (9 patients and respectively 6 patients) did not differ between 
progressors and non-progressors (Table 1). The percentage of individuals with new T2 or 
GE lesion(s) on follow-up brain MRIs was significantly higher in the progressors versus non 
progressors (p=0.02).
Additionally, the group was divided based on EDSSplus. From the 89 patients, 77 patients 
could be included for the analyses (12 patients had missing data), 33 patients (42.9%) 
showed EDSSplus progression and 44 (57.1%) did not.  
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Table 1. Demographics of the cohort.
Total cohort Non-progressors Progressors p-value 
N (% of whole cohort) 89 (100) 54 (60.7) 35 (39.3) -
% females 74.2 75.9 71.4 ns
Mean age at BL (SD) in years 36.9 (8.5) 35.9 (8.4) 39.3 (8.0) ns
Median disease duration at BL (IQR) in 
years
7.4 (3.8-12.1) 6.4 (3.0-10.4) 9.4 (5.7-15.7) 0.03
Median time from BL to last FU (IQR) 
in years
5.2 (4.3-6.7) 5.0 (4.0-6.3) 5.4 (5.0-7.2) ns
% individuals with relapse during the 
first year of FU, excluding the first 3 
months
6.7 5.6 8.6 ns
% individuals with relapse  during the 
second year of FU
4.5 3.7 5.7 ns
% individuals with relapse  during the 
third year of FU
5.6 7.4 2.9 ns
Cumulative % individuals with relapse 
during first 3 years of NTZ treatment, 
excluding the first 3 months
16.9 11.1 25.7 ns
% individuals with new T2 or GE 
lesions  during the second year of FU
4.5 - 11.4 - 
% individuals with new  T2 or GE 
lesions  during the third year  of FU
2.3 1.9 2.9 ns
Cumulative % individuals  with new  T2 
or GE lesions  during  first 3 years of 
NTZ treatment
6.7 1.9 14.3 0.02
Median EDSS at 12mo FU (IQR) 3.5 (2.5-4.5) 3.5 (2.5-4.0) 3.5 (2.5-5.0) ns
Median EDSS at 24mo FU (IQR) 3.5 (2.5-5.0) 3.0 (2.5-4.0) 4.0 (2.9-5.6) ns
Median EDSS at 36mo FU (IQR) 3.5 (3.0-4.5) 3.0 (2.5-4.0) 4.0 (3.0-5.5) ns
Median EDSS at last FU (IQR) 4.0 (3.0-5.75) 3.5 (2.0-4.5) 5.0 (3.5-6.0) ns
Longitudinal dynamics of serum neurofilament light levels in response to 
natalizumab treatment
NfL was measured in serum on the day of NTZ initiation before the infusion (BL), 3 months, 
1 year, and 2 years after BL, and on the last follow-up visit (Figure 1). In the total cohort, 
median sNfL decreased significantly from 14.8 pg/ml at BL to 11.1 pg/ml at 3 months, 
and reached its nadir of 7.9 pg/ml at 1 year. Baseline levels of sNfL did not differ between 
progressors and non-progressors  (Table 1). In addition, the levels still did not differ between 
EDSSplus progressors and EDSSplus non-progressors (p=0.83)
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Figure 1.
Median and interquartile range of serum neurofilament light (sNfL) in picogram per milliliter (pg/mL) at baseline (BL), 
3 months (3 mo), 12 months (12 mo), 24 months (24 mo) and at last follow-up (FU = median total follow-up of 5.2 
years , IQR 4.3-6.7) in the whole cohort (N=89), in EDSS progressors (N=35), and in non-progressors (N=54). *= 
p<0.05; ns=non-significant.
Serum neurofilament light as a predictor of future disability progression
We investigated predictors of EDSS progression between the year 1 and the year 3 visits, 
using a logistic regression model. sNfL at BL or at year 1 did not predict EDSS progression, 
neither did age at NTZ onset, gender and EDSS at year 1. The only significant predictor of 
EDSS progression was disease duration at BL (p=0.03, OR 1.10 95% CI 1.00-1.19).
As an additional analysis we investigated predictors of EDSSplus progression between the 
year 1 and the year 3 visits. sNfL at BL or at year 1 did not predict EDSSplus progression, 




In this study, we aimed to define the potential of sNfL to reflect and predict disability 
progression occurring independently of relapses or new T2/GE MRI lesion formation, 
collectively referred to as focal inflammatory activity. We took advantage of a cohort of 89 
RRMS patients treated with NTZ, a DMT which is very effective in reducing relapse rates and 
novel T2 or GE lesions, but has no effect on disability progression as assessed by EDSS.22 
Indeed, no clinical or radiological signs of focal inflammatory activity were present in over 
80% of our patients during the follow-up period of a median of 5.2 years, showing the 
effectiveness of the treatment. Nevertheless, 39.3% of the patients showed clinical disability 
progression during a 2-year follow-up period (between year 1 and year 3 visits) after NTZ 
initiation.  Thus, this cohort allowed us to examine disease progression largely uncoupled 
from focal inflammatory activity. 
We observed a reduction in sNfL levels of almost 50% in the total group, that reached their 
nadir within 1 year after NTZ initiation, in accordance with other studies.8, 10 Further, we 
found that the levels of sNfL remained low for the entire follow-up period, which extended 
to up to 10 years. However, we observed no difference in the longitudinal dynamics 
of sNfL levels in progressors versus non-progressors, suggesting sNfL does not capture 
neurodegenerative processes underlying disability progression when uncoupled from focal 
inflammatory activity. From a clinical perspective, this indicates that sNfL shows to be only 
useful to monitor the decrease in focal inflammatory activity that occurs in response to NTZ, 
and not to predict disability progression. In clinical trial settings, these results suggest sNfL 
may not be a sensitive end-point to quantify disability progression and its modification in 
response to DMTs. Recent data showing that sNfL correlates with residual inflammatory 
activity, as monitored by CSF inflammation markers, after NTZ treatment, further support 
the concept that sNfL primarily reflects inflammatory activity.23 
Our results of median baseline values of 15 pg/ml are at the lower side of the range of 
results reported by others7, 24 using the Simoa platform. For absolute levels to be comparable 
between studies, more standardization is needed, and the development of reference 
material to calibrate methods against.  
Recently, sNfL was reported to predict EDSS worsening in the following year, 14 regardless 
of DMT status at time of measurement. In our NTZ cohort, sNfL levels at baseline, and at 12 
months did not predict EDSS progression in the following 2 years and sNfL levels at BL and 
12 months did not differ significantly between both groups. In the study by Barro et al14, 
DMT status was heterogeneous at time of sNfL measurement, with some patients treated, 
others not and none of the patients were on NTZ treatment. Moreover, in the present study, 
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all patients were treated during the assessment of progression, uncoupling damage arising 
from focal inflammatory activity from neurodegeneration. 
Our results are supported by the result of Chitnis et al15 and Siller et al.25, similarly, showing 
no correlation between EDSS progression and baseline sNfL levels. In contrast to the lack 
of a relation with clinical progression, at sNfL levels were correlated with 10 year MRI brain 
lesions and brain atrophy in MS patients in the study of Chitnis. The study by Siller et al. 
similarly demonstrated that brain parenchymal volume decreased more rapidly in patients 
with higher baseline sNfL. In addition, cross sectional relations of NfL, measured either in 
CSF or serum, with EDSS were less strong than with atrophy, as an objective measure of 
pathological progression. Since  in our study, atrophy measurements were not available, the 
question whether sNfL can predict pathological progression independent of focus disease 
activity is still open.
Clinical progression in RRMS individuals was recently characterized and the term “silent 
progression” as suggested by Cree et al.4 Whether the mechanisms underlying silent 
progression involve inflammatory processes that are not targeted by currently available 
DMTs, or by mechanisms independent of inflammation, remains to be determined. 
The strength of this study is the prospective nature of the detailed longitudinal clinical 
and radiological data and longitudinal sample collection. However, the study also has 
limitations. The data would have benefited from a larger sample size and longer follow-up 
duration . Nevertheless, the lack of even a trend towards a difference in longitudinal sNfL 
measurements between progressors and non-progressors strengthens the truthfulness of 
our findings.   
In conclusion, our findings confirm the potential of sNfL to monitor the reduction in focal 
inflammatory damage that accompanies NTZ introduction, but fails to capture longer-term 
EDSS worsening (“silent progression”) that is largely independent of relapse activity. 
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Switching natalizumab to fingolimod 
within six weeks reduces recurrence 
of disease activity in MS patients
Chapter 7
Abstract
Background Natalizumab is an effective treatment in relapsing-remitting multiple sclerosis. 
Mainly because of the risk of progressive multifocal leukoencephalopathy (PML), a substantial 
proportion of John Cunningham (JC) virus  positive patients switch to fingolimod. Previous 
reports show a clear benefit when the duration of a wash-out (WO) period of natalizumab is 
0-3 months in comparison to longer WO periods. However, there is no consensus regarding 
the optimal duration of a WO period under 3 months.
Objective We compared MS disease activity after different WO periods. In addition we 
investigated several factors that possibly influence recurrence of disease activity, including 
serum natalizumab concentration and lymphocyte counts.
Methods From a prospective observational cohort study of natalizumab treated patients we 
selected 52 patients who switched to fingolimod. We divided the patients in three groups 
(<6 weeks, 6-8 weeks, >8 weeks WO). Serum natalizumab concentration and lymphocyte 
count were assessed during and after natalizumab treatment.
Results Patients with a WO period of >8 weeks had a significant higher recurrence of disease 
activity (OR 6.8, 95% CI 1.4–32.8) compared to patients with a WO period of <6 weeks. 
Serum natalizumab concentration and lymphocyte count did not predict recurrence of 
disease activity.
Interpretation A short WO period decreases the risk of recurrence of disease activity. The 
possible impact of a short WO period on the risk of carry-over PML in JC virus positive 
patients remains uncertain.
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Introduction
Natalizumab, a humanized monoclonal antibody targeting the α-4-integrin receptor, is an 
effective treatment in relapsing-remitting multiple sclerosis (RRMS).1 Unfortunately, the 
risk of progressive multifocal (PML), an opportunistic brain infection caused by the John 
Cunningham (JC) virus, complicates the long-term use of natalizumab in JC virus positive 
patients.2 Because of the risk of PML, patients often switch to  alternative disease modifying 
therapy like fingolimod, a sphingosine 1-phosphatereceptor modulator. Natalizumab 
limits lymphocyte transport over the blood brain barrier, whereas fingolimod prevents 
recirculation of lymphocytes from the lymph nodes. The different immunosuppressive 
pathways and the fact that natalizumab may be detectable in the serum up to 6 months after 
discontinuation, may theoretically increase the risk of opportunistic infections like PML.3 
Therefore, it has been suggested to consider a wash-out (WO) period between natalizumab 
discontinuation and fingolimod initiation. However, the length of the WO period remains a 
point of discussion as the increase of disease activity after natalizumab discontinuation is 
a well-known and clinically relevant issue.4, 5 Recent publications have reported an increase 
of disease activity with longer WO periods, resulting in an advised WO period shorter than 
3 months.6, 7 However, even though current evidence is pointing towards the superiority 
of very short WO periods,8, 9 uniformity in how short the WO period should be within the 
timeframe of 2-3 months, is still lacking.
Apart from the WO period, disease breakthrough after discontinuation of natalizumab 
may also depend on natalizumab serum concentration which may vary largely between 
patients and are shown to correlate with disease activity.10, 11 Another important factor 
may be the extent and swiftness by which fingolimod succeeds to reduce the number 
of circulating lymphocytes. Whereas natalizumab is associated with a stable increase 
of peripheral lymphocytes12-14, sphingosine 1-phosphatereceptor modulation caused by 
fingolimod aims to lower amounts of circulating lymphocytes.15, 16 The interplay between 
drug-induced increased and subsequently decreased lymphocyte count may have impact on 
the recurrence of disease activity.   
The aim of our study was to investigate the correlation between the recurrence of disease 
activity within six months of natalizumab discontinuation with different WO periods (<6 
weeks, 6-8 weeks and >8 weeks) and the influence of serum natalizumab concentration 





This study is part of an ongoing prospective observational cohort study conducted at the VU 
University Medical Center including all RRMS patients treated with natalizumab. Patients 
in this cohort are at least annually subjected to a brain MRI and clinical testing including 
Expanded Disability Status Scale (EDSS).17 
We included all patients who switched from natalizumab to fingolimod between February 
2013 and August 2016. We excluded patients who did not start fingolimod within six months 
after discontinuation of natalizumab, or without a brain MRI within six months. All patients 
in the observational cohort gave written informed consent for the use of the clinical, 
laboratory and imaging data for research and teaching purposes. A waiver from our local 
institutional review board stating that the requirements of the Medical Research Involving 
Human Subjects Act did not apply and that official IRB approval was not mandatory for the 
use of these data, was obtained. 
Measurement of clinical disease activity
The main outcome is disease activity within six months of natalizumab discontinuation. 
We assessed disease activity according to the 2013 Lublin criteria.18 Following these criteria, 
disease activity was defined as ‘active’ when the patient had a clinical relapse and/or the 
occurrence of contrast-enhancing T1 and/or new or enlarging T2 lesions on brain MRI.
We collected data of the patients’ clinical files regarding relapses one year before, during, 
and one year after natalizumab use. A relapse was defined as a period of new neurological 
deficit, existing longer than 24 hours, and not attributable to another cause than MS. 
Clinical disability was defined by the Expanded Disability Status Scale (EDSS). We collected 
the EDSS scores at time of natalizumab initiation and at time of switch (initiation of 
fingolimod) from the clinical database of the observational cohort. The EDSS was assessed 
by certified raters.
MRI acquisition
The MRI acquisition and the scan interval was performed according to the MAGNIMS 
guidelines on MS diagnosis and patient monitoring.19, 20 MRI examination was performed 
annually during natalizumab usage in patients with a negative JC virus serostatus. In JC 
virus seropositive patients (all patients described in this study), the frequency of brain MRI 
increased to every 3 months, which is our current pharmacovigilance protocol suggested by 
different international panel guidelines.20, 21 Following natalizumab discontinuation, a follow-
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up scan was performed after 3 and 6 months because of the risk of carry-over PML. The scan 
performed within the first three months of fingolimod treatment, was used as the baseline 
scan of fingolimod treatment. MRI scanning was performed at a 1.5 or 3 Tesla scanner 
(Siemens Magnetom Impact, Erlangen, Germany) including 3D fluid attenuated inversion 
recovery and axial PD/T2 weighted sequences. We assessed brain MRI for active T2 lesions 
(new of enlarging) and contrast enhancing lesions in case gadolinium was administered.
Blood sampling
Blood samples were routinely obtained every three months before natalizumab infusion. 
Blood samples during fingolimod treatment were also routinely obtained following 
our protocol: at baseline, month 1 and 3-monthly from month 3 during the first year. 
Hematological count, including lymphocytes were measured in these samples in the clinical 
chemistry laboratory at the VU University medical center. Serum was subsequently stored 
at -80°C at the biobank at the VU University medical center. In order to assess clearance 
of natalizumab, we measured natalizumab concentration before discontinuation of 
natalizumab and within six months after discontinuation. Natalizumab concentration before 
discontinuation was measured right before a new infusion (trough concentration). Intra-
individual natalizumab trough concentration are stable in a four week interval regimen.22 
Sera were sent to Sanquin Laboratory to measure natalizumab concentration using a cross-
linking assay using polyclonal rabbit anti-natalizumab F(ab)2 fragments for capture and 
a mouse anti-IgG4 monoclonal antibody for detection. This method is described in more 
detail elsewhere.11  Serum JC virus status and indexes were obtained every six months via 
Unilabs, Copenhagen, Denmark.
Statistical analysis
In order to assess the association between disease activity and WO period, we divided the 
WO period into three groups; a WO period <6 weeks, 6-8 weeks and >8 weeks. Differences 
between the distinct groups were analyzed using a logistic regression model and potential 
confounders (sex and age) were analyzed via assessing the change of the regression coefficient 
of the risk factor of interest, before and after adjusting for the potential confounder. If the 
regression coefficient changed more than 10%, the confounder was considered relevant and 
will be adjusted for. No confounders were found and the statistical results did not change 
when comparing adjusted regression models with unadjusted regression models.
The association between disease activity and concentration of natalizumab was studied 
using a multivariable logistic regression model. Results are displayed as an odds ratio (OR) 
with the confidence interval (CI) per unit decrease, adjusted for WO-period.
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For comparing mean natalizumab concentration at certain time points we used the 
independent sample T test, as concentrations were normally distributed. For correlation 
analysis between lymphocyte count and disease activity, a logistic regression model was 
used. Potential confounders were analyzed, but not found. In this analysis, the mean 
lymphocyte count over the last year natalizumab treatment was used as continuous 
variable. Calculations were performed using SPSS version 22.0 (Windows). A p-value <0.05 
was considered significant for main effects.
Results
Demographic characteristics
In our observational cohort, 60 patients switched from natalizumab to fingolimod because 
of the risk of developing PML.  Six patients were excluded because of a WO period longer 
than 6 months. Two patients were excluded because of incomplete imaging during follow-
up.
Of the remaining 52 patients, baseline demographics are described in table 1.
Table 1. Demographic characteristics.
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Figure 1. Disease activity and washout period.
Percentage (%) of patients with disease activity (based on MRI and/or relapse according to 2013 Lublin criteria18) in 
each WO period group. Disease activity increases comparing patients with longer WO periods compared to shorter 
periods. *Indicates an OR 6.8 with 95% CI 1.4–32.8, p = 0.02. WOP: washout period.
Disease activity 
Twenty patients (38.5%) experienced disease activity within 6 months of natalizumab 
withdrawal. Seventeen patients (32.7%) had activity on brain MRI (either new T2 lesions 
and or gadolinium enhancing lesions) and six patients (11.5%) experienced a clinical relapse 
within six months of natalizumab discontinuation. No more than one relapse was reported 
per patient. All relapses occurred after at least three months of natalizumab discontinuation 
with a median delay of 3.9 months (IQR 3.7-4.6). None of the patients developed PML.
Disease activity increased with longer WO periods compared to shorter periods (see figure 
1 and table 2). The patients with a WO period > 8 weeks showed a significant increase in 
disease activity with an OR of 6.8 (95% CI 1.4–32.8, p=0.02) when compared with the group 
of patients with a <6 weeks WO period. Comparing the patients with a WO period >8 weeks 
with a WO period 6-8 weeks, there was no significant difference in disease activity with an 
OR of 3.1 (95% CI 0.8–12.5, p=0.1).  
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Table 2. Disease activity and washout period.
In the group with a WO period >8 weeks (n=18), four patients had a WO of 12 to 24 weeks. 
When comparing <6 weeks WO with a WO of 8-12 weeks (n=14), disease activity remained 
significantly correlated with a longer WO period (OR 7.8, 95% CI 1.5–41.2, p=0.02).
Subgroup analysis comparing disease activity in the group with the shortest WO (<4 weeks) 
with 8-12 weeks WO, shows comparable results in favor of the shortest wash-out (OR 7.2, 
95% CI 1.1-47.9, p=0.04).
Of the six patients experiencing a relapse, 3 patients had a WO-period >8 weeks, 1 patient 
had a WO-period of 6-8 weeks and 2 had a WO-period of <6 weeks. Seventeen patients 
experienced radiological activity. The percentage of patients with radiological disease 
activity increased with longer wash-out periods, i.e. 11.1% in WO-period <6 weeks, 33.3% 
in WO-period 6-8 weeks and 50.0% in WO-period of >8 weeks. Comparable with disease 
activity, radiological activity only appeared statistically significant when comparing the 
group with a WO of <6 weeks with a WO of >8 weeks (OR 7.0, 95% CI 1.2–40.1, p=0.03). In 
the 17 patients experiencing radiological activity, the median number of new T2 lesions was 
3 (range 1 to 24).  Seven patients had a T2 increase of ≥5, five of these patients (71.4%) had 
a wash-out period of >8 weeks. The remaining two had a WO of <6 weeks and 6-8 weeks.
Before natalizumab treatment, the annual relapse rate (ARR) was 1.5±1.0, whereas 
the ARR under natalizumab treatment was 0.05±0.1 and for the year after natalizumab 
discontinuation 0.20±0.5. The ARR before natalizumab treatment did not correlate with 
disease activity after six months of natalizumab discontinuation (OR per unit increase in ARR 
1.1; 95% CI 0.6–1.8, p=0.9).   No correlation was found between the duration of natalizumab 
use and disease activity (OR per additional year of natalizumab use 1.0; 95% CI 1.0–1.0, 
p=0.1).
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Natalizumab concentration
The mean natalizumab trough serum concentration during natalizumab treatment was 
21.6±12.1 µg/ml. Natalizumab concentration was not associated with disease activity 
within six months after discontinuation (OR 1.0 after adjustment for the duration of the WO 
period, 95% CI 1.0–1.1, p=0.9). The 20 patients who experienced disease activity had similar 
natalizumab concentration during natalizumab treatment compared to patients who did 
not experience disease activity (mean concentration of respectively 21.1±10.4 µg/ml and 
21.9±13.2 µg/ml, see figure 2).
Of 42 patients (80.8%), a follow-up natalizumab concentration 4 weeks to 6 months after 
the last natalizumab infusion was available. When the mean concentration was assessed 
longitudinally, we observed an exponential decline of natalizumab concentration as 
expected. On average, three months after the last natalizumab infusion, the natalizumab 
concentration drops below therapeutic levels of 1 µg/ml.23 In the six patients of whom we 
had a natalizumab concentration available 5-6 months after discontinuation, natalizumab 
was still measureable, although at very low values. 
From 16 out of 20 patients who experienced disease activity, follow-up data on natalizumab 
concentration was available. Three months after natalizumab discontinuation, the patients 
with disease activity had a mean concentration of 0.9 µg/ml (n=6) versus 4.2 µg/ml in the 
patients (n=18) without disease activity (p=0.3, figure 3).
Figure 2. Natalizumab concentration and disease activity.
Disease activity (either active T2 lesions and/or gadoliniumenhancing lesions on MRI or a clinical relapse) within 6 
months of natalizumab discontinuation. Natalizumab concentration was not associated with disease activity within 6 
months after discontinuation (OR: 1.0, 95% CI: 1.0–1.1, p = 0.9), after correction for the WO period.
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Figure 3. Longitudinal natalizumab concentration in patients with disease activity versus patients without disease activity.
Follow-up mean natalizumab concentration in patients with disease activity versus patients without disease activity (blue 
line) 6 months after natalizumab discontinuation. At 3 months of natalizumab discontinuation the lines divide, this was 
not statistically significant (p = 0.3). NTZ: natalizumab.
Lymphocyte count and disease activity
Based on the last measured lymphocyte count during natalizumab, the patients were divided 
into two groups, one group with normal lymphocyte count (1.0-3.5 x 10E9/L) and the other 
with increased lymphocyte count (>3,5 x 10E9/L). Correcting for the WO period, we found 
no significant correlation for disease activity (OR 1.0, 95% CI 0.3–3.2, p=0.9).
All patients showed an expected decrease in lymphocyte count at the moment of three 
months fingolimod use (mean difference of 2.8±0.7 x 10E9/L, p=<0.01). In the two groups 
(normal and increased lymphocyte count), we investigated the relative difference of 
lymphocyte count between the last measured lymphocyte count under natalizumab and 
the lymphocyte count at approximately 3 months of fingolimod use. We found no significant 
difference in the relative change of lymphocyte count between the two groups (β=0.03, 
p=0.1, figure 4A and 4B).
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Figure 4. Lymphocyte count in patients (a) with disease activity versus (b) without disease activity.
Follow-up mean lymphocyte count during three different moments in time. NTZ: mean lymphocyte count during 
last infusion of natalizumab; NTZ-FTY: lymphocyte count during the washout period (in between natalizumab and 
fingolimod); FTY: lymphocyte count at the moment of 3 months fingolimod use. The red line is the cut off value of 
lymphocytopenia <1.0 × 10E9/L. There was no significant difference between the two groups in lymphocyte count (β = 
0.03, p = 0.1). NTZ: natalizumab FTY: fingolimod.
Discussion
The main finding of this study is that switching patients from natalizumab to fingolimod with 
a WO period of more than 8 weeks increases the likelihood of recurrent disease activity 
almost seven-fold compared to patients with a WO period of less than 6 weeks. 
Our results confirm earlier studies that report an increase of disease activity after 2-4 
months of WO period in comparison to shorter WO periods.5-9, 24 Ideally, to limit the risk of 
recurrence of disease activity, the WO period should be short enough to allow fingolimod to 
be clinically effective before natalizumab concentration drops under therapeutic levels. The 
downside of such a short WO period is the ongoing risk of PML in JC virus positive patients 
after discontinuation of natalizumab and how fingolimod could possibly increase the risk of 
PML and negatively influence the course of this serious complication. 
PML after discontinuation of natalizumab (carry-over PML) is rare with 15 reported cases 
to date.25 PML under fingolimod monotherapy is also described but even rarer, with nine 
reported cases so far (Novartis safety update October 2016). All current literature regarding 
WO periods when switching from natalizumab to fingolimod recommend a delay of less 
than three months because of the risk of recurrence of disease activity.5-9, 25 We estimate 
that the possible increased risk of PML with a decrease of 1-2 months of WO period does 
not outweigh the significant reduction of disease recurrence. Therefore, we recommend 
a WO period of less than 6 weeks when switching from natalizumab to fingolimod. Extra 
precautions regarding the risk of PML in JC virus positive patients may be taken, such as a 
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baseline MRI and repeated scans 3 and 6 months after cessation of natalizumab and timely 
testing of JC virus DNA in the cerebrospinal fluid in case of suspicious MR activity.25
Although intra-individual natalizumab trough concentration during natalizumab treatment 
are stable, concentrations vary widely between patients, presumably because of the 
difference in body mass index and metabolism.26 In agreement with an earlier report, 
we found a large inter-individual variability of natalizumab trough concentration under 
natalizumab treatment.26 We hypothesized that lower concentration would predispose to 
disease recurrence after natalizumab discontinuation. However, we found no significant 
difference in concentration under natalizumab treatment when comparing patients with 
disease activity and patients without disease activity, which is in agreement with a recently 
published study of 12 patients switching from natalizumab to fingolimod.27 In our study, the 
possible explanation could be that, the clinical disease activity appeared after three months 
of natalizumab discontinuation when  concentration of the drug had already decreased 
under therapeutic levels.5 When comparing longitudinal natalizumab concentration in 
patients with and without disease activity, the mean concentration at three months was 
lower in patients who did not experience disease activity (0.8 versus 4.2 µg/ml). However, 
no definite conclusions can be made because of limited sample size of the longitudinal 
concentrations. The α-4-integrin receptor on which natalizumab binds, desaturates when 
natalizumab concentration decrease under 1 µg/ml.23 Our longitudinal results show that 
on average, natalizumab concentration decrease under the therapeutic level 3 to 4 months 
after the last infusion. 
Natalizumab inhibits the adhesion of lymphocytes to the endothelium and is associated 
with a stable increase of peripheral lymphocytes.12 Yet increasing evidence shows that 
natalizumab also plays a role in attachment of hematopoietic precursor cells to bone 
marrow stromal cells and on that account facilitates the release of lymphocytes from the 
bone marrow.28, 29 The return of disease activity after natalizumab discontinuation most 
likely reflects resumption of lymphocyte migration across endothelial membranes of the 
blood brain barrier as natalizumab is cleared from the circulation.30 Fingolimod is probably 
mainly clinically effective because it induces a systemic lymphopenia. When switching from 
natalizumab to fingolimod, we hypothesized that clinical effect of fingolimod might be 
delayed due to the relative lymphocytosis natalizumab causes in a proportion of patients. 
However, this study shows no correlation between lymphocyte count and disease activity. 
T cell subsets are unknown in this study, so describing the fingolimod-mediated changes 
on CD4+ and CD8+ T cells was not possible. The lack of correlation between an overall 
lymphocyte count and disease activity will not rule out the probability that the changes 
in subpopulations of lymphocytes (including CD4+ / CD8+ ratio) may have impact on the 
recurrence of disease activity. 
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Our relatively small sample size warrants cautious interpretation of our data. To determine 
the optimal WO period in case of switching from natalizumab to fingolimod, larger 
randomized trials are needed, preferably comparing different WO periods, including one 
arm starting fingolimod immediately after the final natalizumab infusion. However, in future 
studies the influence of the WO period on the risk of PML will still be difficult to establish 
given the rarity of this serious complication. 
In conclusion we found that a WO period of less than 6 weeks is associated with a reduced 
recurrence of disease activity when compared to a WO-period of 8 weeks. Natalizumab 
concentration and lymphocyte count during natalizumab treatment did not predict disease 
activity after natalizumab discontinuation.
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The majority of NTZ treated 
MS patients have high NTZ 
concentrations at time of re-dosing
Chapter 8
Abstract
Background Natalizumab is efficacious in the treatment of relapsing-remitting multiple 
sclerosis. All patients receive the same treatment regimen of 300mg every four weeks, 
despite differences in pharmacokinetics between individual patients.
Objective To give neurologists insight in natalizumab concentrations at time of re-dosing, 
we investigated longitudinal natalizumab concentrations in 80 patients in relation to disease 
activity, with possible influencing factors.
Methods In a prospective observational cohort study, natalizumab trough serum 
concentrations were measured in 80 patients. Data on demographics, duration of treatment, 
Expanded Disability Status Scale, clinical exacerbations, brain MRI and body weight were 
collected.
Results We measured high (≥10μg/ml)  natalizumab trough concentrations in 94% of 
patients. Intra-individual concentrations were stable. The spread in concentrations was 
substantial and did not correlate with disease activity. We found a negative association 
between natalizumab concentration and body weight (β=-0.30, p=0.010).
Interpretation The majority of patients showed high natalizumab serum concentrations 
at time of re-dosing. Alternative treatment regimens could lead to more efficient use of 
natalizumab, but caution is warranted regarding the possibility of recurrence of disease 
activity. Prospective clinical trials are needed to establish the safety of extended dose 




Natalizumab (NTZ), targeting the α-4 integrin receptor, is an efficacious treatment for 
relapsing-remitting multiple sclerosis (RRMS).1 In a phase I trial, NTZ stayed detectable in 
the serum for 3-8 weeks after infusion with dosing of 1-3 mg/kg.2 Based on the different 
therapeutic dosages of 3-6 mg/kg in phase II trials, a fixed dose of 300mg once in four weeks 
was chosen for phase III trials so the majority of patients (with weights ranging between 
50 and 100kg) would fall between a dose of 3 to 6 mg/kg.3 Nowadays, a dose of 300mg 
every four weeks has been approved by the EMA/FDA for the treatment of RRMS. In this 
treatment regimen, NTZ concentrations may stay detectable in serum in up to 200 days after 
cessation of therapy.4 
Serum NTZ concentration corresponds with the percentage of α-4 integrin receptor 
saturation.5 Desaturation of the α-4 integrin receptor occurs when the serum NTZ 
concentration falls under 1-2 μg/ml.5 Above this threshold of 2 μg/ml, NTZ receptor 
saturation will roughly fall between 70-100%.5 An adequate receptor saturation is estimated 
as ≥70-80% saturation, although prospective data confirming this assumption are lacking.6, 
7 Based on a model with results from a large phase II trial, approximately 90% of patients 
showed NTZ trough concentrations largely exceeding 2.5 μg/ml. Levels exceeding 2.5 μg/
ml could indicate that the approved treatment regimen of NTZ for RRMS results in a relative 
over-treatment; i.e. the patient receives more NTZ than necessary for optimal drug efficacy.3, 
8 Furthermore, it is suggested that higher NTZ receptor saturation could increase the risk of 
progressive multifocal encephalopathy (PML), the feared complication of NTZ treatment.9 
This unconfirmed hypothesis leads to clinicians extending dose intervals in NTZ treatment 
with the aim to reduce the PML risk by decreasing NTZ exposure.9-11 
The aim of our study was to measure NTZ serum trough concentrations and correlate 




In 2006, we initiated a prospective observational cohort study to monitor different aspects 
of NTZ treatment at the MS Centre of the VU University Medical Centre in Amsterdam the 
Netherlands. All patients (nearly 220) starting NTZ have been included in this observational 
cohort. Patients in this cohort are annually subjected to a brain MRI and clinical testing 
including the Expanded Disability Status Scale (EDSS). For this present study we included all 
patients of the cohort who are currently treated with NTZ. Because NTZ concentration can 
fluctuate in the first year, mainly because of transient NTZ antibodies, we excluded patients 
with a NTZ treatment duration less than 12 months.12 All the patients included in this study 
received a strict treatment regimen of 300mg natalizumab every four weeks.
Measurement of NTZ concentration
Of all participants, blood samples were routinely obtained every three months before NTZ 
infusion. Serum was subsequently stored at -80°C at the biobank of the VU Medical Centre. 
For this study we cross-sectionally measured NTZ concentrations of selected samples, using 
a cross-linking assay using polyclonal rabbit anti-NTZ F(ab)2 fragments for capture and a 
mouse anti-IgG4 monoclonal antibody for detection. This method, performed at Sanquin 
Laboratory, has recently been described in more detail.13 The detection limit of the assay is 
approximately 0.01 μg/ml.13 To investigate the stability of trough concentrations we tested 
a second sample, with an interval of 3 to 7 months. Receptor desaturation can occur with 
serum concentrations of ≤2 μg/ml, which is our appointed cut-off point for an inadequate 
concentration.5 Taking into account the differences of individual pharmacodynamics, we 
assumed that serum concentrations of 2 to 10 μg/ml result in adequate receptor saturation. 
Concentrations exceeding 10 μg/ml do not result in higher receptor saturation and is 
therefore labeled as the cut-off for high trough concentration.5
Data collection
Demographic data, number of NTZ infusions, annual relapse rate before NTZ treatment, 
number of gadolinium enhancing lesions on the baseline scan, EDSS at start of NTZ 
treatment, JCV status at time of the measured concentration, clinical exacerbations during 
NTZ treatment and body weight were assessed. The body weight was measured within three 
months of the blood sampling date. A clinical exacerbation was defined as new neurological 
symptoms lasting for more than 24 hours and accompanied by new neurological signs found 
by a neurologist at the examination. All patients were subjected to a yearly MRI scan of the 
brain, including 3D fluid-attenuated inversion recovery, axial PD/T2-weighted sequences and 
gadolinium enhanced T1-weighted sequences. Those patients at higher risk for PML (JCV 
positive and > 12 months on NTZ) were subjected to 3-monthly scans (without gadolinium 
except for the annual MRI scan) as is current recommended protocol.14, 15 All MRI-scans 
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were evaluated by an experienced neuro-radiologist. The 2013 criteria of Lublin et al were 
used when referred to ‘active MS’.16 According to these criteria, when referring to active 
MS, the patient experiences clinical relapses and/or occurrence of contrast-enhancing T1 
or new or enlarging T2 lesions on brain MRI. In the present study we assessed MS activity 
starting 12 months after start of NTZ treatment. If the patient experienced any clinical and/
or radiological disease activity in the follow-up period they were classified as ‘active MS’. 
The local institutional review board approved the observational study and written informed 
consent was obtained from all participants.
Statistics
Continuous variables are expressed as mean and standard deviation if normally distributed 
or as median and interquartile range if not normally distributed. NTZ concentrations were 
normally distributed. For associating NTZ concentrations with different variables, we used 
the mean of the intra-individual longitudinal NTZ concentrations, except for the association 
with the number of NTZ infusions, in which we used the first measured NTZ concentration. 
For calculating the influence of different variables (body weight, NTZ infusions, age and 
gender) on NTZ concentration we used a linear regression model.  For calculating the 
influence of NTZ concentration on disease activity we used a logistic regression model. 
Additional adjustments were made for confounding factors such as body weight, NTZ 
infusions, age and gender.
All reported p values are based on statistic tests, with a significance level set at <0.05. The 
statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) 
version 22.0 (IBM Corp., Armonk, NY, USA). 
Results
Approximately 220 patients have started NTZ treatment at the VU Medical Centre. At 
time of the start of this study, 101 patients were treated with NTZ. The main reason for 
discontinuing NTZ was the risk of PML, other reasons were pregnancy related reasons, 
allergic reactions and progression to the secondary progressive phase. Of the 101 currently 
treated patients, 21 were excluded because of a treatment duration of less than 12 months. 
In the remaining 80 patients, 155 blood samples were tested for NTZ trough concentrations. 
Age of the patients ranged from 20 to 60 years. Patient characteristics are described in table 
1.
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Table 1. Demographic characteristics.
NTZ serum trough concentrations ranged from 0.1 μg/ml to 80.0 μg/ml with a mean of 
26.1 ±14.1 μg/ml. One patient (1.3%) had an inadequate concentration (< 2 μg/ml), 4 
patients (5%) had an adequate concentration (2 to 10 μg/ml) and 75 patients (93.8%) had 
a high concentration (≥10 μg/ml) at time of re-dosing. The patient showing the lowest 
concentration (0.1 μg/ml at two measurements) appeared to have persistent high (>9000 
AE/ml) NTZ antibodies.
Of 75 patients (93.8%) we measured a follow-up trough concentration. The mean 
concentration of all the cross sectional samples did not differ (both 26.1 μg/ml) at the 
two different time points, i.e. at group level no rise or fall in concentration was observed. 
Longitudinal concentrations per patient fluctuated with a median difference of 3.0 μg/ml. 
In 9 patients the two samples differed more than 10 μg/ml, all these patients showed very 
high concentrations above 30 μg/ml. 
The body weight of the patients ranged from 49.1 to 109.0 kg with a mean weight of 75.1 
±13.9 kg. An inverse association was found between body weight and NTZ concentration 
(see figure 1, β = -0.30, 95% C.I.-0.52 to -0.07; p = 0.010; r2 = 0.084). We corrected body 
weight for potential confounders, but none of these variables appeared to be relevant. 
Patients weighing up to 75kg showed a mean concentration of 29.2 ±15.6 μg/ml, whereas 
the mean concentration of patients weighing 75kg or more was 22.7 ±11.9 μg/ml (β = -6.6, 
95% C.I. -12.8 to -0.34; p = 0.039).
There was no association found between the number of NTZ infusions and trough NTZ 
serum concentrations, with a substantial spread in concentrations regardless duration of 
treatment (see figure 2, β = 0.022, 95% C.I. -0.092 to 0.113; p = 0.84).
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The NTZ trough concentration was comparable between males and females, with a mean 
concentration of 25.0 ±13.4 and 26.9 ±14.1 μg/ml respectively (β = -1.46, 95% C.I. -8.27 to 
5.35, p = 0.67). The concentration was not significantly associated with age (β = - 0.011, 95% 
C.I. -0.37 to 0.30; p = 0.94).
Mean duration of NTZ treatment was 5.0 ±2.5 years. 15 patients (17.7%) had active disease 
under NTZ treatment (11 patients with new T2 lesions, 5 patients with a clinical exacerbation). 
Patients who had active disease under treatment received a median treatment duration 
of 5.1 years, patients with non-active disease received a median treatment duration of 
4.9 years. Mean concentrations were similar between patients with active and non-active 
disease with a mean concentration of 26.4 μg/ml and 24.7 μg/ml respectively (see figure 
3). When adjusting for body weight, concentrations were not statistically different for the 
active disease group versus the non-active disease group (OR 0.98, 95% C.I. 0.94 to 1.03; p 
= 0.41). 
Figure 1. Body weight and NTZ trough concentration plot. 
An inverse association is found (β = −0.30, 95% CI = −0.52 to −0.07; p = 0.010; r2 = 0.084).
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Figure 2. Number of NTZ infusions (duration of treatment) and NTZ trough concentration plot. 
NTZ concentration of the first measured sample is displayed with associated number of NTZ infusions. No association 
is found (β = 0.022, 95% CI = −0.092 to 0.113; p = 0.84). We do not see a rise in concentrations in long-term (5−10 years) 
NTZ users.
Figure 3. Active disease (n = 15) versus non-active disease (n = 65) (according to the 2013 Lublin criteria) and NTZ 




NTZ is proven to be efficacious in the treatment of RRMS in a dosing schedule of 300mg 
every four weeks. Despite large variations in patient pharmacokinetics, all natalizumab 
treated patients receive the same treatment regimen, where a personalized approach to the 
treatment schedule might be more appropriate.1 Some neurologists are exploring extended 
dose intervals in order of reducing the risk of PML, although it is not confirmed that higher 
NTZ concentrations increase the risk of PML.9, 11 Obviously, modified treatment schedules 
should not interfere with drug efficacy. Our study addresses two important questions: 1. 
What is the proportion of high NTZ trough concentration in long-term treated MS patients? 
and 2. Can we explain individual differences of NTZ concentrations?
In our study of 80 patients, 99% of patients showed adequate to high trough NTZ 
concentrations (≥2 μg/ml), with 94% having high (≥10 μg/ml) NTZ concentrations. The mean 
trough NTZ serum concentration in our cohort was above 20 μg/ml which is in agreement 
with recently presented data.17 The mean concentration was not lower in patients with 
active versus non active disease, which suggests that high concentrations do not result in 
an increase of treatment efficacy in comparison to lower but still adequate concentrations. 
Considering this and the large proportion of high NTZ concentrations, NTZ could perhaps 
be administered less frequently (or with a lower dose) to reach NTZ concentrations that 
are lower but still cause adequate receptor saturation and consequently, optimal drug 
efficacy.5 Caution is advised though, because of a large spread in concentrations and the 
well-established rebound effect which occurs after cessation of NTZ treatment.18 
In the RESTORE trial, 19% of patients (n=23) stopping NTZ, of whom the majority switched 
to another therapy, experienced a relapse within 28 weeks.19 The rebound effect showed an 
increase over time, although 8% of relapses occurred within 4-8 weeks of NTZ withdrawal. 
A large retrospective study however, showed no increase in disease activity with extending 
intervals up to 8 weeks and five days.9 In our study, 6.25% of patients showed either 
inadequate or adequate NTZ concentrations at time of re-dosing. For this group, extending 
intervals might result in rapidly falling concentrations under the therapeutic level and 
consequently an early rebound effect. 
The large spread in NTZ trough concentrations could be explained by the variation in patient 
pharmacokinetics and characteristics. We associated age, sex, body weight, duration of 
treatment and disease activity with NTZ concentrations. The only factor associated with 
NTZ concentration was body weight. This is in agreement with earlier reports, where some 
studies suggested a dose modification based on patients body weight.20, 21 Our results 
indeed confirmed an inverse association but this correlation was weak, only accounting for 
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less than 10% of the variability in NTZ concentration. Therefore, body weight is an unreliable 
predictor for NTZ concentration.  
NTZ can be found in serum up to six months after cessation of therapy.4 It has been suggested 
that NTZ concentrations increase over time in individual patients.20 In our study, in 75 
patients with a second measurement of NTZ trough concentration, the intra-individual 
concentrations were stable. Although we do not present long-term longitudinal follow-
up trough NTZ serum concentrations, we did not find a correlation between duration of 
treatment and NTZ concentration. This data highlights that we should not expect very high 
concentrations in long-term NTZ treated patients (> 5 years). 
A limitation of the present study is that measurements of saturation of the α-4 integrin 
receptor are lacking. Previous studies show that NTZ concentration is correlated with the 
α-4 integrin receptor saturation, however above a certain concentration threshold the 
receptor will be fully saturated (75-100%). Based on available literature we estimated 
this threshold to be 10 μg/ml NTZ serum concentration, but this cut-off point needs to be 
confirmed in larger trials. Furthermore, if measuring natalizumab levels, it is of importance 
to realize that the drug is a wild-type IgG4 antibody that becomes monovalent in vivo via 
‘Fab arm exchange’. This will affect concentration measurements to various degrees.13, 22 
Comparative studies between assays will be necessary to eliminate potential discrepancies 
between studies.
In conclusion, the large majority (94%) of NTZ patients have high NTZ trough concentrations 
which could be an indication that most patients receive a ‘relative over-treatment’. Extended 
dose intervals could help reduce costs of medication and increase quality of life for the 
patient with fewer hospital visits, but further studies are needed to establish the safety 
of alternative treatment regimens. We are now conducting a prospective clinical trial with 
concentration based extended dose intervals in completely stable NTZ treated patients, 
to assess whether concentration based extended treatment regimens do not result in 
recurrence of disease activity. Results of such trials will hopefully give a decisive answer to 
the question if extending dose intervals in natalizumab treatment is feasible without losing 




1. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of 
 natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354: 899-910.
2. Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ and Koller M. A safety and pharmacokinetic 
 study of intravenous natalizumab in patients with MS. Neurology. 1999; 52: 1072-4.
3. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple 
 sclerosis. N Engl J Med. 2003; 348: 15-23.
4. Rispens T, Vennegoor A, Wolbink GJ, Polman CH and Killestein J. Natalizumab remains detectable 
 in patients with multiple sclerosis long after treatment is stopped. Mult Scler. 2012; 18: 899-901.
5. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab 
 clearance and restoring leukocyte function. Neurology. 2009; 72: 402-9.
6. O’Connor P. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of 
 multiple sclerosis. Expert Opin Biol Ther. 2007; 7: 123-36.
7. EMA. Tysabri: EPAR - Scientific Discussion:  (2007).
8. research FCfdea. Natalizumab: Clinical and Pharmacology and Biopharmaceutical Review(s). 
 U.S. Food and Drug Administration (US FDA)2004.
9. Zhovtis Ryerson L, Frohman TC, Foley J, et al. Extended interval dosing of natalizumab in multiple 
 sclerosis. J Neurol Neurosurg Psychiatry. 2016; 87: 885-9.
10. Bomprezzi R and Pawate S. Extended interval dosing of natalizumab: a two-center, 7-year 
 experience. Ther Adv Neurol Disord. 2014; 7: 227-31.
11. van Kempen ZL, Leurs CE, Vennegoor A, et al. Natalizumab-associated progressive multifocal 
 leukoencephalopathy is not preceded by elevated drug concentrations. Mult Scler. 2016: 
 1352458516684023.
12. Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab concentration 
 and anti-natalizumab antibodies in multiple sclerosis. Mult Scler. 2013; 19: 593-600.
13. Rispens T, Leeuwen A, Vennegoor A, et al. Measurement of serum levels of natalizumab, an 
 immunoglobulin G4 therapeutic monoclonal antibody. Anal Biochem. 2011; 411: 271-6.
14. Wattjes MP, Rovira A, Miller D, et al. Evidence-based guidelines: MAGNIMS consensus guidelines 
 on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients. 
 Nat Rev Neurol. 2015; 11: 597-606.
15. McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab- 
 associated progressive multifocal leukoencephalopathy risk: recommendations from an expert 
 group. J Neurol Neurosurg Psychiatry. 2016; 87: 117-25.
16. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 
 revisions. Neurology. 2014; 83: 278-86.
17. J.F Foley  TH, A Christensen , E Riddle , T Plavina , L Seawright , R Metzger. Natalizumab extended 
 interval dosing reduces serum trough natalizumab concentrations and a4 integrin receptor 
 occupancy. ECTRIMS. 2016.
148 CHAPTER 8
18. Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: 
 poorly tolerated. Ann Neurol. 2010; 68: 392-5.
19. Fox RJ, Cree BA, De Seze J, et al. MS disease activity in RESTORE: a randomized 24-week 
 natalizumab treatment interruption study. Neurology. 2014; 82: 1491-8.
20. J. Foley RM, T. Hoyt, A. Christensen. The Effect of Dosing Interval Extension and Patient Weight 
 on Long term Natalizumab Pharmacokinetics (P3.258). Neurology. 2015; vol. 84 no. 14 
 Supplement P3.258.
21. Tanaka M, Kinoshita M, Foley JF, Tanaka K, Kira J and Carroll WM. Body weight-based natalizumab 
 treatment in adult patients with multiple sclerosis. J Neurol. 2015; 262: 781-2.
22. Labrijn AF, Buijsse AO, van den Bremer ET, et al. Therapeutic IgG4 antibodies engage in Fab-arm 




Summary and general discussion 
152 SUMMARY AND GENERAL DISCUSSION 
General objective
In MS, there are only very few body fluid biomarkers that are accepted as reliable and 
practicable parameters so far. Biomarkers play a role in determining MS (e.g. cerebrospinal 
fluid-specific oligoclonal bands (OCB)), in differential diagnosis (e.g. anti-aquaporine-4 and 
anti-MOG serology in NMO-SD), in monitoring disease modifying treatment (DMT) (e.g. 
anti-interferon antibodies and anti-natalizumab antibodies) and predicting adverse effects 
(screening anti-JCV antibodies in natalizumab treatment for the risk of PML). 
The problem of diagnosing MS is largely solved by using MRI, clinical presentation and 
neurological assessment which led to the formulation of the revised diagnostic criteria.1 
However, making a timely diagnosis can still be complicated in a minority of patients. 
This may occasionally result in an undesirable late diagnosis and subsequently delayed 
treatment. To date, validated and discriminative body fluid biomarkers reflecting and 
predicting natural disease progression and disease activity are lacking.2, 3 Such biomarkers 
are crucial for personalized medicine and may provide guidance in the rapidly evolving 
treatment armamentarium in MS.
The main aim of this thesis was to explore novel biomarkers that are associated with disease 
progression and to explore biomarkers in monitoring treatment and treatment safety. With 
this aim different markers reflecting potential roles in neuroinflammation, demyelination, 
and axonal damage were analyzed. For monitoring DMT and DMT safety natalizumab 
concentrations and neurofilament light were explored. 
During this search, two biomarkers with a more diagnostic purpose were also worthy to 
analyze namely kappa free light chains and mRNA-sequencing of blood platelets. After all, 
biomarkers useful in determining MS can likewise be potential biomarkers in predicting 
disease progression and treatment monitoring.
The following section summarizes the main results of our biomarker studies in MS. In 
addition, main findings are discussed in relation to the existing literature, and clinical 
implications and future perspectives will be addressed.  
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PART 1 Diagnostic biomarkers
Chapter 1.  
Kappa free light chains, a valid tool in the diagnostics of MS.
In the latest 2017 revisions of the McDonalds criteria the OCB have a prominent role in 
patients with clinically isolated syndrome (CIS). However, the assessment of OCB is 
labor intensive, requires trained personnel and is in some cases examiner- and method-
dependent, which may affect its reliability. The question raised: ‘Is there a biomarker that 
can be measured with an automated and quantifiable procedure?‘
Since the late 1970s, multiple studies have reported increased CSF levels of kappa free light 
chains (KFLC) in MS4-14 and due to the development of the more sensitive nephelometric and 
turbidimetric FLCs assays4-8 KFLC and lambda free light chains (LFLC) can be easily detected. 
However, until our study described in chapter 1, a large multicenter study to validate this 
biomarker was lacking. 
In chapter 1 we validated KFLC and LFLC indices as a diagnostic biomarker in MS compared 
with OCB in a large multicenter study including samples from eighteen MS-centers across 
Europe (219 controls and 526 CIS/MS patients) with a known OCB status. We measured 
KFLC and LFLC in paired CSF and serum samples. We defined cut-offs for abnormal FLC 
indices and based on the defined cut-off, subjects were classified as positive or negative for 
kappa or lambda FLC as binary result. The sensitivity, specificity and accuracy between the 
two different diagnostic tools (OCB and FLC) were compared. 
We found a cut-off for the KFLC index of 6.6, and for the LFLC index a cut-off of 6.9. Compared 
to OCB the KFLC-index is more sensitive (.88 vs .82) at the cost of a lower specificity (.83 vs 
.92). This resulted in a higher negative predictive value for the KFLC-index compared to 
OCB, but a lower positive predicted value. This suggest that the KFLC-index is a valid test for 
diagnosing MS. In addition, our results indicated that the LFLC-index is not a valid test for 
diagnosing MS.
Discussion and future perspectives
Validating FLCs in a large multicenter study is necessary assuming it can be a valid tool as 
a potential cost-effective replacement of the OCB. The sensitivity and specificity found in 
chapter 1 for the KFLC index in CIS/MS were lower compared to other smaller studies.13-17 
However, in these previous studies, there was a less heterogeneous control group (except in 
the study described by Senel et al. 2019). For example, similar as for the OCBs, KFLCs can be 
elevated in inflammatory controls18, and thus specificity will be lower when included. The 
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large number of patients and the large heterogeneous control group in our study gave us a 
reflection of the real-life clinical situation thus avoiding spectrum bias and allowed us to give 
a more representative sensitivity and specificity for OCB, KFLC and LFLC indices. 
It is challenging to establish cut –off values for biomarkers. The cut-off in this study was 
calculated using a data-driven Gaussian mixture modeling approach. This is a different 
approach compared to other studies. We reasoned that the cut-off should be defined 
by biological levels and not based on clinical diagnosis, since the latter contains clinical 
uncertainty due to lack of a golden standard. The cut-off found in chapter 1 for KFLC is in line 
with results from previous multi-center studies showing a KFLC-index cut-off of 5.9 and 7.0.8, 
13 This almost comparable cut-off for the KFLC index in two multi-center studies  supports its 
robustness and implies that it may be used as an universal cut-off. 
The last two decades multiple revisions were published of the McDonald MS criteria. This 
resulted in that not all included patients were diagnosed based on the same MS criteria 
in our study, which may have influenced the diagnosis of CIS patients particularly. We 
addressed this problem by pooling all CIS and MS patients. We performed several sensitivity 
analyses in CIS or MS patients separately, and by reclassifying and excluding specific clinical 
groups. No relevant differences were seen when comparing MS to control group. 
We concluded that for clinical practice, the KFLC index is more accurate in excluding CIS/MS 
compared to OCB but for ruling in a diagnosis of CIS/MS, analysis of OCB appears to be more 
accurate.  By replacing OCB with KFLC in diagnostic practice there is a slightly higher chance 
that a patient with a diagnosis different from MS will get the diagnosis of MS and maybe 
unnecessarily exposed to potential negative side effects of early treatment. Since the KFLC-
index is more sensitive at the cost of a lower specificity, we should stress that replacement 
of OCB by the KFLC-index is not optimal to arrive at high diagnostic certainty.
An advantage of the higher sensitivity of KFLC, is that an earlier diagnosis and subsequent 
treatment start may be considered. It may be an option to start treatment based on the 
KFLC result and clinical/MRI findings according to the novel McDonald criteria, or to use 
KFLC results in patients on treatment when a switch may be considered while on DMT. This 
could be considered as a subject for future studies.  
One important note is that the best set up for a future study would be to include a test 
population of suspected MS cases instead of already diagnosed cases. The use of the KFLC 
values as a predictor for CS conversion to MS is demonstrated in several studies.19-21  However, 
a recent study showed that FLC concentrations at CIS diagnosis were not significantly higher 
in CIS-converters.13
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Since 1995 different papers have been published exploring KFLC values as a disease 
progression marker. Different studies found that KFCL predicted subsequent physical 
deterioration in MS patients.22-24 Nonetheless, one study did not find evidence for a relation 
of KFCL with disease progression.25 The role of KFLC in predicting disease activity or disease 
progression is interesting for future studies using large cohorts of patients with long-term 
follow up.
Chapter 2.  
mRNA-sequencing of blood platelets as novel diagnostic 
biomarker in MS.
So far, no blood biomarker has been convincingly confirmed as a useful tool in the diagnostic 
work-up of MS. Blood-based approaches harbor obvious advantages and recently, the long-
neglected blood platelets, being the second most abundant cell type in peripheral blood, 
have shown emerging potential as a new source for biomarker discovery in several diseases, 
but not yet for MS.26, 27
During the final stages of platelet production, platelets are loaded with pre-messengerRNAs 
before developing from the megakaryocyte.28, 29 As a result, platelets contain a rich 
messengerRNA (mRNA) repertoire that can change during megakaryocyte development 
but also during platelet formation and platelet circulation. Especially the change of RNA 
transcripts during circulation, possibly achieved by specific splicing queues, is of relevance 
in this chapter. 
Platelets are known to respond to activating signals from their environment with specific 
splicing of their pre-mRNAs and uptake of RNA from different cell types, leading to a unique 
and dynamic RNA repertoire 30-35. The diagnostic potential of this specific splicing of mRNAs 
in platelets has already been demonstrated, as recent findings have shown that mRNA 
sequencing from tumor educated blood platelets distinguishes healthy controls (HC) from 
cancer patients with an accuracy of 95% 36.
Platelets seem to not just be involved in inflammatory and immune responses but may 
also contribute to the pathogenesis of MS.37-39 As a result of their involvement in immune 
response and apparent causal role in the progression and development of the disease, we 
hypothesized in chapter 2 that blood platelets contain a disease specific mRNA signature, 
thereby investigated their potential as diagnostic biomarker for MS. In this chapter, we 
isolated and sequenced platelet RNA of blood samples from 57 MS patients and 66 age- and 
gender-matched healthy controls (HCs). 60% of the matched samples were employed to 
develop a particle swarm-optimized (PSO) support vector machine classification algorithm. 
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The remaining 40% of the samples served as an independent validation series. In total, 1249 
RNAs with differential spliced junction expression levels were identified between platelets 
of MS patients as compared to HCs. The spliced platelet RNA was subsequently used as 
input for the development of a diagnostic MS classifier capable of detecting MS with >80% 
accuracy in the independent validation series (n=50, AUC: 0.87, 95%-CI: 0.77-0.97, p<0.001).
Discussion and future perspectives
The blood-based approach presented in this chapter could assist in the diagnosis of MS 
without being as invasive as CSF collection, therefore allowing for easy disease determination 
in case of a diagnostic challenge. Ultimately, it would be favorable if blood platelets mRNA 
could replace CSF OCB to substitute the requirement of fulfilling dissemination in time on 
MRI according the 2017 revisions of the McDonald criteria.1
To our knowledge, our study was the first utilizing mRNA found in circulating platelets as 
a blood-based biomarker for distinguishing MS patients from asymptomatic individuals. 
Recently, the protocol determining mRNA in platelets was published, enabling the MS 
community to test platelet RNA for diagnostic algorithm development.40
Obviously, there are limitations that need to be discussed concerning our data. First, aside 
use of age- and gender-matched asymptomatic controls, no individuals were included with 
other auto-immune or (neuro-) inflammatory disease potentially reducing the diagnostic 
accuracy. Second, all MS patients have been diagnosed with the disease for a minimum 
of ten years. Third, the sample size analyzed is still relatively small, potentially resulting in 
algorithm overfitting. To reach true clinical relevance, additional studies should also focus on 
early-stage MS cases and CIS patients to assess the early-detection potential. Despite above 
mentioned problems, we provided evidence for the clinical potential of circulating blood 
platelet derived mRNA as liquid biomarker for RRMS. More studies are needed, however, to 
assess the performance of this diagnostic tool in various presentations of MS. Also, platelet 
derived mRNA may have potential as progression marker in MS and as a response marker in 
DMT users. We are currently expanding our measurements to our treatment cohorts.
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PART 2 Disease course biomarkers
Chapter 3.  
Exploring cerebrospinal fluid mtDNA concentration as a 
biomarker in MS disease progression and activity. 
In this part of the thesis we explored markers reflecting disease course, with a focus on 
disease progression.
In recent years, impaired mitochondrial function is increasingly recognized as a key 
pathological hallmark of MS.41, 42 Demyelination leads to an increase in energy demand 
in order to maintain an appropriate intra-axonal ion balance and could thereby affect the 
number, transport and activity of mitochondria.43-46 The number of mitochondria is highly 
increased in chronically demyelinated axons as well as in reactive astrocytes43, 45 and extensive 
neuronal mtDNA deletions have been observed in MS cortical brain samples.47 Based on the 
observations that mitochondrial dysfunction plays a crucial role in MS pathology and the 
possible role of mitochondrial dysfunction in clinical disease progression, we explored in 
chapter 3 the potential of mtDNA levels in the CSF as a candidate biomarker of identifying 
patients with progressive disease in a Dutch cohort (50 RRMS patients, 40 PMS patients, 23 
non-inflammatory and 7 inflammatory controls). 
The main conclusion of this chapter was that concentrations of free circulating mtDNA copies 
are increased in CSF of patients with progressive MS compared with non-inflammatory 
control patients. Also, there was a trend (p=0.08) for a modest positive correlation with 
Expanded Disability Status Scale (EDSS) specifically in progressive MS patients. In addition, we 
showed that patients with a high T2 lesion volume displayed higher mtDNA concentrations 
compared to patients with a relative low T2 lesion volume. The group with lower normalized 
brain volumes showed higher mtDNA concentrations compared to patients with higher 
normalized brain volumes, suggesting a positive correlation between the concentration of free 
circulating mtDNA copies and brain atrophy. Altogether, our data may suggest that increased 
concentrations of cell free mtDNA are associated with MS disease activity and progressive 
disease.
Furthermore, we explored the effect of disease modifying treatment on free mtDNA levels 
in longitudinally obtained CSF samples in a Swedish cohort (42 RRMS patients, 20 other 
neurological disease controls and HC). We showed that patients treated with fingolimod had 
significantly decreasing (almost 50%) mtDNA copy levels at follow-up compared to baseline.
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Discussion and future perspectives
Previous studies showed reduced levels of mtDNA in both Alzheimer48, 49 and Parkinson50 
disease cases and it has been speculated that a decrease in mtDNA might be a common 
phenomenon observed in neurodegenerative diseases. In contrast to this, elevated mtDNA 
levels as we found in PMS, have also been detected in CSF samples from children with 
traumatic brain injury and were highly predictive of a poor outcome.51 This might suggest that 
high values of free circulating mtDNA in CSF can be seen as a potential biomarker of acute 
cellular and mitochondrial stress. It is nowadays widely accepted that neurodegeneration 
and concomitant brain atrophy are common pathological features of MS, particularly in 
the progressive phase of the disease. Demyelination leads to an increase in axonal energy 
demand, which may superimpose effects of neurodegeneration in MS, which is a possible 
explanation for the higher concentrations of mtDNA in progressive MS in this chapter. 
However, a recent study analyzing mtDNA in PMS, showed that when mtDNA was analyzed 
in ventricular CSF (post mortem) at the end-stage of progressive multiple sclerosis mtDNA 
levels were depressed.52  This study used a small sample size and comparing post mortem 
with samples taken from living patients warrants cautious interpretation of the data. 
The cellular origin of enhanced mtDNA levels in the CSF of progressive MS patients found 
in our study is yet unknown, however it is conceivable that mtDNA is released upon neuro-
axonal injury or oligodendrocyte damage, as these are prominent features of progressive MS. 
Alternatively, mtDNA might be secreted into the extracellular compartment by extracellular 
vesicles derived from distinct CNS cells, such as reactive astrocytes, particularly in lesions 
that are packed with mitochondria. 
In line with our results, Varhaug et al. showed increased levels of cell free mtDNA in CSF of MS 
patients compared with controls.53 Further, they found an inverse correlation between the 
duration of the specific symptoms and levels of mtDNA, concluding that increased mtDNA 
concentration may reflect early, active inflammatory activity. Increased mtDNA levels in 
the CSF might also contribute to the disease process by activating an immune response. 
Mitochondrial DNA is a damage-associated molecular pattern (DAMP), which can bind to 
glial Toll-like receptor-9 and trigger an inflammatory response.54 Hence, it is conceivable 
that enhanced mtDNA levels in the CSF might elicit a glial immune response. Fissolo et al. 
further explored the potential role as a diagnostic and disease activity biomarker in MS by 
measuring CSF cell-free mtDNA levels in a large cohort of individuals with relapse-onset 
and progressive clinical forms of MS, patients with CIS and control subjects.55 No significant 
differences were observed between MS patients, CIS patients and neurologic disease 
controls. Within the CIS group, mtDNA levels did not significantly differ between CIS patients 
who converted to MS and those who continued as CIS.  Similar to our results, no significant 
differences were observed between relapsing and progressive forms of MS. Within the 
MS group, they showed that mtDNA levels were similar between patients in relapse and 
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remission, patients with and without gadolinium enhancing lesions, and patients with and 
without progression on the EDSS score during follow-up. 
All the above mentioned results signify that additional research is needed to explore the 
functional effects and use of mtDNA concentrations in the CSF of MS patients.
A possible role of mtDNA as a biomarker of fingolimod treatment response can also be the 
subject of future studies. It is likely that fingolimod reduces inflammation-mediated cellular 
damage and subsequent release of mtDNA based on the significant decrease of mtDNA 
after initiating fingolimod. However the precise mechanism underlying reduced mtDNA 
CSF levels upon fingolimod treatment warrants further investigations and CSF as source for 
monitoring treatment effects has its obvious drawbacks. Also, further comparisons with 
other disease modulatory treatments are needed in order to understand if this effect is 
specific for fingolimod or a generic response to reduced inflammation and concomitant CNS 
cell injury. 
Chapter 4.  
Acid sphingomyelinase, no potential marker for disease 
progression.
Recent evidence suggests that alterations in the sphingolipid pathway may reflect disease 
activity in MS.56, 57 Due to the activity of enzymes essential in the sphingolipid pathway, such 
as sphingomyelinases, ceramides of different chain lengths may be produced and participate 
in different cellular processes such as differentiation, proliferation and programmed cell 
death.58, 59 Increased ceramide levels have been detected in CSF of patients with MS.60, 61 
An altered protein expression of acid sphingomyelinase (ASM) in MS brain tissue samples 
(obtained at rapid autopsy and immediately frozen in liquid nitrogen or fixed in formalin) 
has been demonstrated in a previous study. They identified that reactive astrocytes are the 
primary source of enzyme activity and subsequent ceramide production.57 
The study in chapter 4 explored the potential of acid sphingomyelinase (ASM) activity levels 
in the serum as a candidate biomarker to identify MS patients with an active or progressive 
disease course. Furthermore, we explored several targets of the sphingolipid metabolism in 
relation to DMT.
Levels of serum ASM activity were longitudinally analyzed in 40 CIS, 64 RRMS and 10 primary 
progressive MS patients (PPMS), and 22 HC. ASM activity and sphingolipid levels were 
measured in a different sample of 61 RRMS patients using DMT. Analyses of ASM activity 
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levels showed that when pooling all types of MS, a significant higher ASM activity level was 
observed than in HC. The levels did not significantly differ in the serum between patients 
with RRMS, SPMS and PPMS and we did not find an association between ASM activity and 
the annualized relapse rate, disease activity, MRI variables or EDSS progression.
In the second part of this chapter we investigated the association between the sphingolipid 
metabolism and DMT.  Despites ASM activity levels did not reflect treatment response, we 
did observe a significant increase of two types of ceramides (Cer-C16:0 and Cer-C24:0) and four 
types of sphingomyelin (SM-C20:0, SM-C22:0, SM-C24:0 and SM-C24:1) during fingolimod use.
Discussion and future perspectives
The activity of ASM allows conversion of sphingomyelin into ceramides. Ceramides 
may induce neuronal mitochondrial dysfunction and axonal damage by participating in 
different cellular signaling cascades and processes such as differentiation, proliferation  and 
programmed cell death.58, 59 So far, ASM activity levels have only been determined in the CSF 
of MS patients, demonstrating increased levels compared to other neurological diseases 
(OND).62 Besides higher levels of ASM activity, the number of exosomes that carry ASM 
in the CSF was significantly higher in MS patients than in patients with OND and this was 
correlated to CSF ASM activity.62 
In contrast with other studies60, 62, we did not observe correlations between EDSS and ASM 
or other components in the sphingolipid metabolism. In these previous studies the markers 
were measured in CSF, suggesting more potential for CSF than serum with respect to suitable 
MS biomarkers.
Regarding the possible effect of fingolimod on reducing the production of pro-inflammatory 
lipids (such as ceramide), we could not confirm this within chapter 3. Only one previous 
study explored the effect of fingolimod (and other MS therapies) on different sphingolipids 
in MS patients63. They observed that IFN-ß treatment strongly increased plasma levels of 
Cer-C16:0, Cer-C18:0, Cer-C20:0, and Cer-C24:1 compared to healthy controls, untreated patients, 
or patients receiving fingolimod or natalizumab medication.64 
One hypothesis why increasing levels of ceramides and sphingomyelin were observed, in 25 
treated MS patients in our study, is that fingolimod is an S1P mimicking agent and thereby 
may decrease levels of endogenous S1P, which in turn may lead to increasing levels of 
ceramides and sphingomyelins due to the sphingolipid rheostat.
Although higher levels in MS patients were found, we concluded that ASM activity levels did 
not show potential as a biomarker for predicting disease activity, progression or response 
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to DMT. Two ceramides and four types of sphingomyelin require further investigation as 
potential markers for treatment response.
Chapter 5.  
Serum tissue transglutaminase associates with disease 
progression.
Tissue Transglutaminase (TG2) is a Ca2+-dependent crosslinking enzyme, regulated by 
inflammatory mediators.65-67 Recently, the presence of TG2 in infiltrating MHC-II positive 
cells in MS lesions was demonstrated 68 as well as increased TG2 mRNA in MS patient-
derived monocytes69 suggesting a possible role for TG2 in the pathophysiology of MS. The 
clinical implications of TG2 have already been described for several human diseases. 70-72 
Nevertheless, the clinical implication of TG2 in MS patients has not been studied yet. The 
aim of chapter 5 was to assess whether TG2 expressed by peripheral blood mononuclear 
cells (PBMC) is altered in patients with MS and whether this correlates with measures of 
disease activity and progression. 
In this chapter, peripheral blood mononuclear cells (PBMCs) were isolated from 151 HC and 
103 RRMS patients, 36 secondary-progressive MS patients (SPMS) and 22 PPMS patients. We 
observed that TG2 mRNA levels were differentially expressed in healthy controls compared 
to RRMS patients and that the mRNA levels were associated with disease progression 
measured as either high EDSS score (std ß=0.26; p=0.02), normalized brain volume (NBV, std 
ß=-0.18; p=0.02), normalized white (NWMV, std ß=-0.17; p=0.03) and grey matter volume 
(NGMV, std ß=-0.15; p=0.03) in MS patients. In addition, in PPMS patients, TG2 mRNA levels 
were also associated with T1-hypointense lesion volume and T2-lesion volume. Our results 
suggest that PBMCs-derived TG2 mRNA levels can be used as a biomarker for multiple 
sclerosis progression, especially for PPMS.
Discussion and future perspectives
We observed no differences in TG2 mRNA levels between MS patients and HC subjects. 
Nevertheless, TG2 showed significant associations with EDSS as well as NBV, NGMV and 
NWMV at baseline thus suggesting that TG2 mRNA levels could represent a quantitative 
measure of neuronal loss. No significant evidences were found for a contribution of TG2 
in disease activity measured as both relapse or annualized relapse rate (ARR) in RRMS 
patients. Those data suggest that alterations in TG2 mRNA levels are not attributed to the 
inflammatory phase of the disease. In addition, a trend toward expressing lower TG2 mRNA 
levels was observed in RR patients with active disease (presence of gadolinium enhancing 
lesions at the baseline) who represent the most inflammatory group of MS patients. In line 
with those findings, TG2 mRNA levels were not affected by the applied DMT, which target 
162 SUMMARY AND GENERAL DISCUSSION 
infiltration of immune cells in the CNS and/or the production of inflammatory cytokines. 
Those results were unexpected as TG2 expression is known to be modulated by inflammation 
and inflammatory mediators.65-67, 73 An association profile similar to what was observed in 
the whole MS patients group was also observed in PPMS patients, where TG2 correlates 
also with T1-hypointense lesion volume and T2-lesion volume. Those data could suggest 
that in particularly in PPMS patients, alteration in PBMC-derived TG2 mRNA expression are 
associated with progression of the disease and ongoing axonal damage. 
To characterize TG2 expression in PPMS patients,  the expression profile of full-length TG2 
and TG2 splice variants in PBMCs of PPMS patients were compared to those of HC subjects 
in an additional study74 carried out by our own researchers at the MS center Amsterdam. 
The TG2 variant V4b was significantly higher expressed, and both V4a and V4b variants 
were relatively more expressed in relation to full-length TG2. These observations open new 
avenues to unravel the importance of TG2 alternative splicing in the pathophysiology of 
PPMS.
Furthermore, when pooling RRMS with SPMS patients we observed that TG2 mRNA was 
significantly associated with clinical disability (EDSS) and MRI measurements (normalized 
brain volume and normalized white matter volume). Interestingly, in this pooled group, TG2 
association with NGMV was not significant.  Remarkably, in both RRMS and RRMS/SPMS 
patients, TG2 mRNA levels showed predictive power for the course of the disease. In fact, 
TG2 mRNA was associated with worsening of the clinical symptoms (change of EDSS) over 
a 2 year follow-up. Future studies in an independent cohort are needed to validate our 
findings. In addition, a prospective study with repeated and long-term measurement of 
PBMC-derived TG2 mRNA would help to evaluated the stability of TG2 mRNA in time and 
the robustness of the assay.
PART 3 Treatment monitoring biomarkers
Chapter 6. 
Serum neurofilament light in natalizumab treated MS patients.  
As already mentioned, biomarkers reflecting and predicting disease activity and progression 
are crucial for personalized medicine and may provide guidance in the rapidly evolving 
treatment armamentarium in MS. 
Natalizumab (NTZ)(Tysabri, Biogen Inc, Cambridge, MA, USA) is a humanized monoclonal 
antibody constraining the migration of leukocytes over the blood–brain barrier and it is 
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well known the be very effective in MS treatment.75 Several studies showed a decrease in 
the annualized relapse rate (ARR) and stabilization75-77 or even improvement in physical 
disability. 78, 79  In contrast, a recent study showed that when taking into account early 
inflammation and the impact of natalizumab on disease activity during the initial treatment 
phase, a higher than expected proportion of patients treated with NTZ showed disability 
progression.80 
Neuroaxonal injury may be found in several neurological disorders and is accompanied 
by release of neuron-specific neurofilament (NF) proteins into extracellular space. These 
proteins can leak into CSF and into blood and can reach abnormal levels as a result of axonal 
damage in neurodegenerative, inflammatory, vascular and traumatic diseases.81, 82
Neurofilament light (NfL) has  increases in CSF and serum of RRMS patients during relapses, 
returning to baseline within a couple of months of the acute event.83-86 There are findings 
that serum NfL (sNfL) levels are also associated with EDDS progression. 84, 87 It remains 
unclear, however, whether sNfL may, in addition, predict or reflect disability progression 
in the absence of relapse-related neuroaxonal damage. In chapter 6 we investigated the 
potential of sNfL as a biomarker of disability progression in the almost complete absence of, 
or with limited contribution of acute focal inflammation in a cohort of 89 NTZ-treated RRMS 
patients. We examined whether sNfL at initiation and after 12 months of treatment predicted 
disability progression in the following 2 years and whether the longitudinal trajectories of 
sNfL levels differed in individuals with disability progression from individuals without. In 
this chapter we observed a significant reduction in sNfL levels at 3 months (almost 50%) 
and reached its nadir within 12 months after NTZ initiation. We found no difference in the 
longitudinal dynamics of sNfL levels in patients with or without progression based on EDSS 
or EDSSplus.  sNfL levels at initiation and at 12 months did not predict EDSS or EDSSplus 
progression in the following 2 years.
Discussion and future perspectives
The significant reduction in sNfL that we observed in chapter 6 after initiation of NTZ is 
similar to other studies84, 87 85 However, the focus on long-term disease progression in a 
population without remaining disease activity has been a rather new approach. Recently, in 
a cohort of MS patients, sNfL was reported to predict EDSS worsening in the following year, 
87 regardless of DMT status at time of measurement. In our NTZ cohort, sNfL levels at BL, 
and at 12 months did not predict EDSS progression in the following 2 years and sNfL levels 
at BL and 12 months did not differ significantly between both groups. In the study by Barro 
et al87, DMT status was heterogeneous at time of sNfL measurement, with some patients 
treated, and others not. In our cohort, all patients were untreated for at least 2 months prior 
to sNfL assessment at BL.  Moreover, in the present study, all patients were treated during 
the assessment of progression, uncoupling damage arising from focal inflammatory activity 
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from neurodegeneration. Our results are supported by the other studies88, 89 They showed 
that no significant correlations were measured concerning EDSS progression and baseline 
sNfL levels. 
For future plans, atrophy measurements need to be taken into consideration as it seems 
that brain atrophy and sNfL levels are correlated.88, 89 In our study, atrophy measurements 
were not available yet.  
The strength of this study is the prospective nature of the detailed longitudinal clinical and 
radiological data and longitudinal sample collection. However, the study also has possible 
limitations. The data would have benefited from a larger sample size and longer duration of 
follow up. Nevertheless, the complete lack of a trend towards a difference in longitudinal sNfL 
measurements between progressors-  and non-progressors strengthens the truthfulness 
of our findings. In conclusion, our findings confirm the potential of sNfL to monitor the 
reduction in focal inflammatory damage that accompanies NTZ introduction, but fails to 
capture longer-term EDSS worsening (“silent progression”) that is largely independent of 
relapse activity. 
Chapter 7.  
Treatment response markers: serum natalizumab concentration 
and lymphocyte count during treatment in RRMS patients 
switching from natalizumab to fingolimod.
Natalizumab is an effective treatment in relapsing-remitting multiple sclerosis, but is 
associated with an increased risk to develop progressive multifocal leukoencephalopathy 
(PML). PML is a severe, potential lethal disease, caused by the John Cunningham (JC) virus. 
Mainly because of the risk of PML, a substantial proportion of JC virus  positive patients 
switch to fingolimod. The main question in switching from natalizumab to fingolimod is, what 
the optimal wash-out (WO) period is between the two treatments. Previous reports show a 
clear benefit when the duration of a WO period of natalizumab is 0-3 months in comparison 
to longer WO periods. However, there is no consensus regarding the optimal duration of a 
WO period under 3 months. In chapter 7 we compared MS disease activity after different 
WO periods. In addition, we investigated several factors that possibly influence recurrence 
of disease activity, including serum natalizumab concentration and lymphocyte counts.
From a prospective observational cohort study of natalizumab treated patients we selected 
52 patients who switched to fingolimod. We divided the patients in three groups (<6 
weeks n=16, 6-8 weeks n=18, >8 weeks n=18 WO). Serum natalizumab concentration and 
lymphocyte count were assessed during and after natalizumab treatment.
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Patients with a WO period of >8 weeks had a significant higher recurrence of disease activity 
(OR 6.8, 95% CI 1.4–32.8) compared to patients with a WO period of <6 weeks. Serum 
natalizumab concentration and lymphocyte count did not predict recurrence of disease 
activity.
Discussion and future perspectives
The results we observed in chapter 7 confirm earlier studies that report an increase of 
disease activity after 2-4 months of WO period in comparison to shorter WO periods.90-95 
Ideally, to limit the risk of recurrence of disease activity, the WO period should be short 
enough to allow fingolimod to be clinically effective before natalizumab concentration drops 
under therapeutic levels. The downside of such a short WO period is the ongoing risk of 
PML in JC virus positive patients after discontinuation of natalizumab and how fingolimod 
could possibly increase the risk of PML and negatively influence the course of this serious 
complication. 
All current literature regarding WO periods when switching from natalizumab to fingolimod 
recommend a delay of less than three months because of the risk of recurrence of disease 
activity.90-94, 96 We estimated that the possible increased risk of PML with a decrease of 1-2 
months of WO period does not outweigh the significant reduction of disease recurrence. 
Therefore, we recommend a WO period of less than 6 weeks when switching from 
natalizumab to fingolimod. Extra precautions regarding the risk of PML in JC virus positive 
patients may be taken, such as a baseline MRI and repeated scans 3 and 6 months after 
cessation of natalizumab and timely testing of JC virus DNA in the cerebrospinal fluid in case 
of suspicious MR activity.96
We hypothesized that lower concentration of NTZ would predispose to disease recurrence 
after NTZ discontinuation. However, we found no significant difference in concentration 
under natalizumab treatment when comparing patients with disease activity and patients 
without disease activity, which is in agreement with a recently published study of 12 
patients switching from natalizumab to fingolimod.97 In our study, the possible explanation 
could be that, the clinical disease activity reappeared after three months of natalizumab 
discontinuation because the  concentration of the drug had already decreased under 
therapeutic levels.92 When comparing longitudinal natalizumab concentration in patients 
with and without disease activity, the mean concentration at three months was lower in 
patients who did not experience disease activity (0.8 versus 4.2 µg/ml). 
When switching from natalizumab to fingolimod, we hypothesized that clinical effect of 
fingolimod might be delayed due to the relative lymphocytosis natalizumab causes in a 
proportion of patients.98 However, this study showed no correlation between lymphocyte 
count and disease activity. T cell subsets are unknown in this study, so describing the 
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fingolimod-mediated changes on CD4+ and CD8+ T cells was not possible. The lack of 
correlation between an overall lymphocyte count and disease activity will not rule out the 
probability that the changes in subpopulations of lymphocytes (including CD4+ / CD8+ ratio) 
may have impact on the recurrence of disease activity. 
To determine the optimal WO period in case of switching from natalizumab to fingolimod, 
larger randomized trials are needed, preferably comparing different WO periods, including 
one arm starting fingolimod immediately after the final natalizumab infusion. However, in 
future studies the influence of the WO period on the risk of PML will still be difficult to 
establish given the rarity of this serious complication. Future biomarker studies in switchers 
should include serum NfL as this biomarker may capture both the recurrence of MS disease 
activity as well as damage due to early (carry-over) PML.
Chapter 8. 
Natalizumab concentrations
As mentioned in chapter 7, natalizumab is an effective treatment in relapsing-remitting 
multiple sclerosis. All patients receive the same treatment regimen of 300mg every four 
weeks, despite differences in pharmacokinetics between individual patients. In this 
treatment regimen, natalizumab concentrations may stay detectable in serum in up to 200 
days after cessation of therapy.99 Serum natalizumab concentration corresponds with the 
percentage of α-4 integrin receptor saturation.100 Desaturation of the α-4 integrin receptor 
occurs when the serum NTZ concentration falls under 1-2 μg/ml.100 Above this threshold of 
2 μg/ml, natalizumab receptor saturation will roughly fall between 70-100%.100 An adequate 
receptor saturation is estimated as ≥70-80% saturation, although prospective data confirming 
this assumption are lacking.101, 102 Based on a model with results from a large phase II trial, 
approximately 90% of patients showed natalizumab trough concentrations largely exceeding 
2.5 μg/ml. Levels exceeding 2.5 μg/ml could indicate that the approved treatment regimen 
of natalizumab for RRMS results in patients receiving more natalizumab than necessary for 
optimal drug efficacy.103, 104 Furthermore, it is suggested that higher natalizumab receptor 
saturation could increase the risk of PML.105 This unconfirmed hypothesis leads to clinicians 
extending dose intervals in natalizumab treatment with the aim to reduce the PML risk by 
decreasing natalizumab exposure.105-107 
The aim of the study in chapter 8 was to measure natalizumab serum concentrations and 
correlate concentrations with disease activity and possible influencing factors. We explored 
if natalizumab concentration has potential as a marker of treatment response.
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In chapter 8, natalizumab serum concentrations were measured in serum of 80 patients from 
a prospective observational cohort study. Data on demographics, duration of treatment, 
EDSS, clinical exacerbations, brain MRI and body weight were collected.
We measured high (≥10μg/ml)  natalizumab concentrations in 94% of patients. Intra-
individual concentrations were stable. The spread in concentrations between patients was 
substantial and did not correlate with disease activity. We found a negative association 
between natalizumab concentration and body weight (β=-0.30, p=0.010).
Discussion and future perspectives
In part 3.3 of this thesis natalizumab concentrations were explored as potential treatment 
monitoring markers. 
The variation in natalizumab concentrations was substantial.  However it did not correlate 
with disease activity (chapter 8). The mean natalizumab serum concentration in our cohort 
was above 20 μg/ml which is in agreement with recently presented data.108 The mean 
concentration was the same in patients with active versus non-active disease, which suggests 
that high concentrations do not result in an increase of treatment efficacy in comparison to 
lower but still adequate concentrations. Considering this and the large proportion of high 
natalizumab concentrations, natalizumab could perhaps be administered less frequently 
(or with a lower dose) to reach natalizumab concentrations that are lower but still cause 
adequate receptor saturation and consequently, optimal drug efficacy.100 Caution is advised 
though, because of a large spread in concentrations and the well-established rebound effect 
which occurs after cessation of natalizumab treatment.109 Therefore, monitoring natalizumab 
serum concentrations during treatment should be essential. 
Extended dose intervals could help reduce costs of medication and increase quality of life 
for the patient with fewer hospital visits, but further studies are needed to establish the 
safety of alternative treatment regimens. At this moment a prospective multicenter single-
arm trial with one-year follow-up and an extension phase of one year (ClinicalTrials.gov; 
NCT03516526) is completed at the MS Center Amsterdam (Amsterdam University Medical 
Center, Vrije Universiteit), with the aim to evaluate if natalizumab efficacy is maintained 
when switching to personalized extended interval dosing based on individual natalizumab 
trough concentrations in stable RRMS patients (reference: Neurology in press). 
Results of such trials will hopefully give a decisive answer to the question if extending dose 
intervals in natalizumab treatment is feasible without losing drug efficacy.    
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Key issues 
 •	 For clinical practice, the KFLC index is more accurate in excluding CIS/MS compared to 
  OCB but for ruling in a diagnosis of CIS/MS, analysis of OCB appears to be more 
  accurate.
 •	 mRNA derived from blood platelets could assist in the diagnosis of MS without being 
  as invasive as CSF collection.
 •	 The functional effects of mtDNA concentrations in the CSF of MS patients should be 
  explored in additional research.
 •	 Analyses of ASM activity levels showed that when pooling all types of MS, a significant 
  higher ASM activity level was observed than in healthy controls. The levels did not 
  significantly different in the serum of patients with RRMS, SPMS and PPMS and we 
  did not find an association between ASM activity and the annualized relapse rate, 
  disease activity, MRI variables or EDSS progression.
 •	 Despites ASM activity levels did not reflect treatment response, we observed a 
  significant increase of two types of ceramides (Cer-C16:0 and Cer-C24:0) and four types of 
  sphingomyelin (SM-C20:0, SM-C22:0, SM-C24:0 and SM-C24:1) during fingolimod use.
 •	 When pooling RRMS with SPMS patients TG2 mRNA was significantly associated 
  with clinical disability (EDSS) and  several MRI measurements, including those reflecting 
  neurodegeneration (NBV). 
 •	 In both RRMS and  relapse-onset (RRMS/SPMS) patients, TG2 mRNA levels showed 
  predictive power for the course of the disease. 
 •	 There is no difference in the longitudinal dynamics of serum neurofilament light  levels 
  in patients with or without progression based on EDSS or EDSSplus during natalizumab 
  treatment. 
 •	 Serum neurofilament light levels at initiation of natalizumab and at 12 months did not 
  predict EDSS or EDSSplus progression in the following 2 years.
 •	 Patients with a WO period of >8 weeks had a significant higher recurrence of disease 
  activity compared to patients with a WO period of <6 weeks. 
 •	 No significant difference in natalizumab concentration when comparing patients with 
  and without MS disease activity.
The road forward
Making progress on the road to clinical application of MS biomarkers will require time and 
thorough research.  The design of future studies should most optimally be adjusted to 
the intended purpose of the study i.e. the research question. Although this seems rather 
obvious, in biomarker research this is not always the case and sometimes cannot even 
be achieved. Using existing biobanks and datasets may inflate biomarker sensitivity and 
increase bias. However, this may also hold for prospective studies or studies labelled as 
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such.110 When used appropriately and interpreted carefully, the use of existing biobanks and 
datasets may speed up biomarker discovery and its clinical use. For body fluid biomarker 
research ideally repeatedly collected longitudinal samples are available together with 
clinical and radiological data from large cohorts that include the full clinical spectrum of 
disease phenotypes and disease duration and followed for a sufficiently long time to capture 
crucial milestones. Depending on the focus of the biomarker research specific (additional) 
requirements can be defined with respect to the dataset.
Early detection and diagnostic certainty in MS may be important for the long term outcome 
of individual patients. Since prevention of disability is within reach when immunomodulatory 
treatment is started early, a certain diagnosis soon after the onset of clinical symptoms is 
crucial. Apart from clinical judgement and radiological signs of dissociation in space and 
time, biomarkers may add to diagnosis certainty. This is already the case for CSF analyses, 
but if more easily collected body fluids could avoid a lumbar puncture, this would be a 
step forward. Regarding early detection, the dataset should include a sufficient number of 
early cases, subsequently proven to be MS. In addition, control groups have to be more 
heterogeneous than we applied in our studies, to reflect the real world and need to be 
supplemented with suspected MS cases and more inflammatory neurological disease 
controls. 
The issue of early treatment can also be approached in at least two different ways in which 
biomarkers could play a role. First prediction of the disease course. If biomarkers could 
help in predicting the course of the disease this would greatly help in selecting patients 
who would mostly need early intervention.  And the other way around, if biomarkers could 
predict a benign disease course, early treatment is not necessary and potential side effects 
of treatment could be avoided. A pure approach to study the natural course of the disease 
from onset would be to analyze biomarkers in large groups of untreated patients with 
variable disease courses. It is questionable whether these datasets including body fluids are 
available. Collecting prospective data in this way i.e. while not treating patients, is neither 
feasible nor ethical. This seriously hampers this approach.
Second the prediction of a treatment response. If biomarkers can reliably predict the 
response to a treatment in an individual patient, early treatment would change form a ‘trial 
and error’ approach to a real personalized choice with reasonable certainty of success. In 
case of monitoring treatment and predicting treatment response large cohorts should be 
followed for many years, requiring repetitive systematic bio banking and data collection 
of many patients before and after initiation of treatment. This should not only be analyzed 
regarding the effect of treatment, but also for treatment safety (to detect side effects such 
as PML in the earliest possible stage). This is essential for a well-balanced timely treatment 
strategy in an individual MS patient.
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Another area in which body fluid biomarkers may be very promising is the distinction of 
the underlying pathophysiological process responsible for clinical deterioration. In MS it is 
assumed that both inflammation and neurodegeneration can cause disability. However, the 
possibilities for modulating these two mechanisms using available therapeutic interventions 
are very different. Understanding and detecting the underlying process may help in drug 
discovery and also in tailored treatment. Blood based biomarkers offer the potential for 
the development of a low-cost, non-invasive and more time efficient tool compared to 
both CSF markers and neuroimaging. Blood is much easier to obtain and can be sampled 
repeatedly over time without much burden for the patient. The results for NfL presented 
in this thesis show great promiss that blood based biomarkers will be developed for these 
purposes in the near future. Indisputable, when a potential biomarker is detected, validation 
for the intended purpose, at both technical and clinical levels, is an important next step. 
International collaboration and the help of real-world and registry data is warranted. 
This thesis focusses on specific single body fluid biomarkers. Although no single blood 
biomarker is yet able to detect MS, combinations of biomarkers (also called panels or 
profiles) can be a promising focus for future perspectives. For example, combining sNfL with 
serum tissue transglutaminase could result in a more sensitive marker for predicting disease 
progression. Realizing a panel with reduced number of markers will have significant impact 
on the complexity and cost of diagnosis, treatment monitoring and predicting disease 
progression. 
New (combinations of) biomarkers can also be discovered using an “-omics studies” 
approach. The general term “-omics” refers to a group of rapidly emerging novel technologies 
offering the opportunity of large-scale analysis and identification of candidate biomarkers in 
multiple levels of cell biology (DNA, RNA, proteins, lipids and metabolites). For example, a 
novel proteomics technology is the SOMAscan, which is based on aptamers that are able to 
bind conformational protein epitopes with high specificity and sensitivity.111 The assessment 
of blood proteomics for MS would aid in gaining insight into the proteins and pathways 
involved in MS progression. This technique is already used in our center and revealed eight 
novel biomarkers related to clinical and radiological progression in MS.111 Another novel array 
based technology is the Olink Proximity Ligation Assay, which combines complementary 
antibody based analysis with PCR-based reporting. The technology thereby has a high 
analytical specificity and sensitivity, and allows analysis of >1500 proteins simultaneously. 
This novel technology is currently used in multiple biomarker initiatives in our center. 
Besides “omic studies”, non-coding RNA molecules (microRNA, equal to miRNA) is of 
interest in ongoing and upcoming studies. miRNA analysis is more manageable and requires 
fewer resources than microarray or proteomics analysis. Another advantage is durability 
because miRNAs are more resistant to ribonucleases than messenger-RNA. Lastly, miRNAs 
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can be detected in a large number of samples, including tissue biopsies, whole blood, blood 
cells, serum, plasma and urine. Several miRNA profiling platforms, from microarray to deep 
sequencing, are currently available to prospectively identify miRNAs.112
Although the focus in this thesis is on body fluid biomarkers, in the future a more 
comprehensive dataset including multimodal outcomes may offer a more complete 
representation of the disease phenotype. In addition to body fluid markers, clinical 
observations and imaging data also digital biomarkers using sensors and algorithms across 
an abundance of available connected hardware and software tools could be included. At the 
moment a study performed at our MS center Amsterdam is monitoring MS symptoms with 
digital questionnaires using an app in combination with a Fitbit device to predict relapses. 
The amount of data that will become available will grow exponentially. There will be a need 
for new ways to discover the golden needle in the haystack. Artificial intelligence (AI) is the 
study of methods to imitate intelligent human behavior. Machine learning (ML) is a subset of 
AI that focuses on the study of algorithms that enable a computer to perform specific tasks 
without specific instructions, but instead inferring patterns from big data. Using ML, it is 
possible to extract patterns within patient data, and exploit these patterns to predict patient 
outcomes for improved clinical management. Instead of analyzing potential biomarkers that 
are hypothesized by human intelligence and biological processes (also based on human 
intelligence), ML could discover potential (new) biomarkers from big data.
The road forward is challenging, but with all the new technologies it will be a road full of 
interesting side roads. It may be long, but it will certainly be exciting. Hopefully leading to 
better possibilities to guide patients with MS on their journey. 
172 SUMMARY AND GENERAL DISCUSSION 
References
1. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the 
 McDonald criteria. The Lancet Neurology 2017. DOI: 10.1016/s1474-4422(17)30470-2.
2. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions 
 to the McDonald criteria. Ann Neurol 2011; 69: 292-302. DOI: 10.1002/ana.22366.
3. Lublin FD, Reingold SC, Cohen Ja, et al. Defining the clinical course of multiple sclerosis: the 2013 
 revisions. Neurology 2014; 83: 278-286. DOI: 10.1212/WNL.0000000000000560.
4. Kaplan B, Golderman S, Yahalom G, et al. Free light chain monomer-dimer patterns in the 
 diagnosis of multiple sclerosis. Journal of immunological methods 2013; 390: 74-80. DOI: 
 10.1016/ j.jim.2013.01.010.
5. Kaplan B, Aizenbud BM, Golderman S, et al. Free light chain monomers in the diagnosis of multiple 
 sclerosis. Journal of Neuroimmunology 2010; 229: 263-271. DOI: 10.1016/j.jneuroim.2010.09.002.
6. Senel M, Tumani H, Lauda F, et al. Cerebrospinal fluid immunoglobulin kappa light chain in 
 clinically isolated syndrome and multiple sclerosis. PloS one 2014; 9: e88680-e88680. DOI: 
 10.1371/journal.pone.0088680.
7. Desplat-Jégo S, Feuillet L, Pelletier J, et al. Quantification of immunoglobulin free light chains in 
 cerebrospinal fluid by nephelometry. Journal of Clinical Immunology 2005; 25: 338-345. DOI: 
 10.1007/s10875-005-5371-9.
8. Presslauer S, Milosavljevic D, Brücke T, et al. Elevated levels of kappa free light chains in CSF 
 support the diagnosis of multiple sclerosis. Journal of Neurology 2008; 255: 1508-1514. DOI: 
 10.1007/s00415-008-0954-z.
9. Rudick RA, Peter DR, Bidlack JM, et al. Multiple sclerosis: free light chains in cerebrospinal fluid. 
 Neurology 1985; 35: 1443-1449.
10. Bracco F, Gallo P, Menna R, et al. Free light chains in the CSF in multiple sclerosis. Journal of 
 neurology 1987; 234: 303-307.
11. DeCarli C, Menegus MA and Rudick RA. Free light chains in multiple sclerosis and infections of 
 the CNS. Neurology 1987; 37: 1334-1338.
12. Presslauer S, Milosavljevic D, Huebl W, et al. Validation of kappa free light chains as a diagnostic 
 biomarker in multiple sclerosis and clinically isolated syndrome: A multicenter study. Multiple 
 sclerosis (Houndmills, Basingstoke, England) 2015: 1-9. DOI: 10.1177/1352458515594044.
13. Saez MS, Rojas JI, Lorenzon MV, et al. Validation of CSF free light chain in diagnosis and prognosis 
 of multiple sclerosis and clinically isolated syndrome: prospective cohort study in Buenos Aires. 
 J Neurol 2019; 266: 112-118. 2018/11/06. DOI: 10.1007/s00415-018-9106-2.
14. Senel M, Mojib-Yezdani F, Braisch U, et al. CSF Free Light Chains as a Marker of Intrathecal 
 Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large 
 Cohort. Frontiers in immunology 2019; 10: 641. 2019/04/16. DOI: 10.3389/fimmu.2019.00641.
15. Duranti F, Pieri M, Centonze D, et al. Determination of κFLC and κ Index in cerebrospinal fluid: a 
 valid alternative to assess intrathecal immunoglobulin synthesis. Journal of neuroimmunology 
 2013; 263: 116-120. DOI: 10.1016/j.jneuroim.2013.07.006.
SUMMARY AND GENERAL DISCUSSION  173
16. Pieri M, Storto M, Pignalosa S, et al. KFLC Index utility in multiple sclerosis diagnosis: Further 
 confirmation. J Neuroimmunol 2017; 309: 31-33. 2017/06/12. DOI: 10.1016/j. 
 jneuroim.2017.05.007.
17. Susse M, Hannich M, Petersmann A, et al. Kappa free light chains in cerebrospinal fluid to 
 identify patients with oligoclonal bands. Eur J Neurol 2018; 25: 1134-1139. 2018/04/24. DOI: 
 10.1111/ene.13667.
18. van der Heijden M, Kraneveld A and Redegeld F. Free immunoglobulin light chains as target in 
 the treatment of chronic inflammatory diseases. European journal of pharmacology 2006; 533: 
 319-326. 2006/02/04. DOI: 10.1016/j.ejphar.2005.12.065.
19. Villar LM, Espino M, Costa-Frossard L, et al. High levels of cerebrospinal fluid free kappa chains 
 predict conversion to multiple sclerosis. Clin Chim Acta 2012; 413: 1813-1816. 2012/07/21. DOI: 
 10.1016/j.cca.2012.07.007.
20. Voortman MM, Stojakovic T, Pirpamer L, et al. Prognostic value of free light chains lambda 
 and kappa in early multiple sclerosis. Mult Scler 2016: 1352458516681503. 2016/12/03. DOI: 
 10.1177/1352458516681503.
21. Vasilj M, Kes VB, Vrkic N, et al. Relevance of KFLC quantification to differentiate clinically isolated 
 syndrome from multiple sclerosis at clinical onset. Clinical neurology and neurosurgery 2018; 
 174: 220-229. 2018/10/03. DOI: 10.1016/j.clineuro.2018.09.031.
22. Rudick RA, Medendorp SV, Namey M, et al. Multiple sclerosis progression in a natural history 
 study: predictive value of cerebrospinal fluid free kappa light chains. Mult Scler 1995; 1: 150- 
 155. 1995/11/01. DOI: 10.1177/135245859500100303.
23. Rinker JR, 2nd, Trinkaus K and Cross AH. Elevated CSF free kappa light chains correlate with 
 disability prognosis in multiple sclerosis. Neurology 2006; 67: 1288-1290. 2006/10/13. DOI: 
 10.1212/01.wnl.0000238107.31364.21.
24. Vecchio D, Crespi I, Virgilio E, et al. Kappa free light chains could predict early disease course 
 in multiple sclerosis. Multiple sclerosis and related disorders 2019; 30: 81-84. 2019/02/11. DOI: 
 10.1016/j.msard.2019.02.001.
25. Presslauer S, Milosavljevic D, Huebl W, et al. Kappa free light chains: diagnostic and prognostic 
 relevance in MS and CIS. PloS one 2014; 9: e89945-e89945. DOI: 10.1371/journal.pone.0089945.
26. Sabrkhany S, Kuijpers MJE, Verheul HMW, et al. Platelets: an unexploited data source in biomarker 
 research. The Lancet Haematology 2015; 2: e512-e513. DOI: 10.1016/s2352-3026(15)00225-2.
27. Holly SP, Chen X and Parise LV. Abundance- and Activity-Based Proteomics in Platelet Biology. 
 Curr Proteomics 2011; 8: 216-228. 2012/02/07. DOI: 10.2174/157016411797247512.
28. Best MG, Vancura A and Wurdinger T. Platelet RNA as a circulating biomarker trove for cancer 
 diagnostics. J Thromb Haemost 2017; 15: 1295-1306. 2017/07/04. DOI: 10.1111/jth.13720.
29. Cecchetti L, Tolley ND, Michetti N, et al. Megakaryocytes differentially sort mRNAs for matrix 
 metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic 
 events. Blood 2011; 118: 1903-1911. 2011/06/02. DOI: 10.1182/blood-2010-12-324517.
30. George JN. Platelets. Lancet 2000; 355: 1531-1539. 2000/05/09. DOI: 10.1016/s0140- 
 6736(00)02175-9.
174 SUMMARY AND GENERAL DISCUSSION 
31. Denis MM, Tolley ND, Bunting M, et al. Escaping the nuclear confines: signal-dependent 
 pre-mRNA splicing in anucleate platelets. Cell 2005; 122: 379-391. 2005/08/13. DOI: 10.1016/ 
 j.cell.2005.06.015.
32. Power KA, McRedmond JP, de Stefani A, et al. High-throughput proteomics detection of novel 
 splice isoforms in human platelets. PLoS One 2009; 4: e5001. 2009/03/25. DOI: 10.1371/ journal. 
 pone.0005001.
33. Gawaz M, Langer H and May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 
 115: 3378-3384. 2005/12/03. DOI: 10.1172/jci27196.
34. Koenen RR. The prowess of platelets in immunity and inflammation. Thromb Haemost 2016; 
 116: 605-612. 2016/07/08. DOI: 10.1160/th16-04-0300.
35. Rowley JW, Schwertz H and Weyrich AS. Platelet mRNA: the meaning behind the message. Curr 
 Opin Hematol 2012; 19: 385-391. 2012/07/21. DOI: 10.1097/MOH.0b013e328357010e.
36. Best MG, Sol N, Kooi I, et al. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based 
 Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell 2015; 28: 666- 
 676. 2015/11/04. DOI: 10.1016/j.ccell.2015.09.018.
37. Behari M and Shrivastava M. Role of platelets in neurodegenerative diseases: a universal 
 pathophysiology. Int J Neurosci 2013; 123: 287-299. DOI: 10.3109/00207454.2012.751534.
38. Langer HF, Choi EY, Zhou H, et al. Platelets contribute to the pathogenesis of experimental 
 autoimmune encephalomyelitis. Circ Res 2012; 110: 1202-1210. DOI: 10.1161/ 
 CIRCRESAHA.111.256370.
39. Wachowicz B, Morel A, Miller E, et al. The physiology of blood platelets and changes of their 
 biological activities in multiple sclerosis. Acta Neurobiol Exp (Wars) 2016; 76: 269-281. 
 2017/01/18.
40. Best MG, In ‘t Veld S, Sol N, et al. RNA sequencing and swarm intelligence-enhanced classification 
 algorithm development for blood-based disease diagnostics using spliced blood platelet RNA. 
 Nature protocols 2019; 14: 1206-1234. 2019/03/22. DOI: 10.1038/s41596-019-0139-5.
41. Witte ME, Mahad DJ, Lassmann H, et al. Mitochondrial dysfunction contributes to 
 neurodegeneration in multiple sclerosis. Trends Mol Med 2014; 20: 179-187. DOI: 10.1016/j. 
 molmed.2013.11.007.
42. Lassmann H, van Horssen J and Mahad D. Progressive multiple sclerosis: pathology and 
 pathogenesis. Nat Rev Neurol 2012; 8: 647-656. DOI: 10.1038/nrneurol.2012.168.
43. Witte ME, Bø L, Rodenburg RJ, et al. Enhanced number and activity of mitochondria in multiple 
 sclerosis lesions. The Journal of pathology 2009; 219: 193-204. DOI: 10.1002/path.2582.
44. Zambonin JL, Zhao C, Ohno N, et al. Increased mitochondrial content in remyelinated axons: 
 implications for multiple sclerosis. Brain 2011; 134: 1901-1913. DOI: 10.1093/brain/awr110.
45. Mahad DJ, Ziabreva I, Campbell G, et al. Mitochondrial changes within axons in multiple sclerosis. 
 Brain 2009; 132: 1161-1174. DOI: 10.1093/brain/awp046.
46. van Horssen J, Witte ME and Ciccarelli O. The role of mitochondria in axonal degeneration and 
 tissue repair in MS. Multiple sclerosis (Houndmills, Basingstoke, England) 2012; 18: 1058-1067. 
 DOI: 10.1177/1352458512452924.
SUMMARY AND GENERAL DISCUSSION  175
47. Campbell GR, Ziabreva I, Reeve AK, et al. Mitochondrial DNA deletions and neurodegeneration 
 in multiple sclerosis. Ann Neurol 2011; 69: 481-492. DOI: 10.1002/ana.22109.
48. Podlesniy P, Figueiro-Silva J, Llado A, et al. Low cerebrospinal fluid concentration of mitochondrial 
 DNA in preclinical Alzheimer disease. Ann Neurol 2013; 74: 655-668. DOI: 10.1002/ana.23955.
49. Podlesniy P, Llorens F, Golanska E, et al. Mitochondrial DNA differentiates Alzheimer’s 
 disease from Creutzfeldt-Jakob disease. Alzheimers Dement 2016; 12: 546-555. DOI: 10.1016/j. 
 jalz.2015.12.011.
50. Pyle A, Brennan R, Kurzawa-akanbi M, et al. Reduced CSF mitochondrial DNA is a biomarker for 
 early-stage Parkinson’s disease. Running Head: Cell-free mtDNA in Parkinson’s disease. Ann 
 Neurol 2015; 78: 1000-1004. DOI: 10.1002/ana.
51. Walko TD, Bola RA, Hong JD, et al. Cerebrospinal fluid mitochondrial DNA: a novel DAMP 
 in pediatric traumatic brain injury. Shock (Augusta, Ga) 2014; 41: 499-503. DOI: 10.1097/ 
 SHK.0000000000000160.
52. Lowes H, Pyle A, Duddy M, et al. Cell-free mitochondrial DNA in progressive multiple sclerosis. 
 Mitochondrion 2019; 46: 307-312. 2018/08/12. DOI: 10.1016/j.mito.2018.07.008.
53. Varhaug KN, Vedeler CA, Myhr KM, et al. Increased levels of cell-free mitochondrial DNA in the 
 cerebrospinal fluid of patients with multiple sclerosis. Mitochondrion 2017; 34: 32-35. 
 2016/12/27. DOI: 10.1016/j.mito.2016.12.003.
54. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses 
 to injury. Nature 2010; 464: 104-107. DOI: 10.1038/nature08780.
55. Fissolo N, Cervera-Carles L, Villar Guimerans LM, et al. Cerebrospinal fluid mitochondrial DNA 
 levels in patients with multiple sclerosis. Mult Scler 2018: 1352458518786055. 2018/07/10. 
 DOI: 10.1177/1352458518786055.
56. Wheeler D, Bandaru VV, Calabresi PA, et al. A defect of sphingolipid metabolism modifies 
 the properties of normal appearing white matter in multiple sclerosis. Brain 2008; 131: 3092- 
 3102. 2008/09/06. DOI: 10.1093/brain/awn190.
57. van Doorn R, Nijland PG, Dekker N, et al. Fingolimod attenuates ceramide-induced blood-brain 
 barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol 
 2012; 124: 397-410. 2012/07/20. DOI: 10.1007/s00401-012-1014-4.
58. El Alwani M, Wu BX, Obeid LM, et al. Bioactive sphingolipids in the modulation of the 
 inflammatory response. Pharmacology & therapeutics 2006; 112: 171-183. 2006/06/09. DOI: 
 10.1016/ j.pharmthera.2006.04.004.
59. Piccinini M, Scandroglio F, Prioni S, et al. Deregulated sphingolipid metabolism and membrane 
 organization in neurodegenerative disorders. Mol Neurobiol 2010; 41: 314-340. 2010/02/04. 
 DOI: 10.1007/s12035-009-8096-6.
60. Checa A, Khademi M, Sar DG, et al. Hexosylceramides as intrathecal markers of worsening 
 disability in multiple sclerosis. multiple sclerosis journal 2015; 20: 1271-1279.
61. Vidaurre OG, Haines JD, Katz Sand I, et al. Cerebrospinal fluid ceramides from patients with 
 multiple sclerosis impair neuronal bioenergetics. Brain 2014; 137: 2271-2286. 2014/06/05. DOI: 
 10.1093/brain/awu139.
176 SUMMARY AND GENERAL DISCUSSION 
62. Pieragostino DA-Ohoo, Cicalini I, Lanuti P, et al. Enhanced release of acid sphingomyelinase- 
 enriched exosomes generates a lipidomics signature in CSF of Multiple Sclerosis patients.
63. Ottenlinger FM, Mayer CA, Ferreiros N, et al. Interferon-Beta Increases Plasma Ceramides of 
 Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab. Frontiers 
 in pharmacology 2016; 7: 412. 2016/11/20. DOI: 10.3389/fphar.2016.00412.
64. Dawson G and Qin J. Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar 
 to tricyclic antidepressants. Biochem Biophys Res Commun 2011; 404: 321-323. 2010/12/07. 
 DOI: 10.1016/j.bbrc.2010.11.115.
65. Shin DM, Jeon JH, Kim CW, et al. TGFbeta mediates activation of transglutaminase 2 in response 
 to oxidative stress that leads to protein aggregation. Faseb j 2008; 22: 2498-2507. 2008/03/21. 
 DOI: 10.1096/fj.07-095455.
66. Bayardo M, Punzi F, Bondar C, et al. Transglutaminase 2 expression is enhanced synergistically by 
 interferon-gamma and tumour necrosis factor-alpha in human small intestine. Clin Exp Immunol 
 2012; 168: 95-104. 2012/03/06. DOI: 10.1111/j.1365-2249.2011.04545.x.
67. Yanagawa Y, Hiraide S, Matsumoto M, et al. Enhanced transglutaminase 2 expression in response 
 to stress-related catecholamines in macrophages. Immunobiology 2014; 219: 680-686. 
 2014/05/28. DOI: 10.1016/j.imbio.2014.04.002.
68. van Strien ME, de Vries HE, Chrobok NL, et al. Tissue Transglutaminase contributes to experimental 
 multiple sclerosis pathogenesis and clinical outcome by promoting macrophage migration. 
 Brain, behavior, and immunity 2015; 50: 141-154. 2015/07/03. DOI: 10.1016/j.bbi.2015.06.023.
69. Sestito C, Breve JJP, van Eggermond M, et al. Monocyte-derived tissue transglutaminase 
 in multiple sclerosis patients: reflecting an anti-inflammatory status and function of the cells? J 
 Neuroinflammation 2017; 14: 257. 2017/12/23. DOI: 10.1186/s12974-017-1035-y.
70. Shao M, Cao L, Shen C, et al. Epithelial-to-mesenchymal transition and ovarian tumor 
 progression induced by tissue transglutaminase. Cancer research 2009; 69: 9192-9201. 
 2009/12/03. DOI: 10.1158/0008-5472.Can-09-1257.
71. Mangala LS, Fok JY, Zorrilla-Calancha IR, et al. Tissue transglutaminase expression promotes cell 
 attachment, invasion and survival in breast cancer cells. Oncogene 2007; 26: 2459-2470. 
 2006/10/18. DOI: 10.1038/sj.onc.1210035.
72. Verma A and Mehta K. Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug 
 resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 
 2007; 10: 144-151. 2007/07/31. DOI: 10.1016/j.drup.2007.06.002.
73. Kim SY, Jeong EJ and Steinert PM. IFN-gamma induces transglutaminase 2 expression in 
 rat small intestinal cells. Journal of interferon & cytokine research : the official journal of the 
 International Society for Interferon and Cytokine Research 2002; 22: 677-682. 2002/08/07. DOI: 
 10.1089/10799900260100169.
74. Sestito C, Breve JJP, Killestein J, et al. Differential Expression of Tissue Transglutaminase Splice 
 Variants in Peripheral Blood Mononuclear Cells of Primary Progressive Multiple Sclerosis 
 Patients. Medical sciences (Basel, Switzerland) 2018; 6 2018/11/30. DOI: 10.3390/ 
 medsci6040108.
SUMMARY AND GENERAL DISCUSSION  177
75. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of 
 natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910. 2006/03/03. DOI: 
 10.1056/ NEJMoa044397.
76. Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple 
 sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 2014; 85: 
 1190-1197. 2014/02/18. DOI: 10.1136/jnnp-2013-306936.
77. Pucci E, Giuliani G, Solari A, et al. Natalizumab for relapsing remitting multiple sclerosis. The 
 Cochrane database of systematic reviews 2011: Cd007621. 2011/10/07. DOI: 10.1002/14651858. 
 CD007621.pub2.
78. Phillips JT, Giovannoni G, Lublin FD, et al. Sustained improvement in Expanded Disability Status 
 Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment 
 effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler 2011; 17: 970- 
 979. 2011/03/23. DOI: 10.1177/1352458511399611.
79. Prosperini L, Sacca F, Cordioli C, et al. Real-world effectiveness of natalizumab and fingolimod 
 compared with self-injectable drugs in non-responders and in treatment-naive patients with 
 multiple sclerosis. J Neurol 2017; 264: 284-294. 2016/11/24. DOI: 10.1007/s00415-016-8343-5.
80. Dekker I, Leurs CE, Hagens MHJ, et al. Long-term disease activity and disability progression in 
 relapsing-remitting multiple sclerosis patients on natalizumab. Multiple sclerosis and related 
 disorders 2019; 33: 82-87. 2019/06/08. DOI: 10.1016/j.msard.2019.05.017.
81. Teunissen CE and Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012; 
 18: 552-556. 2012/04/12. DOI: 10.1177/1352458512443092.
82. Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. 
 Nat Rev Neurol 2018; 14: 577-589. 2018/09/02. DOI: 10.1038/s41582-018-0058-z.
83. Malmestrom C, Haghighi S, Rosengren L, et al. Neurofilament light protein and glial fibrillary 
 acidic protein as biological markers in MS. Neurology 2003; 61: 1720-1725. 2003/12/25. DOI: 
 10.1212/01.wnl.0000098880.19793.b6.
84. Disanto G, Barro C, Benkert P, et al. Serum Neurofilament light: A biomarker of neuronal damage 
 in multiple sclerosis. Ann Neurol 2017; 81: 857-870. 2017/05/18. DOI: 10.1002/ana.24954.
85. Novakova L, Zetterberg H, Sundstrom P, et al. Monitoring disease activity in multiple sclerosis 
 using serum neurofilament light protein. Neurology 2017; 89: 2230-2237. 2017/10/29. DOI: 
 10.1212/wnl.0000000000004683.
86. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis 
 is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83-89. 2011/02/01. DOI: 10.1002/ 
 ana.22247.
87. Barro C, Benkert P, Disanto G, et al. Serum neurofilament as a predictor of disease worsening 
 and brain and spinal cord atrophy in multiple sclerosis. Brain 2018; 141: 2382-2391. 2018/06/04. 
 DOI: 10.1093/brain/awy154.
88. Chitnis T, Gonzalez C, Healy BC, et al. Neurofilament light chain serum levels correlate with 10- 
 year MRI outcomes in multiple sclerosis. Annals of clinical and translational neurology 2018; 5: 
 1478-1491. 2018/12/20. DOI: 10.1002/acn3.638.
178 SUMMARY AND GENERAL DISCUSSION 
89. Siller N, Kuhle J, Muthuraman M, et al. Serum neurofilament light chain is a biomarker of acute 
 and chronic neuronal damage in early multiple sclerosis. Mult Scler 2019; 25: 678-686. 
 2018/03/16. DOI: 10.1177/1352458518765666.
90. Cohen M, Maillart E, Tourbah A, et al. Switching from natalizumab to fingolimod in 
 multiple sclerosis: a French prospective study. JAMA Neurol 2014; 71: 436-441. DOI: 10.1001/ 
 jamaneurol.2013.6240.
91. de Seze J, Ongagna JC, Collongues N, et al. Reduction of the washout time between natalizumab 
 and fingolimod. Mult Scler 2013; 19: 1248. DOI: 10.1177/1352458513490551.
92. Fox RJ, Cree BA, De Seze J, et al. MS disease activity in RESTORE: a randomized 24-week 
 natalizumab treatment interruption study. Neurology 2014; 82: 1491-1498. DOI: 10.1212/ 
 WNL.0000000000000355.
93. Jokubaitis VG, Li V, Kalincik T, et al. Fingolimod after natalizumab and the risk of short-term 
 relapse. Neurology 2014; 82: 1204-1211. DOI: 10.1212/WNL.0000000000000283.
94. Kappos L, Radue EW, Comi G, et al. Switching from natalizumab to fingolimod: A randomized, 
 placebo-controlled study in RRMS. Neurology 2015; 85: 29-39. DOI: 10.1212/ 
 WNL.0000000000001706.
95. Iaffaldano P, Lucisano G, Pozzilli C, et al. Fingolimod versus interferon beta/glatiramer acetate 
 after natalizumab suspension in multiple sclerosis. Brain 2015; 138: 3275-3286. 2015/09/13. 
 DOI: 10.1093/brain/awv260.
96. Giovannoni G, Marta M, Davis A, et al. Switching patients at high risk of PML from 
 natalizumab to another disease-modifying therapy. Pract Neurol 2016; 16: 389-393. DOI: 
 10.1136/practneurol-2015-001355.
97. Harrer A, Pilz G, Oppermann K, et al. From natalizumab to fingolimod in eight weeks - 
 Immunological, clinical, and radiological data in quest of the optimal switch. Clin Immunol 2017; 
 176: 87-93. DOI: 10.1016/j.clim.2017.01.001.
98. Koudriavtseva T, Sbardella E, Trento E, et al. Long-term follow-up of peripheral lymphocyte 
 subsets in a cohort of multiple sclerosis patients treated with natalizumab. Clin Exp Immunol 
 2014; 176: 320-326. DOI: 10.1111/cei.12261.
99. Rispens T, Vennegoor A, Wolbink GJ, et al. Natalizumab remains detectable in patients 
 with multiple sclerosis long after treatment is stopped. Mult Scler 2012; 18: 899-901. DOI: 
 10.1177/1352458511431073.
100. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab 
 clearance and restoring leukocyte function. Neurology 2009; 72: 402-409. DOI: 10.1212/01. 
 wnl.0000341766.59028.9d.
101. O’Connor P. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of 
 multiple sclerosis. Expert Opin Biol Ther 2007; 7: 123-136. DOI: 10.1517/14712598.7.1.123.
102. EMA. Tysabri: EPAR - Scientific Discussion. (2007).
103. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple 
 sclerosis. N Engl J Med 2003; 348: 15-23. DOI: 10.1056/NEJMoa020696.
SUMMARY AND GENERAL DISCUSSION  179
104. research FCfdea. Natalizumab: Clinical and Pharmacology and Biopharmaceutical Review(s), 
 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/125104s000_Natalizumab_ 
 Biopharmr.pdf (2004).
105. Zhovtis Ryerson L, Frohman TC, Foley J, et al. Extended interval dosing of natalizumab in multiple 
 sclerosis. J Neurol Neurosurg Psychiatry 2016; 87: 885-889. DOI: 10.1136/jnnp-2015-312940.
106. Bomprezzi R and Pawate S. Extended interval dosing of natalizumab: a two-center, 7-year 
 experience. Ther Adv Neurol Disord 2014; 7: 227-231. DOI: 10.1177/1756285614540224.
107. van Kempen ZL, Leurs CE, Vennegoor A, et al. Natalizumab-associated progressive multifocal 
 leukoencephalopathy is not preceded by elevated drug concentrations. Mult Scler 2016: 
 1352458516684023. DOI: 10.1177/1352458516684023.
108. J.F Foley  TH, A Christensen , E Riddle , T Plavina , L Seawright , R Metzger. Natalizumab extended 
 interval dosing reduces serum trough natalizumab concentrations and a4 integrin receptor 
 occupancy. ECTRIMS 2016. Poster.
109. Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: 
 poorly tolerated. Ann Neurol 2010; 68: 392-395. DOI: 10.1002/ana.22074.
110. Petzold A, Bowser R, Calabresi P, et al. Biomarker time out. Mult Scler 2014; 20: 1560-1563. 
 2014/02/22. DOI: 10.1177/1352458514524999.
111. Malekzadeh A, Leurs C, van Wieringen W, et al. Plasma proteome in multiple sclerosis disease 
 progression. Annals of clinical and translational neurology 2019; 6: 1582-1594. 2019/08/01. 
 DOI: 10.1002/acn3.771.
112. Guerau-de-Arellano M, Alder H, Ozer HG, et al. miRNA profiling for biomarker discovery 
 in multiple sclerosis: from microarray to deep sequencing. J Neuroimmunol 2012; 248: 32-39. 











In dit proefschrift zijn verschillende biomarkers onderzocht die te maken hebben met de 
ziekte Multiple Sclerosis. In deze samenvatting wordt uitgelegd wat de ziekte Multiple 
Sclerosis inhoudt en waarom er zogenaamde biomarkers nodig zijn om de ziekte beter te 
begrijpen. In elk hoofdstuk wordt een andere biomarker onderzocht die bij het bespreken 
van de resultaten steeds kort wordt geïntroduceerd. 
Wat is Multiple Sclerosis?
Multiple sclerose (MS) is een ziekte van het centrale zenuwstelsel (hersenen en ruggenmerg) 
en wordt gekenmerkt door ontstekingen. In Nederland treft MS ongeveer 17.000 mensen, 
wereldwijd zijn dat er meer dan 2 miljoen. De ziekte komt vooral voor bij jong volwassenen 
(20 tot 40 jaar) en uit zich twee keer zo vaak bij vrouwen als bij mannen.
Op weefselniveau zie je bij MS dat het myeline, het witte vetachtige omhulsel dat de 
uitlopers van zenuwcellen bedekt als een soort isolatie laagje, wordt afgebroken. Het 
eigen afweersysteem valt het gezonde weefsel aan middels ontstekingsreacties. Waarom 
het afweersysteem zo overactief reageert is onbekend. Door de afbraak van myeline, 
demyelinisatie, neemt de werking van zenuwen af en kunnen patiënten neurologische 
klachten ervaren. Indien de ontstekingsreacties opvlammen en neurologische klachten 
geven spreken we van exacerbaties. 
Op MRI-scans kunnen we de ontstekingsgebieden, laesies, herkennen aan de typische 
kenmerken en lokalisatie. De klachten van de patiënt, de neurologische beoordeling en de 
MRI-beelden worden alle gebruikt om te bepalen of iemand MS heeft. Toch kan het stellen 
van een tijdige diagnose bij een klein deel van de patiënten ingewikkeld zijn. Daarnaast is 
het lastig te voorspellen of de patiënt veel of juist weinig ontstekingen, ziekteactiviteit, zal 
krijgen en in welke mate de patiënt lichamelijk geïnvalideerd, ziekteprogressie, zal raken. Er 
is dus een dringende behoefte aan biologische markers, biomakers, uit lichaamsvloeistoffen 
die de ziekteactiviteit en de ziekteprogressie weerspiegelen en voorspellen. Dergelijke 
biomarkers zijn cruciaal om geneeskunde op maat te kunnen leveren.
Doel van het proefschrift
Het doel van dit proefschrift is het vinden van biomarkers gerelateerd aan 1) de vroegtijdige 
diagnose van MS, 2) de ziekteactiviteit en ziekteprogressie en 3) het monitoren van de 
behandeling. 
Resultaten 
Deel 1. Diagnostische biomarkers
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Zoals hierboven beschreven is het in sommige gevallen lastig om de diagnose MS te stellen. 
In de eerste twee hoofdstukken ligt de aandacht bij twee biomarkers die hier mogelijk bij 
kunnen helpen: kappa free light chains en messengerRNA. Tot op heden zijn de oligoclonale 
banden (OCB) de enige lichaamseigen biomarkers die in de praktijk gebruikt worden voor het 
stellen van de diagnose MS. Deze bandjes, gevormd door immunoglobulinen (antilichamen) 
zijn in grote mate aanwezig in het hersenvocht van MS patiënten. Bij gezonde mensen 
worden deze specifieke banden niet aangetoond in het hersenvocht. De beoordeling van 
OCB in het laboratorium is echter arbeidsintensief, vereist geschoold personeel en de juiste 
beoordeling is sterk afhankelijk van de examinator en de methode. Dit deed de volgende 
vraag opkomen: ‘Is er een biomarker die kan worden gemeten met een geautomatiseerde 
en kwantificeerbare procedure?’
Immunoglobulinen bestaan uit twee ketens, light chains en heavy chains. Light chains zijn 
weer opgebouwd uit kappa- en lambdaketens. Light chains kunnen ook in ongebonden 
vorm vrij rond circuleren in het hersenvocht en het bloed. In hoofdstuk 1 hebben we kappa 
free light chains (KFLC) gevalideerd als diagnostische biomarker in MS en vergeleken met 
de OCB. 
Voor hoofdstuk 1 hebben we van 745 patiënten bloed en hersenvocht verzameld. Dit deden 
we in samenwerking met 18 andere MS centra in Europa. In deze samples hebben we KFLC 
en OCB gemeten. We definieerden cut-offs voor abnormale KFLC waarden en op basis van 
deze cut-offs werden de patiënten geclassificeerd als positief of negatief. Vervolgens hebben 
we gekeken welke test, OCB versus KFLC beter is in het diagnosticeren van de ziekte MS. We 
concludeerden dat KFLC beter zijn in het excluderen van de diagnose. De OCB blijven beter 
in het bevestigen van de ziekte MS. 
In hoofdstuk 2 is de potentie van messengerRNA (mRNA) van bloedplaatjes onderzocht als 
diagnostische marker. Tot dusver is geen enkele biomarker uit bloed overtuigend bevestigd 
als nuttig hulpmiddel bij het diagnostisch onderzoek van MS. Op bloed gebaseerde markers 
bieden duidelijke voordelen en recentelijk hebben studies laten zien dat bloedplaatjes als 
nieuwe bron voor het ontdekken van biomarkers bij verschillende ziekten zeer veel potentie 
hebben. De reden dat bloedplaatjes interessant zijn komt omdat ze een rijk mRNA repertoire 
bevatten. RNA is een transcript van DNA waarmee genetische informatie tot expressie 
wordt gebracht en gereguleerd. Het mRNA repertoire van bloedplaatjes is veranderlijk en 
biedt waardevolle informatie. 
Bloedplaatjes reageren op activerende signalen uit hun omgeving waardoor het mRNA 
zich kan splitsen. Daarnaast kunnen bloedplaatjes ook RNA opnemen uit verschillende 
celtypen, wat leidt tot een nog unieker RNA repertoire. Onze hypothese in hoofdstuk 2 is 
dat bloedplaatjes een MS specifieke mRNA signatuur bevatten. Dit unieke mRNA signatuur 
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zou daarmee potentie hebben als diagnostische biomarker in MS. In bloedsamples van 57 
MS patiënten uit het Amsterdam cohort ontdekten we 645 unieke mRNA signaturen die 
verhoogd aanwezig waren bij MS patiënten in vergelijking met bloedsamples van gezonde 
mensen. Deze mRNA’s werden vervolgens gebruikt als input voor de ontwikkeling van een 
diagnostische MS classificator die MS kon detecteren met meer dan 80% nauwkeurigheid.
Deel 2 Ziektebeloop biomarkers
In dit deel van het proefschrift hebben we biomarkers onderzocht die het ziektebeloop 
weerspiegelen, met daarbij de nadruk op de ziekteprogressie.
In hoofdstuk 3 onderzochten we de potentie van vrij circulerend mitochondrieel DNA 
(mtDNA) in het hersenvocht als biomarker voor het identificeren van patiënten met 
progressieve MS. 
Demyelinisatie leidt tot een toename van de energievraag in cellen. Bij een verhoogde 
energievraag kan de activiteit van mitochondriën, de organellen van de cel die energie 
produceren, in zenuwcellen toenemen. In tegenstelling tot andere organellen hebben 
mitochondriën hun eigen DNA (mitochondrieel DNA, afgekort: mtDNA). Mogelijk komt dit 
specifieke mtDNA vrij doordat de mitochondriën stress ervaren door de MS ontstekingen 
en is dit meetbaar in het hersenvocht van MS patiënten. In dit hoofdstuk hebben we vrij 
circulerend mtDNA gemeten in twee cohorten uit het Amsterdam cohort (120 MS patiënten) 
en uit een Zweeds cohort (42 MS patiënten). De belangrijkste conclusie van dit hoofdstuk 
is dat onze gegevens laten zien dat een verhoogde concentratie vrij circulerende mtDNA 
verband houdt met de ziekteactiviteit van MS en progressieve ziekte.
In hoofdstuk 4 onderzochten we het enzym acid sfingomyelinase (ASM). De hersenen 
bestaan voor een groot deel uit vetten, ook wel lipiden. Een specifiek soort, de sfingolipiden, 
hebben mogelijk een rol in de ziekteactiviteit van MS. Vanwege de activiteit van bepaalde 
enzymen die essentieel zijn bij het aanmaken van sfingolipiden kunnen ceramiden worden 
geproduceerd. Ceramiden hebben vervolgens weer een rol in allerlei processen van de 
cel. Een belangrijk enzym dat betrokken is bij dit proces is acid sfingomyelinase. De levels 
van ASM activiteit hebben we gemeten in het bloed van MS patiënten. De ASM activiteit 
verschilde niet tussen progressieve en niet progressieve MS patiënten. We vonden ook geen 
verband tussen ASM activiteit en het aantal exacerbaties op jaarbasis, ziekteactiviteit, MRI 
variabelen of lichamelijke invaliditeit.
In hoofdstuk 5 staat de Tissue Transglutaminase (TG2) centraal. Dit enzym heeft een 
belangrijke rol in gereguleerde celdood, bij membraantransport en bij het verstevigen 
van het celskelet. Er werd beoordeeld of de expressie van dit enzym veranderd is bij MS 
patiënten en of dit overeenkomt met de mate van de ziekteactiviteit en de ziekteprogressie. 
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We observeerden dat TG2 levels niet geassocieerd waren met de ziekteactiviteit maar wel 
met de ziekteprogressie.
Deel 3 Ziektebehandeling biomarkers
In dit laatste deel kijken we naar biomarkers die kunnen helpen bij het monitoren van de 
behandeling van MS. Er zijn medicijnen op de markt die het ziekteproces gedeeltelijk kunnen 
remmen. Deze medicijnen hebben verschillende bijwerkingen en kunnen zelfs ernstige 
complicaties geven. Het zijn namelijk medicijnen die ingrijpen op het immuunsysteem. 
Het werkzame effect van het medicijn kan men meten op basis van nieuwe laesies op 
de MRI en/of er nieuwe neurologische klachten ontstaan. Natalizumab is het eerste MS 
medicijn met een hoge effectiviteit waarbij exacerbaties en MRI afwijkingen grotendeels 
worden voorkomen. Dit middel wordt maandelijks toegediend via een infuus en voorkomt 
dat de witte bloedcellen, lymfocyten, zich naar het centrale zenuwstelsel verplaatsen. Het is 
zeer effectief en wordt goed getolereerd door patiënten. Het aantal aanvallen op de myeline 
neemt af door dit medicijn maar we zien bij een groot deel van de MS patiënten dat er toch 
mettertijd lichamelijke achteruitgang optreedt. 
In hoofdstuk 6 hebben we onderzocht of er in het bloed van patiënten die natalizumab 
gebruiken en die op het moment van afname vrijwel geen ziekteactiviteit hebben, een 
biomarker aanwezig is die kan voorspellen of lichamelijke achteruitgang zal optreden. 
De hiervoor onderzochte biomarkers zijn neurofilamenten. Dit zijn afbraakproducten van 
zenuwuitlopers die bij schade aan de hersenen aanwezig kunnen zijn in het hersenvocht en 
het bloed. In een groep van 89 met natalizumab behandelde MS patiënten onderzochten 
we deze neurofilamenten in het bloed. Na drie maanden van de behandeling met 
natalizumab vonden we een afname van bijna 50%. Na twaalf maanden was de afname van 
neurofilamenten maximaal. 
We vonden geen verschil in concentraties neurofilamenten bij patiënten met en zonder 
lichamelijke achteruitgang. Tevens voorspelde de concentratie van neurofilamenten bij het 
starten van natalizumab niet of een patiënt later meer lichamelijke invaliditeit ontwikkelt. 
Natalizumab wordt goed getolereerd door MS patiënten. Er is echter wel een potentieel 
dodelijke complicatie: progressieve multifocale leukoencefalopathie (PML). Dit is een virale 
hersenontsteking veroorzaakt door het John Cunningham virus (JCV). Vanwege het risico 
op PML schakelt een aanzienlijk deel van de JCV positieve patiënten over op fingolimod. 
Fingolimod is een MS medicijn dat patiënten elke dag innemen in tabletvorm. Fingolimod 
zorgt ervoor dat lymfocyten niet uit de lymfeklieren kunnen treden en daardoor niet 
richting het centraal zenuwstelsel verplaatsten. De belangrijkste vraag bij het switchen van 
natalizumab naar fingolimod is: hoe lang moet je wachten tussen de twee behandelingen? 
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Eerdere studies laten een duidelijk voordeel zien wanneer de duur van deze periode, washout 
periode, niet langer dan 3 maanden is. Te lang wachten kan zorgen voor opvlamming van 
ziekteactiviteit maar te snel switchen brengt mogelijk ook complicaties met zich mee omdat 
er dan twee middelen in het lichaam zitten die beide effect hebben op het afweersysteem. 
Er bestaat geen duidelijkheid wat de optimale duur is van deze periode onder de 3 maanden. 
In hoofdstuk 7 vergeleken we de ziekteactiviteit van MS na verschillende washout perioden 
bij 52 patiënten die van natalizumab switchten naar fingolimod. Daarnaast hebben we 
verschillende factoren onderzocht die mogelijk van invloed zijn op het terugkeren van de 
ziekteactiviteit, waaronder de natalizumabconcentraties en het aantal lymfocyten in het 
bloed. Patiënten met een washout periode van langer dan 8 weken hadden een hogere kans 
op terugkomst van ziekteactiviteit vergeleken met patiënten met een washout periode van 
minder dan 6 weken. De natalizumabconcentraties en het aantal lymfocyten voorspelden 
geen terugkomst van ziekteactiviteit.
Wat opvallend is bij natalizumab is dat alle patiënten elke vier weken hetzelfde 
behandelschema van 300 mg krijgen, ondanks de verschillen in farmacokinetiek tussen 
individuele patiënten. Met deze dosering kunnen natalizumabconcentraties in het bloed 
tot 200 dagen na stopzetting van de therapie detecteerbaar blijven. Het zou erop kunnen 
wijzen dat dit ertoe leidt dat patiënten meer natalizumab krijgen dan nodig is. Het doel 
van de studie in hoofdstuk 8 was om de concentraties te meten en deze te correleren 
met ziekteactiviteit en mogelijke andere beïnvloedende factoren. We onderzochten of 
de natalizumabconcentratie potentie heeft als marker voor de behandelingsrespons. De 
serumconcentraties werden gemeten in het bloed van 80 MS patiënten onder behandeling 
met natalizumab. We maten hoge natalizumabconcentraties bij 94% van de patiënten. 
De spreiding in concentraties tussen patiënten was aanzienlijk en correleerde niet met 
ziekteactiviteit. We vonden een negatief verband tussen de concentratie natalizumab en 
het lichaamsgewicht.
Toekomstperspectief
Wereldwijd is er een behoefte aan MS biomarkers die kunnen helpen bij het stellen van een 
tijdige diagnose en die de ziekteactiviteit en de ziekteprogressie kunnen weerspiegelen en 
voorspellen. Dergelijke biomarkers zijn cruciaal om geneeskunde op maat te kunnen leveren. 
Dit proefschrift voegt nieuwe informatie toe aan de bestaande wetenschappelijke kennis 
over potentiele biomarkers. De daadwerkelijke klinische toepassing van MS biomarkers zal 
nog lang op zich wachten. Er is namelijk tijd en grondig onderzoek nodig. 
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Dankwoord
Een promotieonderzoek is een lange reis  die je samen met zeer wijze, leuke en ambitieuze 
mensen aflegt. Graag  wil ik iedereen bedanken die direct of indirect een bijdrage hebben 
geleverd aan de totstandkoming van dit proefschrift. 
Ten eerste wil ik alle MS patiënten bedanken die hebben meegewerkt aan het onderzoek dat 
wordt uitgevoerd in het MS centrum Amsterdam. Dankzij hen is er een enorme hoeveelheid 
aan data welke keer op keer onderzocht kan worden.
Daarnaast wil ik natuurlijk mijn promotor en copromotors bedanken voor het vertrouwen 
dat zij in mij stelden om samen dit promotietraject invulling te geven. Professor Uitdehaag, 
beste Bernard, als een helikopter boven mijn hoofd hou je alles in de gaten. Niet alleen 
gedurende mijn promotie maar ook bij mijn opleiding tot neuroloog. Ondanks de drukte heb 
je altijd tijd om mij te voorzien van goede adviezen, feedback of voor een gezellig praatje.
Professor Killestein, beste Joep, het is inspirerend te zien hoe jij koers uitzet in MS land 
op zoveel verschillende vlakken. Jouw ongelofelijke passie voor het vak neurologie en de 
wetenschap gaf mij elke keer weer net dat beetje energie om door te gaan op momenten 
dat ik dacht dat ik er even klaar mee was. Mijn proefschrift bestaat uit zoveel verschillende 
onderwerpen waardoor ik soms door de bomen het bos niet meer zag maar de rode draad 
verloor jij nooit uit het oog. Naast goede adviezen geven, aansturen en weloverwogen 
beslissingen nemen, kan je goed mopperen. Dat laatste maakte mij altijd aan het lachen dus 
op jouw manier ben je ook goed in het creëren van een prettige werksfeer.
Professor Teunissen, beste Charlotte, met jouw vooruitstrevende visie en enorme kennis op 
neurochemie en biomarkers had ik mij geen betere copromotor kunnen wensen. Je bent 
praktisch ingesteld, altijd enthousiast en daardoor hielden we de vaart erin.  
Geachte leden van de leescommissie, bedankt dat u de tijd wilt nemen om mijn proefschrift 
te beoordelen en erover van gedachten te wisselen tijdens de verdediging. 
Alle co-auteurs, in het bijzonder Zoé van Kempen en Claire Bridel, enorm bedankt voor jullie 
bijdrage.
Mijn proefschrift is mede tot stand gekomen door een goede samenwerking van de 
verschillende onderzoeksgroepen binnen het MS Centrum. Hierdoor werkte ik samen met 
prof. dr. de Vries, prof. dr. Barkhof, prof. dr. Geurts, dr. van Horssen, dr. van Dam, dr. Hulst, 
dr. Schoonheim en dr. Steenwijk. Wat een geluk dat jullie mij konden bijstaan met al jullie 
kennis. 
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Beste Bob en Brigit, misschien hebben jullie niet direct bijgedragen aan mijn proefschrift, 
jullie zijn nauw betrokken bij alles wat er afspeelt in het MS centrum. Jullie zijn altijd 
geïnteresseerd in wat de arts onderzoekers doen en ook altijd benaderbaar voor advies, 
waarvoor dank! 
Lieve collega’s van het MS centrum, wat zaten we daar heerlijk in het nostalgische 
stoffige kamertje op poli J en later in de fancy kamer met airco. Dankzij jullie was het 
onderzoeksleventje helemaal zo gek nog niet. We deden allemaal ons eigen ding maar het 
vele EDSS-en en het net iets te vaak ASSMS-poli doen, zorgde voor verbondenheid. Martijn, 
Lisanne, Judith, Djoeke, Danko, Iris, Anke, Prejaas, Jenny, Ilse en Jessica, dank voor alle 
gezelligheid. 
Geen onderzoek zonder data. Geen data zonder de ‘Data-Unit’. Laura, Sara, Niels en Louk, 
dank voor al het verzamelen van gegevens maar zeker ook voor jullie bijdrage aan de 
heerlijke sfeer op poli J. 
Tijdens mijn onderzoekswerk, mocht ik ook meewerken aan verschillende medical trials. De 
scepter werd gezwaaid door Danielle en Gianina, ook wel de ‘Reseach-Unit’. Het was altijd 
leuk om met jullie samen te werken en de beste zorg voor de patiënten te leveren. Soms 
was het wel even stressen als de monitor langskwam maar jullie hadden altijd alles op orde! 
Vier andere personen die ook onmisbaar zijn voor MS onderzoek zijn; José Spruijt, Annette 
Schoorl, Eyse Koca en Kim Bakker. De MS verpleegkundigen van de dagbehandeling en 
polikliniek. We hebben nauw met elkaar samengewerkt om allerlei gegevens te verzamelen 
maar bovenal om goede zorg te leveren.
Van de MS-biobank wil ik graag Harry, Mariska, Layla en Cees bedanken voor het verzamelen 
van alle bloed en liquor samples, het was elke keer een hele klus.
Lieve vrienden, uit Hilversum en Amsterdam, jullie zorgen ervoor dat ik geniet van het leven! 
Femke, Suzanne, Dicky, Celine, Meertien, Miriam, Ilona, Tamar, Jette, Marijntje, Hendrik, 
Diederik en Guido. Alles wat ik met jullie onderneem is fenomenaal!  
Lieve papa en mama, woorden schieten te kort om te beschrijven hoe dankbaar ik ben. Jullie 
hebben mij altijd gestimuleerd om te ontwikkelen en de wereld te ontdekken. Hard werken 
en eindeloze inzet tonen is de lijfspreuk van de familie Leurs. Dat heeft ervoor gezorgd dat ik 
ben waar ik ben! Jullie hebben altijd in mij geloofd. Ik hou van jullie. 
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Kim, lieve zus, je bent altijd mijn inspiratiebron geweest. Dankzij jou wilde ik arts worden en 
is de passie voor de neurologie aangewakkerd. Er is niemand zo lief en goed als jij. Je bent 
altijd positief, ondanks alles. Hier put ik mijn energie uit. Ik ben zo trots op je.  
Mijn paranimfen. Marloes, vier jaar lang zaten we elke werkdag naast elkaar. Je bent 
mijn bondgenoot. Samen hebben we dit gedaan! Pleuni, bondgenoot op afstand, 
dankzij jouw kritische vragen, bodemloze interesse in de wetenschap en natuurlijk onze 
unieke vriendschap, ben jij ook een logische keus als paranimf. Ik ben trots op deze twee 
powervrouwen naast mij!
Luck, deze gouden medaille (weliswaar in de vorm van een proefschrift), is mede tot stand 
gekomen door jou. Je brengt rust op momenten waar mijn hoofd op ontploffen staat. Je 
danst op dat soort momenten met mij door de woonkamer, je laat mij jouw lievelingsmuziek 
horen en je kletst honderduit over de held Aeneas of keizer Augustus. Lieve Luck, lieve 
echtgenoot, straks na de Olympisch Spelen wacht op ons, een nieuw hoofdstuk. Ik kan niet 
wachten daar aan te beginnen. Ik hou zielsveel van jou.  
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